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Translation of genomic discoveries
The Human Genome Project marked the beginning of the genome era, and was 
expected to revolutionize the field of biomedical science and unlock the secrets 
of the role of genetic variants in human disease. Indeed, “the magnitude, scope 
and pace of discovery in genetics and genomics research are at unprecedented 
levels and continue to increase exponentially” [1]. It also raised the bar on the 
expectations for the impact these discoveries will have on advances in clinical 
application of genomic knowledge. Today, many gene–disease associations 
are proven and genetic/genomic testing has acquired a role in guiding clinical 
decision making and in treatment of disease. 
However, there is a prevailing sense that the process of integration and 
translation of genomic discoveries in clinical practice is hindered by the lack of 
information on the clinical validity and utility of these discoveries on one hand, 
and the lack of knowledge on the side of the health providers about the proven 
benefits of the discoveries [2].
Recently it has been estimated that more than 15,000 tests exist for more than 
2,800 genes [3]. Performing horizon scanning for new genomic tests on the 
Internet, Gwinn et al. detected approximately 2 to 3 new genomic tests coming 
out per week [4]. 
Large number of genomic tests appear at the market every year, yet only few of 
them are sufficiently supported by evidence to justify their clinical use [5]. This 
chasm between the use of these tests and improved health outcomes has been 
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9the problem of translation gap of genomic discoveries through approach called 
Public Health approach to genetics (Figure 1). 
Figure 1. Public Health Genomics model of the translational research (T0-T4) needed to convert 
discoveries into better health (source: Khoury, Genome-Based Diagnostics: Clarifying Pathways to 
Clinical Use: Workshop Summary, 2012) [7]
Phase T0 represents discovery research, Phases T1 and T2 include observational 
studies and clinical trials, starting with gene discovery, progressing through 
the development of the health application and ending with the development 
of evidence based guidelines. Phase T3 of the translation research aims at 
ensuring the success of the evidence based health intervention in practice. It 
involves dissemination of the knowledge about the intervention and activities 
aiming at successful implementation of the intervention. Phase T4 is concerned 
with the impact that the new application/intervention will have on the clinical 
and public health outcomes [6]. 
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process of translation of genomic discoveries into clinical practice, the lack of 
resources in translational research [8]. 
Despite the existing problems, there are successful examples of genomic 
information being used in prevention and everyday clinical practice, improving 
health outcomes and supporting some of expectations bestowed upon 
genomic discoveries. The most commonly described are BRCA1/BRCA2 test 
and pharmacogenetic tests. Mutation in the BRCA1 or BRCA2 genes (genes 
responsible for production of tumor suppressor proteins, with a role in repairing 
damaged DNA) significantly increases risk of developing breast and/or ovarian 
cancer in women who inherited them. Genetic tests can check for BRCA1 and 
BRCA2 mutations in people with a family history of cancer, suggesting the 
presence of a harmful mutation in one of these genes. Women identified with 
having mutations in one or both BRCA genes are candidates for more frequent 
breast cancer screening, risk reducing surgery or chemoprevention, as ways of 
managing their cancer risk [9]. A different example of successful use of genomic 
information in practice are pharmacogenetic tests aiming at improving the 
safety and efficacy of drug treatment, as well as guiding appropriate dosing of 
medicines.  
Oral anticoagulant Warfarin is a well-known example of a drug made safer and 
more effective by determining the dosage based on the genetic makeup of a 
patient. Polymorphisms in the gene encoding for the enzyme cytochrome P-450 
2C9 (CYP2C9) are associated with variability in sensitivity to warfarin. Patients 
with certain genetic variants of CYP2C9 are at risk for over-anticoagulation and 
serious bleeding, therefore require a lower dose of warfarin and a longer time to 
reach a stable dose [10].
In both mentioned examples (BRCA1/BRCA2 test and pharmacogenomics 
tests) the useful application of a genetic test is linked to an intervention that 
improves health outcomes [11]. 
The trends in using genome based information with the aim to improve health 
outcomes of population have been changing over time.  Initially, most of the 
tests were developed to diagnose or confirm classic Mendelian disorders 
[12].  These diseases are characterized by traits inherited in a monogenic 
fashion, the changes in a single gene are responsible for almost all the disease 
manifestations, individual alleles are inherited in families according to Mendel’s 
law [13]. Technological advances allowing the new generation of genome wide 
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association studies contributed to the attention gradually moving towards 
common complex diseases, such as diabetes, cancer and heart diseases, whose 
pathophysiology is characterized by an interplay of genetic and environmental 
factors [14].
Recent review of the new genomic tests, categorized by diseases or condition, 
showed that 65% of these tests are designed for oncology (Table 1) [4].
Table 1. Distribution of new genomic tests by disease or condition (source: Gwinn 
et al., 2011) [4]
Cancer
Colorectal
Lung
Breast
Prostate
Ovary
Leukemia/lymphoma 6
Skin
Bladder
Mesothelioma
Pancreas
Gastric
Other
Multiple sites
Not speciﬁed
Cardiovascular
Conorary heart disease 
Clotting disorders
Cardiac conduction disorders
Hypertension
Not speciﬁed
Gastrointestinal disorders
Neurodegenerative disorders
Developmental disorders/birth defects
Age related macular degeneration
Autoimmune disorders
Diabetes/metabolic syndrome
Psychiatric disorders
Hereditary disorders
Other
Total
Number Percent
122 65
25
21
17
13
6
6
5
3
3
2
4
3
8
19
7
6
4
1
1
5
4
4
2
2
2
2
11
13
188
6
1
1
1
2
2
2
3
10
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Genotyping of somatic mutations in cancer cells, for the purpose of guiding 
medical decisions in cancer diagnosis and therapy, for selected cancers, 
is leading the way among the genomic technologies which reached clinical 
therapy and/or disease outcome. For example, lung cancer, melanoma and 
Myeloproliferative disorders with mutations in the genes EGFR, BRAF and JAK 
2 respectively have a tendency of being sensitive to tyrosine kinase inhibitors 
(TKI) [15,16]. Furthermore, in order to identify individuals genetically at risk 
of developing cancer, relatives of patients with germline mutations cancers are 
undergoing screening (e.g. Lynch syndrome and aforementioned BRCA1,2). 
Pharmacogenetic tests, as important tools in personalized approach to 
medication therapy follow. Identifying patients genetically unable to use certain 
drugs and guiding the adequate dosing of other medications improves drug 
whole genome and whole exome sequencing is used in diagnosis of rare unknown 
was used to reach a clinical diagnosis and guide the treatment of a child with a 
Genomic Information and Infectious diseases
The understanding of the importance of genomic information in diagnosis and 
treatment of infectious diseases has been staidly increasing in recent years 
[19].
Traditionally infectious diseases have been observed as a result of the interplay 
developments in genomics changed the way we think about infectious diseases. 
The recent evidence of genetic factors in the pathogenesis of infectious 
diseases transformed our view of such diseases by recognizing the role of host 
genetic determinants that modulate immune response. Progress in genomics 
led to the characterization of molecular biomarkers and pathways as targets 
for diagnosis or intervention [20]. Furthermore, this new understanding of 
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infectious diseases explains why some individuals are just more resistant/
the infection by, among other factors, host genetic makeup. A great amount 
an aim of developing genomic applications and translating them into everyday 
clinical practice and prevention (Table 2). 
Table 2. Examples of replicated genetic associations with human infectious 
diseases (adopted from Hill, 2006) [20]
When it comes to public health strategies regarding infectious diseases 
conventional approach can be summarized in 3 words: prevention, treatment, 
and control. Revolutionary breakthrough in genome research facilitated 
improvements in public health interventions, widening its scope of interest and 
translation of genome-based knowledge and technologies into public policy and 
part of the burden of disease in developing countries [23]. They are still the leading 
death cause worldwide. Despite the epidemiological transition characterized by 
infectious diseases to chronic complex diseases [15], some infectious diseases 
are on the rise in the developed countries.
In Europe, data obtained from the Sexually Transmitted Infections (STI) 
surveillance reports of the EU countries are showing stable or increasing trends 
DISEASE GENETIC LOCUS
Malaria alpha-globin, beta-globin, G6PD, 
SLC4A1, MAL/TIRAP, DARC
Tuberculosis HLA-DR, INF-γ, SLC11A1, 
VDR, MAL/TIRAP, CCL2
HIV/AIDS HLA-B, CCR5, CCR2
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in recent years, in most of the countries [24]. Reports show that STIs represent 
a major public health problem in Europe. Indeed, European surveillance data 
show that Chlamydia trachomatis genital infection has been on the rise since 
the mid-1990s and, in fact, is at the moment the most commonly diagnosed 
bacterial STI [25].
Chlamydia trachomatis
Chlamydia trachomatis is a sexually transmitted intracellular pathogen causing 
more cases of Sexually Transmitted Infections than any other bacteria. [26]. 
The WHO estimated the global incidence of Chlamydia to be 105.7 million 
cases in 2008, an increase of 4.1 percent compared to 101.5 million cases 
in 2005. In addition to really high incidence what makes Chlamydia infection a 
significant public health problem, despite the fact that the microorganism can 
be successfully cleared by antibiotics, is that 80-90% of infections in women 
and up to 50% in men are asymptomatic [27, 28]. As a result infection often 
remains untreated, and its consequences can be particularly severe in women. 
In untreated women there are two possible outcomes of Chlamydia lower 
genital infection: spontaneous clearing of the infection without consequences 
and ascending of the infection to the upper genital tract and development of 
complication. Research showed that almost half of the women (44.7%) with 
asymptomatic infection and therefore without antibiotic treatment will clear 
infection in one year [29]. In others who do not spontaneously clear the infection, 
bacteria can cause persistent infection and serious complications such as PID 
(Pelvic Inflammatory Disease), endometritis, salpingitis, ectopic pregnancy 
and tubal factor infertility (TFI), result of damaged fallopian tubes [30]. Costs 
associated with diagnosis and treatment of complications of Chlamydial 
urogenital infection pose a significant financial burden on healthcare, and on 
society as a whole, emphasizing its status of as a major public health issue. 
Immunogenetics of Chlamydia 
Human genetic variation is a vital causal factor of susceptibility to many common 
infectious diseases [31]. Immunogenetics is a field in biomedical research 
aiming at identifying immune related genes responsible for susceptibility to 
GENERAL INTRODUCTION
15
many autoimmune and infectious diseases [32].  It also assesses the role of 
genetic variations in genes responsible for host immune responses for the 
course and the outcome of infectious diseases. 
Immunogenetic studies based on twin research for Chlamydia trachomatis 
estimated that 40% of variation in the characteristics of Chlamydia infection 
can be attributed to the differences in host genetic factors [33]. These 
differences are often determined by genetic variation, such as SNPs (Single 
Nucleotide Polymorphisms), in genes responsible for, amongst others, bacterial 
sensing receptors (and the pathways to which they belong) on cells such as 
macrophages as well as local vaginal and tubal epithelial cells. Bacterial 
sensing receptors, such as Toll Like Receptors (TLRs), the most studied of all 
the receptors of innate immune response [34], are responsible for adequate 
recognition of the pathogen and for the following adequate immune response. 
Genetic variations in genes encoding for these receptors can influence the 
susceptibility to Chlamydia, the course and the outcome of the infection in both 
positive and negative ways. Carrying certain SNPs could put an individual at 
high risk of persistent infection and at having increased risk for developing tubal 
pathology. A negative result for the same genetic markers means that a patient 
is not carrier, and thus is not highly susceptible to such a course of Chlamydia 
infection which results in tubal pathology [35]. Additionally, SNPs can also have 
protective role. Carrying certain SNPs can, indeed, protect its carriers from the 
development of tubal factor infertility. These different genetic markers need to 
be combined to provide an accurate assessment of risk factors and protective 
traits. Some of the key examples are described below. 
Chlamydia trachomatis host genetic factors
Toll-like receptors (TLRs) have an important role in identifying pathogens and 
initiating innate immune response. They have been recognized as important 
factors in influencing differences in susceptibility to the course and outcome of 
Chlamydia infection [36, 37]. Immunogenetic research of Chlamydia focuses on 
TLR genes and genes involved in their pathways, assuming that SNPs in TLR genes 
can cause changes on the cell surface, either in the presentation of dysfunctional 
receptors or by changing the number and density of the receptors, thus leading 
to an inadequate immune response [38]. TLR2 showed an important role in the 
16
protection against late inflammatory sequelae following Chlamydia genital tract 
infection [37]. There is also a statistically significant association between certain 
TLR2 haplotypes and the protection from tubal pathology on one, and development 
of late inflammatory complications on the other side (the absence of TLR2 on 
the cell surface is associated with an increase in the severity of the Chlamydia 
infection) [39] Furthermore, there is an indication that certain SNPs in genes for 
TLR4 increase the risk for infertility as a late complication of Chlamydia infection. 
Nod Like Receptors (NODs) are intracellular pathogen recognition receptors 
(PRRs) with a role in recognition of Chlamydia, carrying polymorphism in genes 
responsible for NODs has an effect on the course and the outcome of Chlamydial 
infection [40].
Chemokine receptor CCR5, essential in the activation of T-cell immune response, 
has been indicated in the development of complications associated with Chlamydia 
infection. Research investigating the effect of 32bp deletion in CCR5 gene on the 
development of complications following C. trachomatis found that women with 
positive IgG for Chlamydia without TFI had higher incidence of CCR5delta 32 
deletion compared to controls. Barr et al. demonstrated that this mutation has a 
protective effect against developing tubal pathology when both alleles are mutated 
[41].  CXCR5 chemokine receptor also appears to contribute to inter-individual 
differences in human tubal pathology following Chlamydial infection [42]. 
Chlamydia induced infertility
The most serious late complication of Chlamydial urogenital infection is infertility. 
It is estimated that 10-15% of couples worldwide have a problem conceiving, 
30% of them have subfertility issues related to tubal patency [43].  Of all the 
cases of tubal factor infertility (TFI) 45% is related to Fallopian tubes damage 
by Chlamydia trachomatis infection [44]. Chlamydia infections are characterized 
by subtle and perfidious course and, if untreated, often leading to chronicity 
[45].
Infertility is defined as “any form of reduced fertility with prolonged time 
of unwanted non-conception” [46]. More precisely is defined as 1 year of 
unwanted non-conception with unprotected intercourse in the fertile phase of 
the menstrual cycles [43]. Most clinical guidelines for diagnosis and treatment 
of subfertility agree that the time required for the diagnosis of subfertility is 12 
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months for couples of which the woman is less than 35 years old and 6 months 
in case the woman is older than 36.
The pathogenesis of TFI associated with Chlamydia trachomatis infection is not 
fully understood, however persistent infection is considered to be the most 
important mechanism behind it [38]. It is believed that multiple mechanisms of 
tissue damage are involved at different stages of pathology development. The 
immune response induced by persistent reaction either damages the tissue at 
the site of infection directly or indirectly by triggering autoimmune response 
[47].
Tubal damage and related infertility are conventionally diagnosed by 
hysterosalpingography (HSG), laparoscopy and Chlamydia Antibody Testing 
(CAT). The first two diagnostic procedures are costly and invasive. The third one is 
the most commonly used in the screening of tubal factor subfertility, its sensitivity 
for tubal pathology (of the most accurate CATs) is assessed at approximately 
50-60%, with a specificity of 85-90 % [48]. These numbers indicate that there 
is space for misdiagnosis, where some CAT negative women have in fact tubal 
pathology, and a considerable part of the CAT positive patients do not.
Aforementioned immunogenetic research about the influence of genetic 
variations in genes coding for bacterial sensing receptors, if applied in assessing 
the risk of a persistent infection and development of infertility, could have 
potential to decrease the number of false negative and false positive women. 
Clinical relevance of the TFI screening test based on genomic markers would 
be in its potential of delaying or completely avoiding the use of expensive and 
invasive diagnostic procedures in patients with low risk of having tubal pathology 
and speeding up laparoscopy investigation in patients at high risk.
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Aim of the thesis
The aim of this thesis is to explore the translation of genomic information in the 
diagnosis and treatment of infectious diseases in general and to facilitate this 
translation in diagnosis of Chlamydia induced TFI in particular.
The first objective of the thesis is to provide an overview of the basic genomic 
and genetic findings with translational potential for application in diagnosis 
and treatment of STIs. The same section also aims at exploring the role of 
biobanks in basic research of infectious disease genomics and in this process 
of translation of this basic research into clinical practice. The second part of the 
thesis focuses on the introduction of genetic testing into diagnosis of chlamydia 
induced infertility for the purpose of improvement of predictive value of testing 
by combining genetic with other diagnostic procedures. Its objective is to assess 
the health need of infertile women in the Netherlands. Additionally it explores 
strategies for the introduction of genomic biomarkers into the diagnosis of 
infertility, which would meet those needs. Finally, it evaluates the attitudes of 
the Dutch gynecologist toward the implementation of the genomic biomarkers 
into routine subfertility diagnosis.
Outline of the thesis
Overall, Part 1 (Chapters 1 and 2) of the thesis describes the state of the art on 
Public Health Genomics of infectious diseases. Traditionally Public Health aims 
at understanding, treating, controlling and preventing infectious diseases[21] 
the relatively new field of Public Health Genomics expands on these activities 
and focuses on providing timely and credible information for effective and 
responsible translation of genomics research into health benefits of population. 
Chapter 1 provides insight into the translational potential of basic genomic 
and genetic findings for Human Immunodeficiency Virus (HIV), Human Papilloma 
Virus (HPV) and Chlamydia trachomatis genital tract infections, three sexually 
transmitted diseases of significant public health relevance. Genetic and genomic 
markers found to influence susceptibility and course of these infections are 
described, and their translational potential is outlined. Chapter 2 focuses on 
the role of biobanks in genomics research in Infectious diseases. It identifies 
GENERAL INTRODUCTION
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the potential fields of interaction between infectious disease genomics and 
biobanks, with a goal of facilitating integration of genome-based knowledge into 
clinical practice.
Part 2 (Chapters 3, 4 and 5) of the thesis focuses on Chlamydia trachomatis 
induced infertility. 
Chapter 3 provides an overview of the current state of the art on host genetic 
markers found to influence the susceptibility to, and the course of, Chlamydia 
trachomatis genitourinary infection and proposes a new clinical diagnostic 
approach in subfertility diagnostics based on this overview. It also describe how 
an integrated PHG model can be of value to see if these host genetic markers 
can be translated from the lab to the market and implemented into public health.
Chapter 4 identifies clinical services currently in place in diagnosis and 
treatment of subfertility in the Netherlands, it defines the target population which 
could benefit from the addition of genetic testing in the diagnosis of infertility 
and assess their health needs. Finally, in this chapter the potential of genomic 
testing in meeting these health needs of the target population is explored.
Chapter 5 examines the attitudes of the Dutch gynaecologists towards 
the addition of genetic testing in the screening for TFI caused by Chlamydia 
trachomatis.  In the first phase of the study we performed interviews with 
experienced reproductive specialists working in 4 Dutch Academic Hospitals. 
The results of the interviews were used to develop a questionnaire for the Dutch 
gynaecologists about their attitudes towards the addition of genetic testing in 
the diagnosis of TFI. In the second phase, using the questionnaire, we surveyed 
48 doctors providing fertility care in 3 Dutch Academic hospitals in order to 
investigate what they perceive to be major challenges and major facilitating 
factors in introducing genetic testing in routine fertility work up.
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Abstract
Individual variations in susceptibility to an infection as well as in the clinical 
course of the infection can be explained by pathogen related factors, 
environmental factors, and host genetic differences. In this paper we review the 
state-of-the-art basic host genomic and genetic findings’ translational potential 
of human immunodeficiency virus (HIV), Chlamydia trachomatis (CT), and human 
papillomavirus (HPV) into applications in public health, especially in diagnosis, 
treatment, and prevention of complications of these infectious diseases.  There 
is a significant amount of knowledge about genetic variants having a positive 
or negative influence on the course and outcome of HIV infection. In the field 
of Chlamydia trachomatis, genomic advances hold the promise of a more 
accurate subfertility prediction test based on single nucleotide polymorphisms 
(SNPs). In HPV research, recent developments in early diagnosis of infection-
induced cervical cancer are based on methylation tests. Indeed, triage based on 
methylation markers might be a step forward in a more effective stratification of 
women at risk for cervical cancer.  Our review found an imbalance between the 
number of host genetic variants with a role in modulating the immune response 
and the number of practical genomic applications developed thanks to this 
knowledge.
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Introduction
Infectious diseases represent a major health threat worldwide and a significant 
part of the burden of disease in developing countries [1]. Public health policy has 
traditionally had an important role in tackling such threat through established 
measures of prevention, mostly by controlling social and environmental 
determinants of health and through vaccination. With the recent advances in 
public health genomics, public health moved its focus from a “one size fits all” 
approach in health promotion and prevention activities to targeting populations 
and subpopulations with defined genetic risks and developed its unique role, 
translation of genome-based knowledge and technologies into public health 
policy and practice, and its integration across disciplines [2]. Scientific 
developments in basic research and the development of public health genomics 
have changed many paradigms regarding infectious diseases. Indeed, the 
recent evidence of genetic factors in the pathogenesis of infectious diseases 
transformed the view of such diseases from strictly pathogen-centric to the 
one incorporating host genetic determinants that modulate immune response. 
Though research in the field of genetic susceptibility to infectious diseases 
started in 1954, recent progress in genomics led to the characterization of 
molecular biomarkers and pathways as targets for diagnosis and intervention 
[3]. Furthermore, this understanding of infectious diseases explains the 
individual variation in susceptibility to an infection as well as the clinical 
course of the infection by pathogen related factors, environmental factors, 
and genetic differences.  The field identifies genes responsible for influencing 
susceptibility to infections as well as their severity and response to treatment. 
This is predominantly achieved by studying candidate genes, genome wide 
associations, and twin studies [4].  A great amount of effort and resources 
have been directed to obtaining knowledge about host genetic components of 
infectious diseases and to confirm associations in order to develop genomic 
applications in everyday clinical practice and prevention.  Nonetheless, although 
the amount of genetic data in relation to disease is increasing exponentially [5, 
6], there is a clear lack of translation of such findings to healthcare applications. 
Indeed, the amount of information about basic genome-based scientific findings 
present in the scientific journals is disproportionate to the number of patents 
and marketed products used in hospitals [7].  In this paper, priority was given to 
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three sexually transmitted diseases of significant public health relevance: HIV, 
HPV, and Chlamydia trachomatis (CT) genital tract infections.  The aim of this 
review is to provide a state-of-the-art overview on the translational potential of 
basic genomic and genetic findings related to HIV, CT, and HPV infections, into 
applications in public health focusing on their diagnostics and treatment.  
Methods
Based on our field of expertise in sexually transmitted diseases (STDs) we 
selected the most prevalent bacterial STD Chlamydia trachomatis (CT) and 
the 2 most prevalent viral STDs Human Papilloma Virus (HPV) and the Human 
Immunodeficiency Virus (HIV) knowing that from these infectious diseases 
human genetic and genomic markers are described.  
We used the HuGE Navigator (Version 2.0: an integrated, searchable knowledge 
base of genetic associations and human genome epidemiology (http://
hugenavigator.net/)) [8]  to identify papers with a description of potential 
translation on the basic findings of genetic and genomic markers into diagnostic 
applications and ultimately into public health.  Identified papers and authors 
were expanded using PubMed searches. For each infectious disease a general 
introduction will be given, the key genetic and genomic markers will be 
described, and the translational potential outlined. Finally, a general discussion 
and conclusions will be provided.
Results
HIV
Despite the decrease in incidence of HIV infection (in 2009 the number of newly 
infected individuals dropped by almost 20% compared to the previous year), 
the prevalence of HIV is still very high. At the end of 2009, it was estimated 
that there were 33.3 million people living with HIV.  The growing prevalence and 
the reduction in the AIDS-related mortality are mainly attributed to the success 
of antiviral therapy [9]. Nonetheless, the public health relevance of the disease 
remains indisputable, as tackling HIV requires large financial expenditures, and it 
is still among the sexually transmitted diseases causing the highest morbidity and 
mortality and it is highly preventable [10].  As mentioned earlier, research in the 
CHAPTER 1
31
field of infectious diseases has established that the susceptibility of an individual 
is also modulated by host genomic factors. In this context, recent genomic and 
genetic discoveries using candidate gene and genome wide association studies 
(GWAS) increased our knowledge of the association among genetic loci from 
the so-called “major susceptibility genes.” HIV infection is the most studied 
infection by the aforementioned approaches. The research of a genetic role 
for the individual differences in the course of infection, besides offering new 
strategies for developing a treatment or a vaccine, also provides basic insights 
in the immunopathology of the infection. Moreover, this newly collected evidence 
could provide an opportunity of identifying persons at higher risk of getting 
or progression of the infection. On the other hand, this could detect patients 
having genes that make them long-term non-progressors, thus with delayed or 
no progression to AIDS.
Review of the Host Genetic Variants Found to Influence HIV infection
The review of papers written by the experts in the field of host genomic 
determinants of infection, disease progression, and disease outcome reveals the 
growing body of host genomic “suspects” by the year.  However, few associations 
were positively confirmed. Among these, only 15–20% of observed genetic 
variants have been identified as influencing HIV infection [11].  Many studies 
and reviews place genetic variants of chemokine receptor and chemokine ligand 
genes, HLA and related genes on top of the list of influential genetic factors 
identified in HIV infection [11-16].  Chemokine receptors have an important 
role in modulating HIV-1 early infection. Particular attention has been given 
to CCR5 and CCR2 genes, encoding co- receptors on the surface of the CD4+ 
lymphocytes, crucial for HIV cell entry. In the initial stages of the infection, the 
HIV virus uses CCR5 as a preferred co -receptor [15].  As a result, a mutation in 
the chemokine receptor genes resulting in the absence or significant reduction 
of CCR5 molecules on the cell surface would have a protective effect. Indeed, 
the expression level of this co-receptor influences the HIV infection outcome, 
and mutation of this molecule is associated with the ability of the virus to enter 
the cells in vitro, the in vivo viral load, the CD4+ levels during highly active anti-
retroviral therapy (HAART: combination of three or more antiviral drugs), and 
the progression of the diseases to AIDS.
In 1996, it was discovered that the deletion of 32 base pairs of CCR5 
(CCR5Δ32) results in shortened and inactive proteins. So far, CCR5Δ32 remains 
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the only discovered mutation that completely protects homozygotes from HIV 
infection and in heterozygotes slows down the progression of the disease [11]. 
Moreover, the discovery of CCR5Δ32 genetic variant opened the door for the 
development of a new type of anti-HIV medications.  Data obtained fromCCR5 
gene candidate studies have been rather timely applied in the pharmaceutical 
industry, leading to the development of novel therapies, as further discussed in 
the next section. In addition, the association between the +190 A>G mutation 
of CCR2 chemokine receptor and the delayed onset of AIDS was discovered in 
1997.  The resulting substitution of the amino acid Valine, at the position 64 of 
CCR2, to isoleucine influences HIV progression, but not the risk of HIV infection. 
HIV positive patients carrying this mutation showed delayed progression to 
AIDS by 2–4 years [17].
Application of Research Based on Chemokine Receptors 
As stressed earlier, the major goal of the research on host immunogenetics of 
HIV is to acquire knowledge of how differences in genetic variants are influencing 
individual susceptibility to infection and developing new drugs based on that. 
The research provided insights into the effects of CCR5 co-receptor blockade 
and down regulation on HIV infection [18].
As a result drugs with a new mechanism of action, the blockage of CCR5 receptors, 
were developed. These drugs are also known as entry inhibitors. So far there are 
only two approved such drugs in clinical use, Maraviroc (Pfizer) and Enfuvirtide 
(Roche) [19, 20]. Of the two, Enfuvirtide was the first to be FDA approved. The 
success of this drug, despite its proven antiviral efficacy in patients’ treatment, 
was constrained by the difficulties related to its subcutaneous administration, 
causing skin abscesses.  The first orally administered HIV entry inhibitor was 
Maraviroc, approved by the FDA for patients with R5 virus types in 2006. The 
drug binds to the CCR5 chemokine receptor causing a conformational change 
that blocks the gp41-mediated fusion of viral and cellular membranes [19]. 
The next most promising HIV entry inhibitor is Vicriviroc (Schering-Plough), a 
medicine with the same action mechanism as Maraviroc, but expected to be 
more effective. Vicriviroc has still not been approved by FDA, but phase III 
clinical trials have been recently completed [21].  A recent extensive review 
of HIV-1 entry inhibitors patented from 2004–2010, [20], revealed 35 small 
CCR5 antagonist molecules patented by 5 different pharmaceutical companies 
(Astra Zeneca, ViroChem Pharma, Anormed, Inc./Genzyme Corp., Euroscreen, 
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and Ono Pharmaceuticals).  In the same review, it was found that the number 
of patents for CXCR4 (co-receptors for X4 HIV strains) antagonists and dual 
CCR5/CXCR4 antagonists is significantly lower. Further, clinical developments 
of CXR4 antagonists have been delayed in preclinical and clinical studies due 
to serious side effects (cardiac abnormalities and liver toxicity) or lack of drug 
efficacy.  Human Leukocytes Antigen (HLA) genes encode proteins that present 
antigens to T and B lymphocytes.  There are two classes of HLA genes: class I 
(loci A, B, and C) and class II genes. A strong association has been observed 
between HLAI alleles and protection/susceptibility to HIV [22].  The effect of 
HLA A, B, and C homozygosis in general is accelerated AIDS.  Other confirmed 
associations include HLA alleles B*27 and B*57 and delayed progression to 
AIDS [15,16] [22, 23].  On the other hand, the B*35 allele is associated with 
increased susceptibility and more rapid progression of the disease.  The median 
time in which homozygous carriers of the B*35 allele develop AIDS is half the 
time of non-carriers of such alleles [24].
The association between genetic variants of HLA class I loci and CCR5 and 
the pathogenesis of HIV infection has been confirmed in recent years by many 
GWAS studies.  However, GWAS did not identify further major susceptibility loci 
[25].  Association studies between HLA class II alleles and the susceptibility to 
the HIV infection has been less consistent.  HLA genes have also been shown to 
have a role in the Mother to Child Transmission (MTCT) of HIV infection.  Indeed, 
HLA class I concordance between mother and child is associated with higher risk 
of transmission, vice versa HLA discordance is associated with a lower risk [16]. 
Application of Research on HLA Genes
Although none of the mentioned HLA genes have yet been identified as a target 
for new drugs, the information gathered on the disease progression modulated 
by different genotypes has provided valuable information for clinical trials [22]. 
Research on HLA alleles led to important pharmacogenetic applications.  HLA 
B*5701 positive patients, who are at risk for hypersensitivity to Abacavir (a 
nucleoside reverse transcriptase inhibitor), cannot be treated with this drug. 
This serious, and possibly fatal, adverse drug reaction is present in 5% of 
patients [26].  Genetic testing of all the individuals before prescribing the drug 
prevents serious side effects, building a very strong case for a stratified medicine 
approach, tailored to individual genetic characteristics. The idea behind it is that 
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our personal genetic differences create a need for accordingly different treatment 
approaches. In the case of Abacavir recognizing interpersonal variation in 
reaction to drug is an excellent example of stratifying HIV treatment based on 
genetic research.  In summary, HIV immunogenetic research provided some 
basic insights into the immunopathology of the infection and gave foundations 
to the development of new drugs for the therapy of the infection. Ideally this 
will be just the first step in advancing therapies. Information on individual 
susceptibility, higher or lower individual risks, and delayed or accelerated AIDS 
progression associated with certain gene variants will make a more individually 
tailored treatment possible in the future.
Chlamydia trachomatis
Chlamydia trachomatis is a leading cause for a variety of diseases including 
ocular, respiratory, and sexually transmitted diseases. This section of the 
review will only focus on the latter, since sexually transmitted Chlamydia 
infections are the most common worldwide, whereas, for instance, ocular 
infections are mostly seen in third world countries.  Host genetic twin studies 
of Chlamydia have shown that 40% of the responses to Chlamydia are based 
on host genetics [27]. According to the WHO, “more cases of STD are caused 
by Chlamydia trachomatis than by any other bacterial pathogen” [28].  The 
persisting high incidence of 90–100 million cases per year worldwide makes 
Chlamydia trachomatis infection an enormous health problem throughout the 
world.  The bacteria can be easily eliminated by antibiotic treatment; however, 
as a result of often being asymptomatic, the infection is frequently diagnosed 
too late or not at all.  Infertility, premature delivery, PID, and ectopic pregnancy 
are some serious sequelae of the untreated infection [29]. Evaluation of the 
casual link between Chlamydia lower genital tract infection and tubal infertility 
is very challenging due to the fact that this is a “silent” complication, usually 
diagnosed years after the infection [30]. Infected women can either clear the 
bacteria without any damage to their reproductive functions or develop severe 
late complications, such as tubal occlusion and periadnexal adhesions, leading 
to infertility as the most severe of complications. The differences in disease 
outcome are often determined by genetic variations, such as single nucleotide 
polymorphisms (SNPs) in genes responsible for, amongst others, bacterial 
sensing receptors (and the pathways to which they belong) on cells such as 
macrophages as well as local vaginal and tubal epithelial cells. The higher the 
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number of genes affected by SNPs, the more abnormal the immune response, 
leading to a higher chance of severe complications [31]. Inadequate recognition 
of the pathogen and consequent inadequate immune response lead to a higher 
risk of subfertility [32]. In a research performed on Gambian twins [27], it was 
estimated that 40% of variation in Chlamydia infection characteristics could be 
explained by differences in host genetic factors.
Review of the Host Genetic Variants Found to Influence Chlamydia Lower 
Genital Tract Infection
TLR Receptors
Toll-like receptors (TLRs), with their role in identifying pathogens and initiating 
innate immune response, have been recognized as the most important factors 
in influencing differences in susceptibility to course and outcome of Chlamydia 
infection [33, 34]. Indeed, much of immunogenetic research in this field is 
focused on TLR genes and genes involved in their pathways, not only by mRNA- 
and protein-based studies but also by studying the association between SNPs 
in TLR genes leading to the loss of function of the receptors and the potential 
higher risk of late complications such as tubal infertility.  The application 
of such research could be in the area of early diagnosis of tubal infertility or 
subfertility. Based on this evidence, the time now being lost as a result of late 
or misdiagnosis of tubal infertility could be directed to IVF attempts.  So far, 
there are 10 TLRs identified in humans, recognizing different bacterial and viral 
components.  TLRs activate signaling pathways of immune response against 
different pathogens by activating different inflammatory cytokines [35]. TLR2, 
TLR4, and TLR9 recognize pathogen-associated molecular patterns (PAMPs) 
of Chlamydia trachomatis.  Genes for TLR receptors 2 and 4 are considered 
particularly important in modulating innate immune response to Chlamydia 
trachomatis [36].  Several studies showed that SNPs in TLR4 have a role in 
making women more prone to subfertility as a late complication of Chlamydia 
infection. Nonetheless, the exact role of TLR4 in subfertility has not been yet 
clearly understood [33, 34]. Subfertile women who have IgG antibodies for 
Chlamydia trachomatis have a two times higher likelihood to be carriers of 
the TLR4 +896 A allele, compared to women without tubal pathology [34]. 
Although this observation was not statistically significant, reported trends 
suggest that it could be worthwhile to further explore it in a larger cohort. 
Further, murine studies showed that TLR4 functional mice are more protected 
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against reinfection compared with mice with dysfunctional or absent TLR4 [36]. 
In their study of genetic variants involved in the immune response regulation in 
genetic tract infections, Laisk et al. found that the TLR4 +896 A>G and +1196 
C>T polymorphisms protect against multiple infections with C. trachomatis, N. 
gonorrhoeae, M.  hominis, M. genitalium, U. parvum, and U. urealyticum.
Depending on the patient definition (i.e., including or excluding C. trachomatis 
serology), they found that specific MBL2 high producing haplotypes can have a 
protection of a risk effect in tubal factor infertility. Low-producing MBL2 haplotypes 
are associated with C. trachomatis serology positive tubal factor infertility 
patients [36].  In their study on the role of TLR2 and TLR4 in the development of 
tubal pathology on knock out (KO) mouse models, Darville et al. [33]  showed that 
the amount of cytokines produced by macrophages depends on TLR2 but not on 
TLR4 receptors. Indeed, the deficiency of TLR2 receptors is associated with a 
decreased production of cytokines in vitro.  In vivo, the deficiency or absence of 
TLR2 causes lower levels of inflammatory mediators, but the course of infection 
does not differ compared with naΪve animals.  Microscopic examination of the 
tubal tissue showed that mice with intact TLR2 are, however, more prone to 
the development of late inflammatory sequelae. Finally, their study concluded 
that TLR4 does not modulate innate immune response to Chlamydia, whereas 
in vivo experiments on TLR2 indicated its important role in protection against 
late inflammatory sequelae following Chlamydia genital tract infection [33].  In 
a study aiming at understanding the role of two TLR2 SNPs in the susceptibility 
to infection and contribution to the development of the tubal pathology in Dutch 
women, Karimi et al. [37] revealed a statistically significant association between 
certain TLR2 haplotypes and protection from tubal pathology and development of 
the late inflammatory complications (the absence of TLR2 is associated with an 
increase in the severity of the Chlamydia infection).  As already mentioned, most 
of the studies assessing host genetic determinants of Chlamydia infections are 
focusing on the extracellular TLR2’s and TLR4’s contribution to the differences in 
the susceptibility and severity of the infection.  However, there is also an interest 
in the relevance of the intracellular TLR9.  So far, human cohort data have not 
shown significant differences between carriers of mutant alleles and controls in 
the susceptibility to infection, course of the infection, or frequency of later tubal 
pathology.  On the other hand, experiments in mice models found that TLR9-
deficient mice had a higher level of protection against reinfection [38].  
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HLA Alleles 
In addition to the research directed at TLR genes, there are also indications of 
association between tubal infertility caused by Chlamydia trachomatis and HLA 
alleles.  Cohen et al. [39, 40] found that alleles of the HLA-DQ, DR1, and DRB5 
loci modulate the severity of Chlamydia infections. Kinnunen et al. also found 
that specific HLA-DQ alleles are more frequently present in women with tubal 
infertility [41].
Besides the TLR and HLA alleles, in 2009, Morré  et al. published an extensive 
overview of the then known genetic variants influencing susceptibility and 
severity of Chlamydia infections including SNPs in cytokines and other pathogen 
recognition receptors like NODs [42].
Application of Research. 
Immunogenetics research on Chlamydia trachomatis indicates that a proof of 
principle for the successful application of genetic and genomic markers for the 
prediction of late complications after the infection could have a strong public 
health impact.  Subfertility poses an enormous burden on healthcare and society 
throughout the world. Worldwide, 15% of couples trying to conceive suffer from 
subfertility [43, 44].  One of the major causes of female subfertility is tubal 
pathology (TP) [43], and CT is the single most common cause for infertility.  If 
left untreated, CT may lead to ectopic pregnancy, tubal pathology, and ultimately 
infertility. The cost associated with subfertility is high, as it requires tubal surgery 
and in vitro fertilisation (IVF).  Currently, CT IgG serology is used to assess the 
risk of CT-associated TP in subfertile women (20%) (Figure 1) [45, 46]. 
CT serology has limited sensitivity and specificity and the predictive value is 
poor thus, many women undergo additional diagnostic procedures while not 
needed (40–45%) or do not get intervention while needed (19%).  Laparoscopy 
is widely used to assess the risk of TP in women positive for CT IgG. 
38
Figure 1: Current serology protocol for subfertility resulting from CT infection. Women with a negative 
CT serology are advised to try to conceive for one year; however, 20% of those women actually have 
tubal pathology and are thus misdiagnosed. Of the women with a positive CT serological test, 40–
adapted from Lal et al. [60].
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This procedure is invasive and expensive (on average 3000 Euros including 
additional costs) and requires general anaesthesia.  Furthermore, it holds a 1.5% 
risk of surgical complications (e.g., bleeding, infection, or worse).  Therefore it 
is crucial to develop a companion diagnostic to improve the assessment of risk 
of TP in CT-positive and negative women. By doing so, one is able to prevent 
invasive procedures in patients without TP and reduce both the cost and the 
psychological burden associated with laparoscopy.  This companion diagnostic 
should merge serology, taking into account serological positivity and titres and 
considering new serological responses (e.g., pgp3) [46] and add the predictive 
value of host genetic markers involved, for example, related to the innate 
immune response to pathogens.  The genetic trait should consist of a series of 
markers with a so-called SNP load or gene load linked to decision making for 
performing laparoscopy or not. Future studies should be directed at performing 
studies in larger cohorts to access the true clinical potential of this approach.  
HPV 
Roughly 20% of cancers are linked to various infectious agents [47]. Human 
papilloma virus (HPV) is one of these agents, and the role of different HPV 
subtypes in the etiology of cervical cancer has been well established [48].  HPV 
infections are in most cases cleared by the actions of the immune system within 
one year and often remain asymptomatic throughout that period.  However, 
a small percentage of the infections eventually lead to some form of cancer. 
HPV-induced cancers account for approximately one third of all cancers caused 
by infectious agents [49], and HPV is considered to be the most common 
sexually transmitted infectious agent [50]. However, studies have shown the 
existence of nonsexual modes of HPV transmission (including transplacental 
and transmission via fingers and objects [51–53]), and therefore, HPV cannot 
be referred strictly to as an STI [51].
The HPV virus infects skin or mucosal tissues in the anogenital area or the 
region of the head and neck.  So far more than 100 types have been reported 
[49].  It has however been proven that approximately 15 out of these 100 types 
cause virtually all cases of cervical cancer [54]. Moreover, HPV types 16 and 
18 account for around 70% of cervical cancer cases, and they—particularly 
type 16—have also been identified in anal, as well as some head and neck 
cancers [55].  The strong association between HPV infection and cervical 
carcinogenesis makes cervical cancer preventable, thus fulfilling an important 
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criterion for public health relevancy.  With the introduction of HPV vaccines, a 
major breakthrough in prevention has been made. Vaccines proved to be safe 
have been implemented in many countries.  
Of all the women who are infected with HPV, only a small percentage develops 
cervical cancer. This observation suggests a role of host genetic factors 
The Role of HLA. Alleles have been reported to be associated with the 
development of HPV-related cervical cancer. In their review of evaluating this 
association, Hildesheim and Wang [57, 58] found several alleles of HLA class 
II to be associated with higher risk of developing cervical cancer (DQB1*03 
alleles and DRB1*1501, DQB1*0602).  As for HLA genetic variants’ protective 
are associated with it [57, 58]. Associations between HLA and HPV infection 
and progression to cancer are reported to be population- and HPV type-
dependent. Indeed, HLA DQB1*0301 allele carries an increased risk of cervical 
cancer in the British population in case of infection with all HPV subtypes 
of HLA DRB1*1602 with susceptibility to infection [59].
In their recently published review of the genetic susceptibility to cervical 
cancer, Chen et al. [61] presented the most important genetic polymorphisms 
in addition to HLA genetic variants, genes encoding interleukin-1 , tumor 
necrosis factor   ,  interleukin-2 A and B, interferon-   , interleukin-10, cytotoxic 
t-Lymphocyte antigen-4, p53, BRCA1, and LAMB3 as genes associated with 
persistent HPV infection and progression to cervical cancer [61]. In addition, 
certain genes encoding killer immunoglobulin-like receptors (KIR) also seem to 
be associated with cervical cancer [62].
So far, no genetic or genomic applications have been developed based on these 
strategy known as methylation takes the lead.
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The Role of Methylation
Methylation is a common mechanism through which the silencing of genes, and 
among these tumor-suppressor genes, can be achieved [63].  It represents a 
chemical alteration in regions of DNA referred to as “CpG islands,” commonly 
found in many promoter regions. The alteration leads to the inhibition of 
the transcription of genes controlled by such methylated promoters [64]. 
Methylation markers are easily detected in cervical scrapes, with, for example, 
methylation-specific PCR (MSP).  Hence, positive MSP results in these samples 
are indicators of methylation of relevant genes in the tissue [64].  At the 
moment, the strategy for early detection of cervical neoplasia in screening 
programmes is cervical scraping cytomorphologic assessment (PAP test), which 
has a considerably low sensitivity. Data on sensitivity and specificity of the PAP 
test are highly heterogeneous. Depending on the study done and combination of 
tests and reference standard thresholds applied, they range from 18% to 98% 
for sensitivity and from 17% to 99% for specificity [65].  Furthermore, the 
National Cancer Institute assessed the sensitivity of the PAP smear to be 55–
80% for high grade lesions and around 68% for low grade lesions [66]. Taking 
this into consideration, there is a need for the development of novel approaches, 
and additional tools based on methylation markers might be a step forward.
Application of Methylation in Triage of Cervical Carcinomas.
In the study by Henken et al. [64], 29 tumor-suppressor genes were analyzed 
as potential methylation targets, and 12 of them were found to have methylated 
gene promoters in cervical cancer tissue.  Eight of those were also associated 
with consecutive stages in HPV-mediated transformation in vitro.  The promoter 
that was most commonly methylated (in 92% of the examined carcinoma 
samples) was MGMT.
Methylation of the promoters CCNA1 and C13ORF18 in cervical scrapings is 
found to be strongly associated (  < 0.0005) with CIN2 (moderate cervical 
intraepithelial dysplasia) and higher grade stages of cervical dysplasia, as was 
determined in the study by Yang et al [67]. Hence, these would be suitable 
markers for a triage test, referring a patient to a gynecologist upon a methylation-
positive result.  The more severe the lesion in the sample, the more methylation 
was present in these two gene promoters.  
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Figure 2: Introducing methylation as an addition to the primary hrHPV test would lower the 
number of unnecessary referrals to gynaecologists. Figure based on Yang et al. [67].
and 100%, resp.), as well as high positive predictive value.
Further, Yang et al. [67] suggest that their methylation test should be used 
preventing invasive cervical cancer; however, it is considered to be less sensitive 
than cytology in detecting CINs.  Introducing methylation as a part of a triage 
test to the primary hrHPV test would lower the number of unnecessary referrals 
to gynaecologists; especially in younger women who tend to be over diagnosed 
[68] (see Figure 2).
In another study evaluating the potential value of the methylation markers 
CADM1 and MAL as a triage tool for hrHPV+ women, it was found that there 
of combining methylation patterns in the promoter region of more than one 
suppressor gene with the aim to increase the sensitivity for high grade CINs.  A 
methylation-based test focuses on later phases of the carcinogenesis, given that 
these promoter alterations increase in these late stages.  However, methylation-
driven silencing of MAL promoter takes place at a very early point, before HPV-
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positive keratinocytes undergo tumor transformation. Whereas, silencing of 
CADM1 promoter by methylation correlates more with late stages. Overmeer et 
al. demonstrated that this marker combination is optimal for detection of CIN3 
lesions [69].  In the process of progression into late stages, there are genes other 
than oncogenes and tumor suppressors also relevant. MicroRNAs (miRNAs) are 
short noncoding RNA molecules, which act in regulating expression of protein 
coding genes, by pairing with sequences within such genes.  hsa-miR-124 is an 
miRNA known to be silenced by methylation in many cancers, and Wilting et al. 
(2010) proved that this mode of silencing frequently occurs in cervical lesions 
as well [70].  No methylation was found in normal tissues, while almost 60% 
was detected in CIN3 lesions, and more than 93%methylation of hsa-miR-124 
was present in cervical carcinomas.  The methylation of this gene is not directly 
related to the presence of hrHPV. High positivity is however observed in CIN3 
and cervical carcinomas, which altogether makes it a potentially very useful 
triage marker for hrHPV positive women. This applies however not for setting 
where HPV genotyping is not implemented yet including under development 
countries.  Triage could serve as an additional step that would more aptly bridge 
screening and diagnosis in order for a better stratification of women at risk to be 
achieved [71].  It would be used on those with positive primary screening results 
to determine the further risk of the progression into later stages.  The effects of 
constructing this type of triage test based on methylation would be expected to 
land a formidable impact on policies that currently regulate screening intervals. 
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Discussion and Conclusion 
To our knowledge, this is the first review on the translational potential of basic 
genomic and genetic findings for HIV, CT, and HPV into applications in public 
health and in diagnostics, treatment, and prevention of late complications of 
these infectious diseases.  We found scarce examples of the current application 
of genomic/genetic findings, in pharmacogenomics, and we found examples 
of genomic information with a promise of translation in the near future.  In 
our review, we did not focus on analytic validity, clinical validity, and clinical 
utility and other criteria generally considered to be the most important factors 
in evaluation of the genetic/genomic applications [72]. Since there are still 
no market-ready applications, so the aforementioned criteria could not be 
considered; we focused on an earlier step of this process.  We focused on the 
promising examples of translation of the discovery into a possible application.
Based on the review of the relevant literature some examples can be considered 
promising.  The genes responsible for susceptibility to HIV infection can be 
basically divided in two groups, chemokine receptors genes and HLA genes. 
So far, the discovery of the CCR5Δ32 genetic variant opened the door for the 
development of new anti-HIV drugs. Although undoubtedly a very important 
step forward, CCR5 targeted therapy and the research behind it are just one 
of the possible applications of immunogenetic information. Indeed, there is a 
significant amount of knowledge of certain genetic variants having a positive 
or negative influence on the course and outcome of HIV infection.  Possible 
future use of the knowledge about the expected course of the infection would be 
advancing the standard of care and therapy after routine genetic testing.
In the field of Chlamydia trachomatis caused subfertility there is a promise for a 
more accurate subfertility diagnosis based on SNPs.  Research showed that SNPs 
in TLR4 possibly increase the risk of tubal pathology. Specific TLR2 haplotypes 
are associated with protection from tubal pathology and development of the 
late inflammatory complications.  These findings, together with the one carrying 
multiple SNPs in multiple pattern recognition receptors’ (PRRs) encoding genes 
(TLR9, TLR4, CD14, and CARD 15/NOD2) doubles the risk of tubal pathology 
in Chlamydia trachomatis IgG-positive women compared to IgG-positive women 
carrying less than two SNPs, offer a proof of concept for the development of 
a genomic application in diagnosis of subfertility.  A genetic test as a part 
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of routine subfertility diagnosis should be able to save time and money by 
decreasing the number of unnecessary laparoscopies and the time patients 
unsuccessfully spend trying to get pregnant.  In the field of HPV, there are some 
promising advancements in the early diagnosis of cervical cancer based on 
methylation tests.  The methylation markers CADM1 and MAL were found to 
be an optimal combination for the detection of CIN3 lesions [69]. Moreover, 
the methylation of CCNA1 and C13ORF18 in cervical scrapings is found to 
be strongly associated with CIN2 and higher grade stages [67].  A triage test 
based on such methylation markers might be an important step towards a more 
effective stratification of patients at risk for cervical cancer.  The knowledge 
about the gene-disease associations should lead to growing numbers of genetic 
tests, which will in the future have an increasingly important role, in tailored 
clinical and drug treatment.  However, in order for this translation process to 
succeed, the wide consensus among scientists, clinicians, policy makers, and 
the industry on necessity of going in this direction needs to be achieved [73]. 
Based on what we have shown here, there are many host genetic variants found 
to have a role in modulating the immune response to HIV, HPV, and Chlamydia 
infections.  However, we found an imbalance between the number of host 
genetic variants with a role in modulating the immune response and the number 
of practical genomic applications.  Thus, such new knowledge and technologies 
from basic research are not yet integrated in health in a timely, effective, and 
efficient manner [7].
This imbalance, the lack of translation from bench to bedside, is in favor of basic 
research that seems to be somewhat hermetic in quality, revealing confirmed 
positive association with a certain genetic variant and not exploring the future 
implications of these findings, should not represent a norm in the field.  The next 
step is needed in which gene-disease association leads to the development of 
the genetic/genomic application.  Starting with interdisciplinary collaboration 
is very important in the process of evaluation of role of genetic variants in the 
etiology of human diseases [74].  There are some clear and well-supported 
genetic associations with particular infectious diseases; these should be driving 
forces of the successful translation process.
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Abstract
Biobanks are invaluable resources in genomic research of both the infectious 
diseases and their hosts. This article examines the role of biobanks in basic 
research of infectious disease genomics, as well as the relevance and applicability 
of biobanks in the translation of impending knowledge and the clinical uptake 
of knowledge of infectious diseases. Our research identifies potential fields of 
interaction between infectious disease genomics and biobanks, in line with global 
trends in the integration of genome-based knowledge into clinical practice. 
Furthermore, it examines various networks and biobanks that specialize in 
infectious diseases (including HIV, HPV and Chlamydia trachomatis), as well as 
examples of successful research and clinical uptake stemming from biobanks. 
Our article also outlines key issues with respect to data privacy in infectious 
disease genomics, as well as the utility of adequately designed and maintained 
electronic health records. We maintain that the public should be able to easily 
access a clear and detailed outline of regulations and procedures for sample 
and data utilization by academic or commercial investigators, and also should 
be able to understand the precise roles of relevant governing bodies. This would 
ultimately facilitate uptake by researchers and clinics. As a result of the efforts 
and resources invested by several networks and consortia, there is an increasing 
awareness of the prospective uses of biobanks in advancing infectious disease 
genomic research, diagnostics and their clinical management. 
Key words: biobank; infectious disease; host genomics; HIV; HPV; Chlamydia 
trachomatis  
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Introduction
Over time, the definition of a “biobank” has moved away from an early view of 
a biobank as population-based to include a wider typology of biobanks that we 
find in the literature today.  In a survey conducted in 2012, researchers involved 
in managing sample collections were asked about their definition of biobanks. 
The results of the survey showed the consensus among respondents that the 
term biobank may be applied to biological collections of human, animal, plant 
or microbial samples. Additionally, the term biobank should only be applied 
to sample collections with associated sample data, and to collections that are 
managed according to professional standards [1]. 
In post-Human Genome Project research, the role of biobanking as a component 
of research infrastructure is broadening, as knowledge from biobanks contributed 
to the understanding of the etiology of multifactorial diseases caused by both 
mutations in a variety of genes and the influence of environmental factors and 
lifestyle [2, 3]. Furthermore, biobanks have paved the way for the evolution of 
personalized medicine, especially the development of “tailored” drugs [4]. In 
recent years, integration, analysis and interpretation of data originating from 
biobanks have begun to play a growing role in our understanding of genetic 
susceptibilities of infectious diseases. The actuality of infectious diseases and the 
perpetual challenge they pose for researchers and physicians is reflected in both 
the high prevalence and the high mortality of existing and growing incidence of 
emerging infectious diseases [5]. In fact, infectious diseases represent a major 
health threat worldwide, and are a particularly significant burden to developing 
countries [6].
The importance of genetic factors in the pathogenesis of infectious diseases has 
transformed our understanding of such diseases by incorporating host genetic 
determinants that modulate immune responses as factors of pathogenesis. 
We now understand that host responses can determine the outcome of an 
infection as much as - if not more than - the properties of the pathogen itself [7]. 
Genomics outlined molecular biomarkers and pathways as targets for diagnosis 
or intervention in the field of infectious diseases [8]. Relations between genetic 
factors and susceptibility to the course and the outcome of infectious diseases 
are predominantly studied through candidate genes, genome wide associations, 
and twin studies [9]. This research means that biobanks (especially large 
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international networks of biobanks driven by the needs of researchers, who 
require large collections of samples) are an imperative infrastructure for 
research in host genomics [10].
According to Gotweiss and Zatloukal [4], there are four main types of biobanks:
clinical case/control biobanks, which contain biological samples taken from 
patients with specific diseases and from healthy control patients
population-based biobanks, which contain samples from smaller or larger subsets 
of a population with or without a certain disease;
population isolate biobanks, which contain homogenous genetic material of the 
population represented; and
twin registries, which contain samples from monozygotic and dizygotic twins.
Biobanks contain both samples and data; this twofold nature is the root of 
much of the legal and ethical controversy surrounding biobanks today. Issues 
concerning privacy health-related information, informed consent, secondary 
use of samples, and harmonisation of legislation and networking of biobanks are 
often researched in conjunction with the term “biobanking” [11]. The potential 
impact of biobank-generated knowledge (and its becoming an integral part 
of public health policies) on our understanding of the etiology of disease, on 
improving diagnosis and treatment, and ultimately on the health of individuals 
and populations as a whole has been largely ignored thus far [3].
Uses of biobanks for public health are [2]:
- timely, responsible and effective integration of genome-based health 
technologies and information into health research, policy and practice;
- supporting the translational process from basic knowledge generated 
in existing biobanks to the development and implementation of health 
policies, interventions and programs;
- recognizing the multi-tasking nature  of biobanks in the accommodation 
of different needs by enhancing the ability of biobanks to serve 
researchers and other relevant stakeholders with particular public 
health perspectives. 
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In 1990, Lee identified what he considered to be the ideal properties of a 
biospecimen bank: a secure, ongoing source of funding; a cryogenic storage 
facility; selection criteria for obtaining and keeping the best samples in storage; 
and ensuring the continuation of research to optimize the collection and handling 
of samples [12]. De Paoli [13] also identified what he considered to be the main 
roles of biobanking in microbiology research: 
- to enable unfettered epidemiological research: prospective use of 
biobanking is key to detecting and tracking different strains, comparing new 
strains with previously stored ones, determining modes of transmission, and 
ultimately combating infections 
- to ensure progress in diagnostics: by comparing samples taken from the 
same subjects over time or by comparing samples taken from different subjects 
at the same point in time, or by applying novel diagnostic tools to the analysis of 
samples that exhibit increased sensitivity and specificity.
- to manage studies with large sample sizes: this may refer to research with 
sample collections coming from different geographical locations, or research 
that is conducted in several remote laboratories. 
- to establish biorepositories with characterized host cell lines:  cell lines 
can be used for research, diagnostics and quality control, and other scientific 
pursuits.
- to assist in building a microbial tree of life: such biobanks provide the 
basis for mapping out microbial diversity and evolution. Given the increasingly 
imminent threat that emerging highly virulent or therapy-resistant strains pose 
for global health, the importance of these types of biobank collections will likely 
rise in the near future. 
In addition to these roles, biobanks can serve as the foundation for conducting 
research in host genomics and other ‘omic’ sciences, elucidating the role 
and interactions of the host’s immunogenetic factors in infections [14], as well 
as driving prospective diagnostic and therapeutic advances [15]. 
This article examines the role of biobanks in the basic research in infectious 
disease genomics, and also observes the relevance and applicability of biobanks 
in both the translation of impending knowledge and the clinical uptake of biobank-
generated knowledge in infectious diseases. Our research identifies potential 
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fields of interaction between infectious disease genomics and biobanks, in line 
with the global trend of integration of genome-based knowledge into clinical 
practice. 
Materials and Methods
A literature search was performed on the identification of the existing links 
between biobanking and infectious diseases; on points of potential collaboration 
between biobanks, clinics and surveillance agencies; and on the examination of 
the relevance of electronic health records (EHR) in genomic research of infectious 
diseases. The study focused on examples of the translation of biobank-generated 
genome-based knowledge to everyday clinical practice. Databases (PubMed, 
Cochrane library, Google Scholar), electronic journal collections (Maastricht 
University EJ collection) and the websites of relevant organizations, networks 
and consortia (OECD, EAPM, P3G, BBMRI) were searched for appropriate 
references. The terms used in the searches were [“biobank*” AND (“infectious 
disease*” OR “genomic*”)]. Retrieved articles were further selected based on 
relevance. Additional search terms were “public health”, “data management” 
and “data privacy”.
This article provides examples of existing biobanks with substantial resources 
for infectious disease research, such as those for human immunodeficiency virus 
(HIV), Human papillomavirus (HPV), and Chlamydia trachomatis (CT).
Results   
Human versus microbial sample biobanks
There is an obvious delineation between samples taken from human individuals 
suffering from a pathological condition related to an infection (who may or 
may not be infected with or are carriers of the pathogen) and samples of the 
infectious agent itself. The former is primarily relevant to host ‘omic’ research, 
as it provides the material basis for both candidate gene/SNP-approaches and 
genome-wide association research in seeking (co)morbidity associations, and 
also investigates the pathogen interactions with host proteomes [16]. These 
samples should be paired with relevant categories of patient phenotypic data. 
Pathogen samples enable epidemiological studies, investigate genetic strains 
of that species, and develop better diagnostic tools and novel therapies [13]. 
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Biomaterial samples may differ in processing and storage, as well as in shelf-life. 
As biomedical science moves away from the deconstruction of living systems and 
turns towards a more integrative, all-encompassing approach (through the likes 
of systems biology) [17], it is reasonable to expect that researchers increasingly 
begin to assess host ‘omic’ data together with infectious agents ‘omic’ profiles. 
As a prerequisite, adequate samples should always be accompanied by relevant 
data. 
Infectious disease genomics and the inflow of data
Advances in sequencing technologies have resulted in a relentless influx of data 
that need to be interpreted. Currently, researchers are generating data more 
rapidly than can be analyzed. In particular, the genetic variability of bacteria 
accumulated through evolution is enormous and significantly increases the 
volume of datasets. Public health genomics specifically emphasizes the need 
to examine all ‘omics’ [17, 18], which, in the case of infectious disease, 
involves both the host and the pathogen. This emphasis dramatically increases 
demand for the effective deciphering of large amounts of data. There are, 
however, efforts among members of the microbiology community to develop 
strategies that would make this data manageable. For example, by grouping 
select loci of the pathogenic bacterial strain into schemes (the so-called gene-
by-gene approach) and by implementing themes schemes in conjunction with 
conventional (sequence-based) schemes in adequate database platforms, data 
that is obtained through different studies and can be used more effectively in 
combined analyses [19]. In this way, “genotype summaries” of selected genes 
could be linked to phylogenetic relationships and functional characteristics of 
bacteria, thereby helping researchers navigate vast bacterial genomic diversity. 
Existing infectious disease biobanks and networks
The number of laboratories that are creating their own biobanks is difficult to 
quantify with full precision. However, the number of organizations that are 
developing nation-wide or transnational collections and are building large 
consortia and networks is ever increasing [13]. Large networks such as the 
Public Population Project in Genomics and Society (P3G) (http://p3g.org/) 
and Biobanking and Biomolecular Resources Research Infrastructure (BBMRI) 
(http://bbmri.eu/) are changing the landscape of international collaboration in 
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biobanking, harmonizing regulatory legislation and thus facilitating the use of 
biobanks in research [20]. Promising nation-wide models have also emerged, 
including the United Kingdom Biobank (http://www.ukbiobank.ac.uk/), the 
Swedish National Biobank programme (now the Swedish arm of BBMRI, http://
www.bbmri.se/), the Iceland Biobank, and others. Some biobanks, however, are 
not positioned as public domain entities; in the case of Iceland, for example, the 
biobank is a private company that has been given a commercial data license 
[21].
This article presents several infectious disease biobanks and their effective 
usage, which has led to cases of successful clinical uptake (or its near-future 
prospects) for HIV, CT and HPV (for which there is a more substantial body of 
literature available). These biobanks are founded and governed by hospitals 
and academic institutions and provide clear examples of how biobanking can 
stimulate research in infectious disease genomics.
HIV
The Infectious Diseases Biobank (IDB) at King’s College London is an oft-cited 
example of an infectious disease-oriented biobank [22, 23]. The IDB is actively 
collecting samples from patients infected with HIV, hepatitis B and C viruses, and 
invasive bacteraemias (such as the methicillin resistant Staphylococcus aureus 
(MRSA)).  The IDB is also collecting samples from healthy control subjects. The 
number of HIV patients with archived materials in the IDB is steadily increasing, 
resulting in the availability of distinct patient cohorts (in meaningful numbers) 
to researchers. Data on the IDB’s website indicate that by September 2010, HIV 
sample donations had reached 500 annually. Examples of research stemming 
from this collection are (as stated on the IDB website): the roles of vpu gene 
and tetherin in HIV/AIDS pathogenesis; gene expression signatures in in vivo 
and in vitro HIV-1 infection; non-infectious HIV co-morbidities; renal function 
and bone homeostasis in patients on HAART; the definition of CD161+ CD8+ 
T cell subset function in HIV infection and their response to therapy; the effect 
of Maraviroc on microbial translocation in HIV infected individuals receiving 
antiretroviral therapy; and the metabolic impact of Darunavir/ritonavir 
maintenance monotherapy after successful viral suppression with standard 
Atripla in HIV-1-infected patients. Aside from archiving biological samples, the 
BioBank runs a database in which the following clinical information on HIV donors 
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is archived: histories of CD4+ cell numbers and plasma viral loads; last known 
HAART administering; and other complications. The database also features 
sample processing information (dates and times of venepuncture, processing 
and freezing); and details on aliquots that have been stored or transferred to 
researchers.
Another example of an infectious disease-oriented biobank is the Spanish HIV 
knowledge about HIV infection by providing biological samples from HIV-
infected patients that are included in cohorts for the objective of carrying out 
research. The HIV BioBank receives samples from 28 hospitals, spread across 
characteristics. Any member of the AIDS Network, or any party to a relevant 
collaboration with a member can apply for samples. Sample release applications 
the researcher signs a Release Agreement with the director of the BioBank and 
with the coordinator of the Cohort. The BioBank and the Cohort are responsible 
for locating the type and number of samples needed to carry out the project. 
the BioBank can maintain up-to-date records on all projects.
Chlamydia trachomatis 
Partners of the EpiGenChlamydia Consortium (urogenital and ocular CT 
infections), coordinated by the London School of Hygiene and Tropical 
Medicine (by David Mabey and Robin Bailey and their Gambian partners) who 
secured 1500 case-control pairs (n=3000). More than 4000 specimens that are 
currently in use have been collected by Dutch partners, and 10000 specimens 
are available for further studies [25]. One goal was to build a biobank and data 
warehouse – a biomedical, ethically-developed and run central sample collection 
and data management system. The Consortium is investigating possibilities for 
conducting genetic and epidemiologic Chlamydia research with samples from 
existing biobanks in Northern European countries. 
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that comparative genomics and genetic epidemiology can be performed on 
large numbers of unrelated individuals. The most pivotal deliverables of this 
project were biobanking and data-warehouse building. These deliverables will 
genetic predisposition to CT infection, and the development of tools for early 
detection of this predisposition. The study of sequence variation (mainly SNPs) 
for susceptibility. 
A review by Malogajski et al. [26] gives an overview of immunogenetic factors 
pathogen recognition receptor genes. Women carrying one or a combination of 
risk of developing subfertility-related complications, such as tubal pathology. 
The review proposes the development of novel diagnostic tools for assessing 
individual risk faced by CT-positive women. Currently, clinicians employ CT 
IgG serology when assessing these risks [27]. Due to limited sensitivity and 
a result, many physicians recommend that women undergo additional invasive, 
stressful, and costly diagnostic procedures. It is estimated that 40-45% of 
women undergoing laparoscopy do not have tubal pathology. Additionally, 
false negative serology results account for about 20% of women whose tubal 
pathology will not be properly and timely diagnosed [28]. The proposed tool 
would introduce a diagnostic approach based on a combination of two factors: a 
predictive SNP load; and serological markers for CT infection. On-going research 
infectious diseases severity in the triage of women. 
HPV
Similar to the translation of CT biobank-derived data into diagnostic applications 
for subfertility, the translation of HPV research results should contribute to 
better diagnostics of cervical cancer and its pre-neoplastic stages, cervical 
intraepithelial neoplasia [26].  Large biobanks and patient cohorts are used to 
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achieve this result. Despite the anticipated outcomes of HPV vaccination (which 
should lead to a drop in cervical cancer incidence in a matter of decades), the 
needs of generations of women who were above the age of expected exposure 
to HPV virus (and were therefore left out of vaccination programs) ought to 
be addressed. The cervical scraping cytomorphology assessment, better known 
as the PAP test, is routinely used throughout the world as a screening tool for 
cervical lesions; however, the PAP has low sensitivity. The introduction of high-
risk HPV (hrHPV) assessment will increase sensitivity and ease (especially in the 
case of self-collected vaginal swabs) to determine a woman’s risk of developing 
cervical cancer. Referral to a gynecologist is only needed where a woman is 
found to be infected by a hrHPV type. Some authors propose the development 
of a triage tool for high-risk HPV positive women based on methylation markers; 
this means that a woman should only be referred for further examination if she 
tested positive for one or more hrHPV types and at the same time carries a 
combination of methylation markers indicative of a progression of pre-neoplastic 
stages. This approach builds upon a number of studies that show how epigenetic 
alterations become increasingly present with each successive stage of cervical 
lesion and cervical cancer, mainly in genes that are important to the progression 
of cancer (e.g. tumor suppressors and cell adhesion molecules), or genes coding 
microRNAs, whose role is to bind to the viral nucleic sequences, thereby making 
them inaccessible to enzymes that are replicating or transcribing. Based on the 
available studies at that time, the review [26] highlighted methylation patterns 
in MAL and CADM1 genes as optimal markers for the development of a potential 
triage test [29]. A more recent review by Litjens et al.  [30] reached the same 
conclusion, but added p16INK-4a/Ki-67 dual immunostaining and viral integration 
to the proposed set of markers.
Relevance of electronic health records
The rise in usage – and usability – of electronic health records (EHRs) is a 
demonstrably promising catalyst in the efforts to better utilize and standardize 
biobanks [31]. This pertains to handling the information on the biomaterial 
from the large cohort studies on a plethora of diseases, including infectious 
diseases. ‘EHR-driven genomic research’ can ideally be achieved using two 
distinct workflows. Firstly, patients with a particular infectious disease or 
related sequelae could be selected from the EHR by using language processing 
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tools, such as natural language processing (NLP) tools. In this case, the selected 
population could thereupon be recruited, either for the purpose of providing 
samples for genomic research, or in order to verify whether residual samples 
taken on previous occasions could be utilized. Secondly, EHRs can be used to 
broaden and advance clinical characterization by adding new relevant data to the 
files of those individuals whose samples are already stored in another biobank 
or have been used in the context of a cohort study [31]. Electronic systems for 
the automated detection of notifiable diseases have, in fact, been tested using 
EHRs. In past decades, the term of preference was electronic medical records 
(EMRs).  This term has gradually been overtaken by the previously mentioned 
EHRs, as focus slowly expanded from the inclusion of basic clinical patient data 
to the provision of a more complete insight into their health background and 
care. 
The so-called ESP (Electronic Medical Record Support for Public Health) 
algorithmic system, which has been tested on Chlamydia records and others, 
assists not only in the identification and reporting of cases of notifiable disease, 
but also in the advancement of public health. Prospective applications of EHRs 
include syndromic surveillance; clinical decision support; the construction 
of vaccine registries; and the assessment of areas with higher prevalence of 
disease [32]. The incorporation of patient genome-based information into EHRs 
would undoubtedly act as a major driving force for genomic medicine. It would 
enable the investigation of potential comorbidities of genomic associations 
[31], and would elucidate the ways in which such associations can individually 
or synergistically result in increased susceptibility to or severity of infectious 
disease. That said, the incorporation of patient genome information into EHRs 
has thus far been a daunting task, since most EHR systems are not designed 
to include genomic data [33]. Although the linear DNA sequence is simple by 
nature, the sheer volume of data and the complexity of relations among the 
‘functional components’ of DNA are significant hurdles in attempting to devise 
an EHR system using this information [33, 34].
 
Data privacy and infectious disease genomics
While the issues of data privacy and consent exceed the parameters of this 
article, we will briefly lay out the state of the art in this field, as well as how 
legal frameworks, governance of infectious disease biobanks and the handling 
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generally.  In 2013, during the Irish presidency of the EU Council, the European 
Alliance for Personalised Medicine (EAPM) hosted a conference on innovation 
and patient access to personalized medicine, in which experts discussed recent 
advances in healthcare and formulated conclusions relating to these advances 
[35]. In order to optimize data security and to facilitate access and consent 
(which would allow for re-use and secondary use of data), it was concluded 
implemented. Moreover, cross-border transfers of data for the purposes of 
of governance, a balance must always be struck between the stimulation of 
cross-border transfers of data and individual rights to privacy. 
The importance of data protection cannot be underestimated, especially in 
infections. Genomic discoveries concerning such infections potentially 
create various forms of discrimination in the context of future discovery. For 
example, it was discovered that African-American carriers of a polymorphism 
malaria (Plasmodium vivax infection).  However, subsequent research into this 
polymorphism also revealed that carriers have a 40% increased likelihood of 
becoming infected with the HIV-1 virus [36]. In this case, contrary to the protective 
character of CCR5∆32  deletion as witnessed in European populations, the 
disruption of the expression of a functional receptor is a major disadvantage to 
the carrier. Evidently, the risks of stigmatization and discrimination arising from 
genome-based information (the disclosure of a patient’s illness or infection 
status being a potential infringement of patient rights) cannot be ignored. As 
stated in the EAPM report conclusions [35], progress must be achieved by 
developing trust between researchers and the public, and by promoting the 
equal treatment of health research data (including genome-based information 
included) and the removal of silos for single-use data. Since this information is 
theoretically unlimited in terms of longevity, robust data protection mechanisms 
must be in place for periods longer than the samples’ shelf life [37].
vigilant data protection. Genome-based research necessitates large sample 
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sizes in order to arrive at more reliable results; as a result, overly-restrictive data 
protection policies can impede research and innovation [34]. A large number of 
samples is necessary to identify patient subgroups of interest. There are also 
calls for the provision of research data to the general public, particularly in cases 
where the research itself was funded using taxpayer dollars [38]. Entire human 
genome sequences, including those of several prominent researchers, have 
already been made available to the general public online (open access model). In 
spite of this open access, the debate over balancing the right to consent versus 
the right to privacy is far from resolved. The fact that fewer than 13-15 genomic 
locations with variable repeats (or 30-80 statistically independent SNPs) can 
be used to identify any one individual [39] lends perspective to requests for the 
deregulation of data sharing. Samples that contain a ‘genomic fingerprint’ in 
combination with data relating to the presence of serious infections pose a new 
threat to those safeguards that ensure participant anonymity and prevent partial 
treatment. Due to lack of funding, many academic institutions allow private 
organizations to handle their genomic databases; as a result, the protection of 
the rights of human participants may be at risk in any future commercial uses 
of data [13].
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Discussion
The aim of this review was to explore empirical evidence on the role of biobanking 
in infectious disease genomics and to outline the pertinent issues in setting up 
and utilizing biobank materials. We note that published material that provides a 
detailed overview of existing infectious disease biobanks and their uses to date 
is lacking. In order to facilitate extensive collaboration with researchers and to 
ensure the continuation of research on infection, infectious disease biobanks 
must become more visible, and must emphasize their societal impact. Thus 
far, the authors have encountered underrepresentation of infectious disease 
biobanks in publications and insufficient information on official websites. The 
public should be able to easily access a clear, detailed outline of regulations 
and procedures for sample and data utilization by academic or commercial 
investigators, as well as an account of the precise roles of governing bodies. 
Examples of procedural transparency and extensive online visibility include the 
King’s College Infectious Disease BioBank and the Spanish HIV BioBank [23, 
24]. Appropriate regulation should precede the effective translation of biobank-
based research to clinical settings; such regulation necessitates intensive 
efforts, so as to ensure rapid clinical uptake.
In recent years, several biobanking consortia and extensive networks have 
been formed, and there has been a visible increase in efforts, stakeholders’ 
involvement and resources allocated [20]. Nevertheless, infectious disease 
biobanks have yet to achieve their full potential. This review does, however, 
provide several examples of biobanks that have successfully contributed to the 
translation of data to clinics and patients. In order to successfully utilize biobank 
information in research on infectious disease, and in order to develop ‘tailored’ 
therapies based on pharmacogenomics research, adequate representation 
of ethnic minorities and neglected populations in biobanking is of paramount 
importance. Biobanks must be constructed to account for ethnic differences 
in susceptibility to certain infectious diseases, which themselves have been 
extensively documented [40, 41]. In HIV-AIDS therapy research, for example, 
extrapolations of potential clinical implications of allele frequency differences 
between different ethnicities could significantly assist doctors when prescribing 
therapies. Consortium for the BioBank and Pharmacogenetics database of 
African populations is an example of efforts paving the way for individualised 
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treatments for HIV-AIDS [42]
The  Consortium’s   biobank  of  anonymous samples was used to  determine 
baseline frequency distribution of SNPs of genes affecting drug metabolism; 
this usage enabled the establishment of a pharmacogenetics database. Certain 
information can be essential for optimizing therapeutic approaches and reducing 
ethnic-specific adverse reactions, such as the different drug-metabolizing 
capacities of particular allelic versions of enzymes (such as the CYP2B6*6 allele) 
[42]. There is an argument to be made, however, that these differences are 
neither inherent nor applicable to all infections. Some authors argue, in terms of 
decreased precision of data analysis, against blind ‘social inclusivity’ in biobank 
sampling at the potential expense of ‘analytical acuity.’ [43]. In countries such 
as the UK or the US, acting more fervently upon the two aforementioned views 
could lead to a reevaluation of the manner in which biobanks are governed. 
EHR system designers need to be encouraged to configure these systems so as 
to enable the incorporation of genome-based (or ‘omic’-based) information. The 
addition of pathogen ‘omic’ data to an accompanying registry should be made 
feasible in order to promote research in infectious diseases. Other forms of 
research, the clinical uptake of genome-based knowledge, and the advancement 
of personalized medicine can all invaluably benefit from a shifting approach to 
health record management. Several approaches have been proposed to this 
effect, and each acknowledges the unique nature of genomic data [44, 34]. 
The unique challenges associated with biobank-based research indicate that 
it is in some aspects more complex than other types of health or biomedical 
research. One of the main obstacles to translating biobank data into the clinical 
setting is confidentiality and privacy, which stem from a necessary pairing of 
biobank information with personal and unrelated types of health information. 
The protection of data obtained from samples of patients who are afflicted with 
serious infections is of particular importance due to the potential in such cases 
for discrimination. Discrimination can result both from current interpretations 
of data, and from future research and upcoming innovations in genomic 
technologies.
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Conclusions 
A clear overview of the usage of existing infectious disease biobanks is lacking 
in present literature, and we maintain that this information should be readily 
accessible to the public, along with clear regulatory and procedural guidelines 
for utilization of samples and data. This would ultimately facilitate the currently 
insufficient uptake by researchers and clinics. Several biobanks have, however, 
already set high standards in terms of instating appropriate regulation as well as 
enabling successful translation into clinical setting and can therefore serve as a 
model to other biobanks. In recent years, efforts and resources that have been 
invested in biobanking networks and consortia have surged. As a result, there 
is a higher awareness of the multitude of ways in which biobanking can advance 
basic research, diagnostics and - most importantly – the clinical management of 
infectious disease. These advances will ensure that research in biobank-based 
infectious disease continues to progress.
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Abstract
Chlamydia trachomatis (CT) infections in women can result in tubal pathology 
(TP). Worldwide 10–15% of all couples are subfertile, meaning they did not get 
pregnant after 1 year. Part of the routine subfertility diagnostics is the Chlamydia 
Antibody Test (CAT) to decide for laparoscopy or not in order to diagnose TP. 
The CAT positive and negative predictive value is such that many unneeded 
laparoscopies are done and many TP cases are missed. Addition of host genetic 
markers related to infection susceptibility and severity could potentially improve 
the clinical management of couples who suffer from subfertility. In the present 
study, the potential translational and clinical value of adding diagnostic host 
genetic marker profiles on the basis of infection and inflammation to the current 
clinical management of subfertility was investigated. This review provides an 
overview of the current state of the art of host genetic markers in relation to CT 
infection, proposes a new clinical diagnostic approach, and investigates how the 
Learning-Adapting-Leveling model (LAL, a public health genomic (PHG) model) 
can be of value and provide insight to see whether these host genetic markers 
can be translated into public health. This review shows that the preliminary basis 
of adding host genetic marker profiles to the current diagnostic procedures of 
subfertility is present but has to be further developed before implementation 
into health care can be achieved. CT infection is an example in the field of PHG 
with potential diagnostic to be taken up in the future in the field of subfertility 
diagnosis with a time line for integration to be dependent on enhanced 
participation of many stakeholders in the field of PHG which could be advanced 
through the LAL model.
Keywords: Chlamydia trachomatis , Genomics, Host genetic markers, Learning-
Adapting-Leveling model, Molecular diagnostics, Public health genomics, 
Stakeholders, Subfertility, Translation.
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Introduction
Chlamydia trachomatis infection
Chlamydia trachomatis is the most common bacterial sexually transmitted 
infection throughout the world. An estimated 89 million cases per year 
worldwide are reported. The infection is often asymptomatic resulting in patients 
not seeking treatment. Untreated urogenital C. trachomatis may give rise to 
late complications, including pelvic inflammatory disease, ectopic pregnancy 
and tubal pathology [1–4]. The clinical course of chlamydial infections is 
heterogeneous i.e. transmission, symptoms, clearance, and development of late 
complications differ per patient [5–7].
Sexually acquired C. trachomatis is an important public health concern for its 
effects on reproduction. Women who develop late complications, such as pelvic 
inflammatory disease or tubal pathology, suffer considerable morbidity and 
emotional distress, and are a socio-economic burden [8].
To prevent such outcomes, early diagnosis is important. Currently, screening 
for tubal pathology is performed via laparoscopy, a procedure, which is invasive 
and expensive, labor intensive and has a risk for surgical complications. This has 
resulted in extensive efforts to improve noninvasive diagnostic tests to decrease 
the risks of current screening methods.
Much research on bacterial components, clinical and environmental factors [9, 
10] has been done, but no definitive correlates of late complications have been 
identified [11]. For a variety of infectious diseases (e.g. malaria, hepatitis and 
meningococcal infections), it has been shown that host genetics play a crucial 
role in susceptibility to and severity of disease [12–14]. To estimate the role 
of genetics in course of infection, twin studies are a powerful tool, and Bailey 
et al. [15] have shown that host genetic factors contribute almost 40% to the 
variation in clinical course of Chlamydia infection. These results establish the 
potential importance of genetic studies. Den Hartog et al. [16] showed, in a 
cohort of subfertile women, that single nucleotide polymorphisms (SNPs) in 
several pattern recognition receptors (PRRs) increase the risk of developing 
tubal pathology following a C. trachomatis infection. 
The innate immune response is the first line of defense against a C. trachomatis 
infection. PRRs recognize components of the bacterium, and SNPs in these 
genes may affect the functionality of these PRRs and may, therefore, increase 
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the risk for development of late complications. In addition, SNPs in genes coding 
for cytokines involved in immune responses may also be influential. Recently, 
our group [17] reviewed the role of SNPs in PRRs and cytokines in relation to 
susceptibility to a C. trachomatis infection.
It is important that these scientific findings are utilized in the clinic and 
incorporated in public health policy. The Learning-Adapting-Leveling (LAL) 
model [18] is a model of translating scientific data from the lab through the 
market and implementing it into public health policy; it will be discussed later in 
this review as a possible way to assimilate new findings in clinical settings. 
Outline of the Article
The overarching aim of the current review is to determine if C. trachomatis is 
one of the proof of principles in the field of public health genomics (PHG) with 
the potential to be taken up in the future in the field of subfertility diagnosis. 
Therefore, we provide an overview of the current state of the art on host genetic 
markers in relation to infection, propose a new clinical diagnostic approach in 
subfertility diagnostics based on this overview and describe how the LAL model 
(an integrated PHG model) can be of value to see if these host genetic markers 
can be translated from the lab to the market and implemented into public health.
Overview of CT Host Genetic Determinants of Infection
Several studies have shown the importance of host genetic variation on the 
clinical course of Chlamydia infections. This section will highlight recent findings, 
similar to a recent review [17], divided into detection of the pathogen Chlamydia 
by PRRs and the subsequent intercellular signaling by cytokines, with a focus 
on the innate immune system. Combined carriage of SNPs in so-called traits 
may exhibit a stronger influence on the course of Chlamydia infections, e.g. a 
reduced pathogen recognition capacity in multiple PRRs may result in higher 
susceptibility compared to the susceptibility when only one PRR has a reduced 
recognition capacity. Results for trait analyses are highlighted at the end of this 
section. 
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Pattern Recognition Receptors
Toll-Like Receptors (TLR)
TLRs are a much investigated group of receptors. Studies have shown that TLRs 
are essential in the host immune system by recognizing pathogenic components 
(pathogen associated molecular patterns (PAMPs) and danger associated 
molecular patterns (DAMPs) and inducing an immune response. These receptors 
are present on antigen presenting cells (APC) and epithelial cells; they reside 
both on the cell membrane and within cells. The TLR family has been studied in 
relation to various infectious and autoimmune diseases with varying associations 
[17,19, 20]. TLRs 2, 4 and 9 are well-researched TLR family members. TLR2 
and TLR4, both trans-membrane pathogen receptors, recognize chlamydial 
peptidoglycan (PGN) and lipopolysaccharide (LPS), respectively. TLR9 is an 
intracellular receptor, recognizing CpG islands in bacteria.
Karimi et al. [19] investigated the role of 2 SNPs in TLR2 in C. trachomatis 
infected women and control groups: TLR2 –16934T>A (rs4696480) and 
genotype distribution for both susceptibility to and severity of the infection. 
However, in haplotype analysis, they showed that haplotype TG was protective 
for developing tubal pathology. Laisk et al. [21] also evaluated the role of 
TLR2 +2477G>A (rs5743708) in developing tubal pathology and found no 
et al. 
[19].
Den Hartog et al. [22] studied TLR4 +896A>G (rs4986790). The genotype 
distribution of this SNP in subfertile women with or without C. trachomatis 
C. trachomatis IgG and cHSP60 IgG had tubal pathology. Results of this study are 
had this combination of C. trachomatis and cHSP60 serology, and TLR4 +896 
mutation carriage. Laisk et al. [21] also investigated the role of this SNP in 
et al. [23] 
genotype increases the susceptibility to C. trachomatis infections. Similarly, 
they found that the TLR1 rs5743618 TT genotype increased susceptibility to 
Chlamydia infections [23].
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Caucasian women visiting a STD outpatient clinic and a cohort of subfertile 
between groups. However, haplotype analyses showed, though not statistically 
C (rs5743836), +1174 G (rs352139), and +2848 A (rs352140) was more 
frequently found in women who developed tubal pathology.
C-C Chemokine Receptor Type 5 (CCR5)
CCR5 is a chemokine receptor present on several immune cells, including 
 .segahporcam dna ,sllec 1 repleh T ,sllec lailgorcim ,sllec citirdned ,setyconom
A 32-bp deletion within the CCR5 gene, CCR5 ∆32, results in premature 
termination of the protein, altering its function [25, 26] demonstrated that 
recent study [21]. For this inconsistency, the authors suggest that the ligand of 
CCR5, RANTES (CCL5), binds the CCR1 chemokine receptor as well, therefore 
they addressed the importance of group selection, and as a result this may be a 
Mannose-Binding Lectin (MBL)
MBL is important in the innate immune response.  It binds to various carbohydrate 
structures of a.o. bacteria and either directly kills the pathogen or promotes 
phagocytosis [27].  Studies have shown that MBL inhibits a C. trachomatis
infection [28]. Laisk et al. [21] investigated the role of 6 polymorphisms in 
the MBL2 gene, coding for MBL.  They found that a hyperproduction haplotype 
of MBL2, HYA/HYA, was a risk factor for tubal pathology independent of 
a C. trachomatis infection.  They also found this association, only smaller, 
in C. trachomatis infected patients with tubal pathology. They suggest that 
tract, inducing tubal pathology [21].  The low-producing MBL2 genotypes are 
associated with tubal pathology and adverse outcome of in vitro fertilization 
(IVF) treatment [29].
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Human Leukocyte Antigen (HLA)
HLA codes for the major histocompatibility complex and thus, has an important 
function in the immune system. The HLA system has been linked to a variety of 
infectious diseases and disease outcomes. In the literature, a link between HLA 
-DQA1 * 0102 and HLA -DQB1 * 0602 alleles, and Chlamydia induced tubal 
pathology has been described [30].
Another studied receptor is the major histocompatibility complex class I chain-
related A (MICA), present on a.o. natural killer cells. When its ligand binds, 
activating signals for natural killer cells increase. Allele MICA * 008 had a 
high negative correlation with C. trachomatis IgG antibodies. In this study, IgG 
antibodies were associated with tubal pathology. This group hypothesized that 
MICA alleles might play an important role in the development of tubal pathology. 
However, in the infertile women of their study, they could not establish an 
association between MICA alleles and tubal pathology with or without C. 
trachomatis IgG antibodies [31].
Cytokines
A variety of cytokines have been associated with disease and disease outcomes. 
These cytokines have important immunoregulatory functions, and alterations in 
function may, therefore, influence immune responses. Several cytokines have 
been studied in women who developed tubal pathology. Some associations were 
found: IL10 -1082 A allele together with HLA -DQA1 * 0102 and HLA -DQB1 * 
0602 alleles; these were associated with severe tubal pathology [30, 32]. Both 
the TNF-α -308 A allele and the IL6 CC genotypes were found to be associated 
with tubal pathology: the former as a risk factor and the latter as a protective 
factor for tubal pathology [32].
A statistically significant association between the IFNg +874 polymorphism 
and chlamydial tubal pathology was not found [32], nor for IL1B +3954, IL1B 
–511, and IL1RN gene polymorphisms [33]. However, a study performed in an 
ex vivo model showed that IL1, in the absence of its antagonist IL1RA, causes 
destruction of the ciliated cells in the Fallopian tubes [34]. In addition, SNPs in 
NLRP3 , associated with hypoproduction of IL1β, is involved in tubal pathology 
[35]. Due to these findings, one may hypothesize that SNPs influencing IL1 
functionality may affect the development of tubal pathology and the rate of 
severity.
84
The mutant allele of the IL12B rs3212227 SNP is associated with increased 
susceptibility to tubal factor infertility and with a more severe progression of 
disease [36]. The same group also demonstrated that IL10 and IFNG genotypes 
affect the lympho-proliferative responses in Chlamydia infections [37].
Trait Analyses
Den Hartog et al. [16] investigated the role of 5 SNPs in 4 genes assumed 
to play a role in C. trachomatis infection. The investigated genes were TLR4, 
TLR9, CD14, and CARD15/NOD2. The risk for development of tubal pathology 
doubled if a patient had 2 or more SNPs within the studied genes, compared 
to 1 SNP. In addition, when investigating only 1 SNP in TLR4 or CD14 [38], 
no association with tubal pathology was found. Due to a small sample size, no 
statistical significance was observed in the trait analyses; a statistical trend, 
however, was observed. 
Ohman et al. [37] found that the combined carriage of specific IL10 and IFNG 
genotypes has an additive effect on the risk for Chlamydia infection. Atik 
et al. [39]  demonstrated that combinations of SNPs affect the adverse that 
trachomatous trachiasis risk decreased 5 times with the combination of TNFA 
(–308A), LTA (252A), VCAM1 (–1594C), and SCYA 11 (23T) minor allele, and 
the combination of TNFA (–308A), IL9 (113M), IL1B (5' UTR-T), and VCAM1 
(–1594C). However, trachiasis risk increased 13.5 times with the combination 
of TNFA (–308G), VDR (intron G), IL4R (50V), and ICAM1 (56M) minor allele. 
Although these results are from ocular infections, one might hypothesize that 
similar effects might be observed in urogenital infections.
Although compelling, these results have to be confirmed in other studies, and 
additional SNPs have to be added in order to define the SNP profiles that are 
associated with and would help predict a patient’s predisposition to Chlamydia 
infections and tubal pathology. This requires large cohorts which can be obtained 
via large consortia, in which different disciplines contribute to the overall goal.
Consortium Approaches: EU Framework Program EpiGenChlamydia
To perform large scale typing for the identification of genetic biomarkers, 
large and clinically well-defined cohorts are needed.  Toward this end, a small 
consortium was founded in 2005 with Dutch, Belgian and American partners 
with expertise on clinical, epidemiological, bacterial, animal, immunological, 
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and host immunogenetic studies to have an integrated approach to study C. 
trachomatis infections, especially the clear inter-individual differences in the 
clinical course of infection.  This consortium was named the ICTI consortium 
[40, 41].  Members of the ICTI consortium applied for and obtained funding 
from the European Union as a large international consortium consisting of 20 
partners, the EpiGenChlamydia (EGC) consortium [42].
This Chlamydia consortium was funded by the EU Framework Program 6 under 
the Coordination Actions in functional genomics research for a period of 2.5 
years and provided its closure report in 2010.  The aim of this consortium was 
to structure transnational research to such a degree that comparative genomics 
and genetic epidemiology on large numbers of unrelated individuals could be 
performed with future funding.  This funding made it possible for 20 groups from 
Europe, Africa and the USA to participate (see http://www.EpigenChlamydia.eu 
for details).  The overall goal of the EGC consortium was to accommodate the 
optimal environment to build and prepare a consortium to reliably determine 
the genetic predisposition to infection in both ocular and sexually transmitted 
C. trachomatis.  This will allow the development of diagnostic tools that can 
determine an individual’s predisposition to infection and the risk to develop late 
complications. Further, it was hoped that the knowledge generated through this 
effort would contribute to the understanding of the Chlamydia – host interaction, 
in order to allow the development of novel tools for the detection and treatment 
of and vaccine development for C. trachomatis infections. 
The EGC consortium has provided the final reports to the EU including state-of-
the-art reports on the epidemiology of both ocular and sexually transmitted C. 
trachomatis infections [4], bacterial typing [43, 44], immunogenetics [17] , SNP 
genotyping strategies, and sample validation.  Two deliverables were of major 
importance for the future success in translation of immunogenetic markers 
and for obtaining new funding for a biobank, consisting of physical and virtual 
sample collections, and a data warehouse in which genotyping data together 
with clinical and demographical data is merged and accessible. 
The partners working on ocular Chlamydia diseases coordinated by the London 
School of Hygiene and tropical medicine (David Mabey and Robin Bailey together 
with their Gambian partners) have already defined and secured 1,500 case-
control pairs (total n = 3,000).  The scientific coordinator of the EGC consortium 
(S. Morré) together with Dutch collaborators have collected more than 7,000 
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specimens which are at present in use, while 10,000 specimens are available 
for further studies.
Currently, part of the consortium has obtained new funding from the EU 
based on Small-to-Medium-Enterprise collaborations with universities.  This 
EuroTransBio grant has as main goal to develop a diagnostic test on the basis 
of human genetics and C. trachomatis serology to better assess the presence of 
C. trachomatis -associated tubal damage in subfertile women. This consortium, 
ending in the beginning of 2015, is in progress of performing large scale 
analyses of human genetic variation to identify novel genetic markers that are 
able to stratify patients with tubal pathology.  The identified SNPs in the PRR 
genes have already shown to be highly predictive for the development of tubal 
pathology.  However, single SNPs do not provide a high enough predictive value 
for a diagnostic test. By combining multiple identified and novel SNPs in the 
PRR genes and genes in linked pathways, and exploiting them as susceptibility 
markers, a highly predictive test for tubal pathology-based subfertility can 
potentially be developed.  This will be discussed further in the next section.
Improvement of Subfertility Diagnostics Based on Host Genetics
Subfertility poses an enormous burden on healthcare and society throughout 
the world. Worldwide, 15% of couples trying to conceive suffer from subfertility 
[45, 46].  In women, one of the major causes of female subfertility is tubal 
pathology [45]. In tubal pathology, C. trachomatis is the single most common 
cause for infertility [45].
From all subfertility problems in women, tubal damage is a common cause of 
infertility. It includes tubal obstruction and pelvic adhesions resulting from 
infection, endometriosis and previous surgery. The current diagnostic procedure 
for diagnosing this condition can be performed by sonohysterography/
hysterosalpingo contrast sonography, hysterosalpingography (HSG), fertiloscopy, 
falloposcopy, or laparoscopy and dye hydrotubation, often using detection of 
IgG antibodies against C. trachomatis as first screenings tool.
Despite their effectiveness, the above-mentioned methods are costly and invasive 
[47] and not suitable for screening. There are several test methods available 
to assess the risk of C. trachomatis -associated tubal pathology in subfertile 
women. The reference standard for diagnosing tubal pathology in subfertile 
women is laparoscopy. However, laparoscopy has several disadvantages. First, 
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it is an invasive, expensive procedure (on average 3,000 Euros, including 
additional costs) and requires general anesthesia. Furthermore, it holds a 1.5% 
risk of surgical complications (e.g. bleeding, infection).
Since it is widely recognized that a C. trachomatis infection is the single most 
common cause of tubal peritoneal damage (WHO task force on the prevention 
and management of infertility [48]), detecting evidence of infection using 
serology is noninvasive, simple and quick to perform [47]. As such, Chlamydia 
serology is often used as a first screening test for tubal damage in infertile 
women but has a limited sensitivity of 50–60%.
Currently, women with subfertility are screened for a C. trachomatis using 
serology (see figure 1). Serologic testing (CAT: Chlamydia antibody testing) for 
C. trachomatis is based on micro immunofluorescence assays. Elevated titres 
of IgG are highly predictive for infection with C. trachomatis. These serologic 
assays focus mainly on the major outer membrane protein A, which is an antigen 
present in the outer membrane of a chlamydial particle. When the serology 
outcome is negative, no further action is taken, and the couple is asked to try 
for one more year to get pregnant. Some women undergo HSG. If the outcome is 
negative (in most of the cases), they try as well to conceive for one more year. 
If positive (in around 5–7% of the cases) a laparoscopy will be performed, and 
up to 5% will have tubal pathology and will proceed to IVF procedures. Since 
HSG does not identify many new cases (5% of HSG positive cases), its positive 
predictive value is almost identical to serology. The low specificity of the test 
also causes misdiagnosis because women that are negative in the serology test 
may in fact have tubal pathology in up to 20% of cases (percentages based on 
the cohort described in ref [16], personal communication).
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Figure1. The relation between serology testing (Chlamydia antibody testing) and laparoscopy and 
the percentages of misdiagnosis. CT = C. trachomatis; IVF = in vitro fertilization.
If the serology outcome is positive, laparoscopy will be used for further 
diagnosis.  When tubal damage is detected using laparoscopy, it is likely that an 
IVF procedure will be initiated to get pregnant.  One of the drawbacks of serology 
is that it comes with limited sensitivity: 55–60% of the Chlamydia serology 
positive women actually have tubal pathology.  Subsequently, this means that 
40–45% of the women are serology positive and undergo laparoscopy while 
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there is no tubal disease.  In conclusion, in the serology negative and positive 
groups, a significant percentage of the women get either unneeded laparoscopies 
or get misdiagnosed.
Given the prevalence of subfertility, each year an estimated number of 300,000 
women visit the general practice with C. trachomatis -associated infertility in 
Europe.  Using the current diagnostic procedures, there is still a substantial 
subset of women that are misdiagnosed.  This poses an enormous psychological 
burden on these women.  Additionally, there are tremendous economic costs 
associated with the disease.
Despite the rapid development in the field of human reproductive medicine, 
there is still a medical need for diagnostic tools that are able to stratify clinically 
relevant C. trachomatis infections.  The diagnostic test envisioned should be able 
to predict C. trachomatis -based tubal pathology and subsequent infertility by 
complementing serology in such a way that not only the sensitivity, but also the 
positive and negative predictive values increase significantly.
Epidemiological studies have demonstrated a 40% inheritable component for 
Chlamydia infections in humans [15].  This suggests the need for studies to 
identify which genes are responsible for this 40% component of risk. The innate 
immune system plays a pivotal role in the first recognition of Chlamydia and the 
subsequent immune response.
Since a panel of human PRRs are involved in the recognition of Chlamydia, we 
hypothesized and have shown that carrier traits (i.e. carrying multiple SNPs in 
multiple genes) result in a higher aberrant immune response as compared to single 
gene association studies. Subsequently, these traits synergistically increase 
risk for tubal pathology following C. trachomatis infection. Of 227 subfertile 
Dutch women, we performed genotyping of PRR genes TLR9, TLR4, CD14, and 
CARD15/NOD2 looking for common versus rare alleles [16].  Subfertility was 
defined based on laparoscopic grade of tubal pathology including extensive peri-
adnexal adhesions and/or distal occlusion of at least one tube. Being a carrier 
of several rare alleles was more frequent in women with tubal pathology (who 
had elevated serum IgG titers against C. trachomatis).  We showed that after C. 
trachomatis infection (these infections defined as CT IgG titers >32), subfertile 
women carrying >2 SNPs in PRR genes were at increased risk for tubal pathology 
compared to women carrying <2 SNPs (73 vs. 33% risk).  
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This association was not found among women without IgG antibodies to C. 
trachomatis.  Thus, adequate recognition of C. trachomatis by receptors in the 
genital tract is an important step in the immune response and may play a role in 
protecting the host against developing late sequelae following infection.
The single SNP frequencies of TLR2 SNPs did not alter the risk for tubal 
pathology in subfertile women, but, combined into specific haplotypes, carriage 
of haplotype I significantly reduced the risk of developing tubal pathology after a 
C. trachomatis infection (p = 0.015, OR = 0.28).  This haplotype also showed a 
significant trend in an inverse association with disease severity (asymptomatic 
> symptomatic > tubal pathology; ptrend = 0.021) [19]. In addition, PRRs, 
cytokines and chemokines play an essential role in the immunopathogenesis 
of C. trachomatis infections.  The chemokine receptor, CCR5, is crucial for T 
cell activation and function, since its deficiency causes suppression of T cell 
responses.  We showed that among patients with anti-chlamydial IgG responses, 
tubal pathology correlated with a low incidence of the CCR5Δ32 deletion (7%), 
while women without tubal pathology had a higher incidence of the CCR5Δ32 
deletion (31%), as compared to controls (19%) [26]. Thus, inflammation 
associated with CCR5 may predispose to development of complications of C. 
trachomatis infection. Recent findings show a similar pattern for CXCR5 [49].
Therefore, single SNPs, haplotypes, and eventually larger genetic traits based 
on genetic variation in multiple genes can potentially be used as susceptibility 
or severity markers for tubal pathology as a result of a C. trachomatis infection. 
By combining multiple SNPs in one diagnostic test, high predictive values can 
be achieved which should be suitable as a future companion diagnostic in the 
diagnosis and treatment strategy for subfertility.
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Public Health Genomics Approached and Translation into Public Health
Findings in the field of immunogenetics of C. trachomatis infections are of high 
relevance for public health and healthcare in general.  Such results contribute to 
the understanding of infection with this agent, which is worldwide the leading 
cause of preventable blindness and the most prevalent sexually transmitted 
disease that is strongly associated with ectopic pregnancy, tubal infertility 
and pelvic inflammation.  Furthermore, our findings provide new insights into 
the pathways that help explain individual heterogeneity in the clinical course 
of C. trachomatis infection and the possible development of more targeted and 
personalized approaches in the prevention, diagnosis and treatment of disease.
To improve the health outcomes associated with C. trachomatis infections, 
there is an urgent need to timely translate immunogenetic findings into the 
healthcare system.  The specialty having this task is called PHG, which is defined 
as ‘the responsible and effective translation of genome-based knowledge and 
technologies into public policy and health services for the benefit of population 
health’ [50].  In the context of C. trachomatis infections, such a public health 
initiative has not been advanced, despite sufficient data and the significant need 
to do so.  However, significant public health strategies need to be implemented 
very early after the discovery phase, and proofs of concept need to be obtained 
to promote a faster translational process not only from bench to bedside, but 
also from bedside to healthcare.  Possible bottlenecks for implementation need 
to be identified. 
Developing diagnostic tools based on host genetic predisposition can help 
determine an individual’s risk (as well as late complications) of infection.  However, 
moving forward with such a plan has hurdles along the path. We have seen that 
C. trachomatis infections, symptoms and complications can differ between 
individuals on the basis of host genetic factors, ethnicity and environmental 
factors.  And based on this review and on the literature, it seems likely that 
diagnostic assessment will allow for inclusion of a large number of case-specific 
variables (i.e. more stratified) that may even become ‘truly’ personalized in the 
near future with the incorporation information derived from dynamic fields of 
investigation such as systems biomedicine and epigenomics [50].  The major 
obstacle to implementation is not the CE (Conformtie Europeene) IVD or FDA 
approval of diagnostic application, but originates with the healthcare integration 
[18] and policy embedment processes. In general, a timely translation with 
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direct implementation by the healthcare systems is low [51], which is illustrated 
by the large amount of data present in the literature [52] patents [53, 54] and 
marketed products [55, 56] compared to technologies being used in hospitals 
[51, 57].  In order to minimize failure, it is important that researchers take into 
account the policy aspect and the acceptance of diagnostic applications in the 
healthcare systems [18] itself, instead of just considering the market. 
In order to move into the healthcare systems, it is important to think from 
the decision-making and policy implementation perspective. Health policy is 
generally developed through evidence-based interventions and around general 
public health instruments, such as Health Technology Assessment (HTA) among 
others [58, 59]. We use the term Public Health Assessment Tools (PHAT) [18] 
when we refer collectively to Health Needs Assessment, HTA and Health Impact 
Assessment. Health Needs Assessment is a systematic method of reviewing the 
health issues facing a population, leading to agreed upon priorities and resource 
allocation that will improve health and reduce inequalities [59]. HTA is a multi-
disciplinary field of assessment that evaluates the medical, economic, social, 
legal, ethical, and other implications of the incremental value, diffusion and use 
of a technology in healthcare [60]. Health Impact Assessment is a combination 
of procedures, methods and tools by which a policy, program or project may be 
judged as to its potential effects on the health of a population and the distribution 
of those effects within the population. For simplicity, we will utilize HTA [61]. This 
assessment is generally done by HTA professionals in the form of systematic 
reviews of an emerging or new technology/tool with recommendations forwarded 
to decision-makers. Based on these recommendations, a technique, technology, 
tool, or process is implemented in the policy of healthcare, and these policy 
decisions determine the acceptability, the applicability in healthcare and the 
reimbursements. This in our observations has been generally neglected [18] by 
the academic-industrial complex [62]. Therefore, it is of uttermost importance 
to take into consideration the HTA process while developing a tool, diagnostic 
kit or technology, thus, in order to efficiently, effectively and in a timely manner 
introduce an innovation into the healthcare system. Although HTA or PHAT 
themselves are not sufficient when looking at the whole translational pipeline 
from bench to healthcare, HTA needs to be streamlined and integrated with the 
technology transfer process, which is the process of translating an idea into an 
innovative product on the market.
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In the case of C. trachomatis, it can be said with some certainty that HLA, 
specific cytokines including IL-10 and several TLRs play a role in infection and 
disease progression. These factors will likely vary between ethnical groups. For 
example, the most important TLR4 SNP, associated with tubal factor infertility 
in Caucasians, does not exist in Chinese people at all. Furthermore, the current 
needs of the population, relevant technologies on the market and prioritizing 
technologies based on applicability, the target audience, and stakeholder 
involvement including patient groups need to be taken into consideration. Also, 
the analytical validity (the ability of a test to accurately and reliably measure 
the genotype of interest [63]), clinical validity (the ability of the test to detect 
or predict the phenotype of interest) [63]  and clinical utility (the likelihood 
that the test will lead to an improved outcome and incorporates assessment of 
the risk and benefits of genetic testing as well as economic evaluation) [63] of 
the diagnostic tool will have to be considered. In addition, by performing HTA, 
the economic, ethical, legal, and social implications will have to be thoroughly 
addressed in order to preempt any HTA related assessments by health policy-
makers for technology integration. This collectively covers many aspects of HTA 
investigation. 
Healthcare aims to improve health of the populations and that the perspective from 
which the healthcare decision-maker works is based on HTA recommendations. 
Therefore, at the end of the day, the approval of the technology lies in its clinical 
utility, since the analytical validity and clinical validity have been more or less 
addressed. Furthermore, equal weight is given to its ethical, economic, legal, 
and social implications (ELSI) in society. Generally, ethical, legal and economic 
issues are dealt with during the development of a diagnostic tool or technology; 
however, the social implications may be overlooked. This can be the downfall 
of the tool in healthcare implementation. Also, ELSI can be limited to one 
perspective: the industrial and not the population based perspective. Taking 
into account future developments such as ‘truly’ personalized medicine moving 
from clinical utility to personal utility and the use of ‘personal-genome tests’ 
[64] , current HTA as a tool for decision-making will be challenged [65] . Current 
HTA evaluates a technology on the population or subpopulation, but not on an 
individual level, which will be the need in the era of ‘truly’ personalized medicine.
When talking in terms of economics, reimbursement through insurance companies 
becomes important, which is sometimes addressed during the development of 
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a technology. Financially stable patients with no need of reimbursement, early 
adopters or ‘trendsetters’ do not guarantee acceptance by decision-makers 
as this does not represent the majority. HTA analysis is done based on the 
needs of the population as a whole and not based on a few elite. Therefore, 
these ethical questions have to be addressed here as well. HTA professionals 
generally prioritize technologies listed by them and investigate one or a few of 
them based on what they deem relevant to the current population need, which 
also has to be taken into account during the development of the diagnostic tool. 
This can be done via comparison to what already exists on how one can get 
a competitive advantage based on the current population need and through 
consultation with patient groups. This brings in another important aspect: the 
involvement of stakeholders. These stakeholders represent the needs of the 
population and should be given preference through the development of the 
diagnostic tool or technology. All these several aspects should be taken into 
account while developing a specific diagnostic kit for C. trachomatis subfertility, 
in order to decrease the chance of failure, if not guarantee its success in 
healthcare implementation. As a result among other factors, there is generally 
a delay in uptake and wide usage of diagnostic applications and technologies in 
healthcare systems and hospitals. Consequentially, by the time the technology 
or kit reaches the healthcare system, it becomes inferior in terms of efficiency 
and effectiveness, given the exponential growth of newer versions of emerging 
technologies on the market. The latter again goes through this delaying process. 
Recently, a new framework or model [18] has been developed which addresses 
all the above mentioned issues and others not mentioned here with regard 
to healthcare implementation. The LAL model brings together for the first 
time 2 separate entities, namely technology transfer and PHAT in a pseudo-
parallel initiation. Through this, the model promotes early on involvement of 
all stakeholders (including academics, industry, patient groups, insurance, 
policy makers, doctors, HTA professionals, etc.) via public-private partnership, 
consultation, bilateral communication, exchange of information, feedback loops, 
and relevant lobbying. The model ensures that through the technology transfer 
pipeline, all PHAT aspects are addressed, and it also encompasses the Public 
Health Genomics Wheel [66] as a reference frame which demonstrates the 
essential tasks of Public Health for integration of genome-based technologies 
ensuring all possible gaps are addressed. This ensures that by the time the 
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technology or diagnostic application is developed, it conforms to the standards 
required by decision-makers based on population needs. This decreases the 
likelihood of rejection as a relevant tool for healthcare. The model also puts 
emphasis on the value of information (how much a decision-maker is willing 
to pay to come to a decision) [67]. This is in terms of the end-user clarity, 
including ease of use, relevance to the patient and doctors, and any legal issues 
restricting use of the diagnostic application widely. As a consequence of the 
value of information, adaptations in this case to the diagnostic application 
can be made accordingly. Through this process, by the time the technology or 
diagnostic application is developed, it meets all conditions of healthcare policy, 
therefore, facilitating timely uptake. We believe this overarching LAL model can 
ease the bottleneck of a real-time uptake by hospitals as well as help industry 
to come to an early-on strategic decision on the new technology and thus, save 
on resources [18]. The LAL model seems an appropriate tool and framework 
for the development of the Chlamydia diagnostic kit that will ensure all issues of 
healthcare, as well as public health conformity and industrial requirements, are 
met and addressed. As a result, by the time the diagnostic kit is ready, it can 
be made immediately available for widespread use throughout the healthcare 
system. This can help industry to tap into a generally wider consumer market 
than traditionally accessed as well as help decrease the burden of disease that 
more would result from delay in the technology. It becomes obvious, that public 
health approaches need to adjust to these developments.  Thus, PHG in the 
future will be quite different from PHG in the past [50].
Rapid scientific advances in genomics and its application to epigenomics, 
microbiomics and systems biology not only contribute to the understanding 
of disease mechanisms, and to the characterization of each person’s unique 
clinical, genomic, and environmental information, but also provide the option of 
new promising applications in patient and human health management during the 
whole life-course. In fact, what was just a decade ago a distant vision for a new era 
of public health, in which advances from the -omic sciences would be integrated 
into strategies aiming at benefiting population health, is now the soon-to-be 
realized development of effective personalized healthcare that will be ‘truly’ 
personalized medicine.  The utility of most genetic tests and biomarkers is still 
not evidence-based enough.  In the personalized medicine setting, the traditional 
assessment and evaluation tools are inadequate.  We clearly face the need for 
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a new paradigm because as we start to understand, for example, that what we 
call common complex diseases might be a sum of ‘rare diseases’; we move from 
risk factors to individual pathways or networks, and from that perspective, we 
move from clinical utility to personal utility [68] . However, the real paradigm 
shift depends on the willingness to restructure policies and on the ability to train 
practitioners from various professions. P4 Medicine is a future vision defined by 
biologist Leroy Hood, and is short for ‘Predictive, Preventive, Personalized, and 
Participatory Medicine’ [69].  The premise of P4 Medicine is that, over the next 
20 years, medical practice will be revolutionized by biotechnology, to manage a 
person’s health, instead of manage a patient’s disease.  Although probably not 
around the next corner, there is a clear urgency to prepare healthcare systems 
and policy-makers in advance of the inevitable.
The implementation of PHG requires increased concerted actions not only on 
the global (http://www.graphint.org), but also on the European level. The Public 
Health Genomics European Network (PHGEN II), which is funded by the General 
Directorate for Health and Consumer Protection (DG SANCO) (http://www.
phgen.eu), initiated the National Task Forces on PHG in over 15 EU Member 
States. Due to these initiatives, the National Institutes of Public Health took 
a leading role in PHG in Finland, Belgium, the Netherlands, Croatia, Poland, or 
Germany. PHGEN II has developed ‘European Best Practice Guidelines for Quality 
Assurance, Provision and Use of Genome-based Information and Technologies’ 
[70], which will assist the European Member States. The LAL model has also 
been integrated in these guidelines. A major international research consortium 
called ‘Information and Communication Technology for Future Medicine (ITFoM)’ 
anticipates the medicine of the future, based on molecular, physiological, 
anatomical and environmental data from individual patients (http://www.itfom.
eu).  The ‘ITFoM project’ will create the entirely new ICT that will make it possible 
to make general models of human pathways, tissues, diseases, and ultimately 
of the human as a whole. Patient-individualized versions of ICT replica (‘virtual 
patients’) will be used to identify personalized prevention and therapy schedules 
and side effects of drugs [71].  The LAL model will play an important role in this 
project to make sure that by the time the technology is rolled out, it is adapted 
and conformed for real-time integration in healthcare.
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Conclusions and Future Prospects 
We investigated the potential translational and clinical value of adding diagnostic 
host genetic marker profiles relating to infection and inflammation to the 
current clinical diagnosis and management of subfertility, which is based on 
serology and laparoscopy. It is clear from a large body of evidence that host 
genetic factors play a role in the susceptibility to and severity of C. trachomatis 
infection, as shown by twin studies and many candidate gene studies. To 
bring this current host genetic work to the next level, large scale SNP typing 
and SNP identification in confirmation cohorts is essential and is in progress. 
This work will provide insight into what type of host genetic profile can help 
improve subfertility diagnoses and whether the added sensitivity, specificity, 
and positive and negative predictive value will realize the hope that carrier traits 
will significantly increase the ability to predict and identify those at greatest risk 
of severe complications from C. trachomatis infection.  In addition, as shown by 
the LAL model, stakeholders have to be informed and participate early-on in the 
potential implementation of these findings, a major task and challenge for the 
field of public health genomics which can be realized through the LAL model.
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Abstract
Up to 30% of infertile couples suffer from tubal factor infertility (TFI), and in 
approximately 45% of the cases tubal pathology can be attributed to a previous 
Chlamydia trachomatis infection.  Based on twin research and previous findings, 
host immunogenetic factors have been recognized as the most important factors 
in influencing differences in susceptibility to, course and outcome of Chlamydia 
infection and thus have a major influence on the development of TFI. 
In this study we explored the potential need for introducing genomic testing in 
the routine investigation of TFI, based on the perceived health needs of infertile 
women in the Netherlands and the needs of clinicians for a more accurate 
screening test. 
We identified diagnostic strategies currently in place, defined the population that 
will be targeted by the new intervention and explored the ways in which the use 
of genomic testing could improve the investigation of TFI in the Netherlands.  Our 
new proposed diagnostic strategy is to combine Chlamydia IgG antibody testing 
(CAT), the most widely used screening test so far, with genomic diagnostics 
early in the fertility work-up, in order to increase the accuracy of screening for 
TFI. We postulate that serology and genome-based diagnostics combined could 
have higher PPV and NPV than serology alone.  Additionally, the combination of 
tests could contribute to optimizing the timing of additional, invasive diagnostic 
testing (laparoscopy) in the fertility work-up, as well as optimizing the timing 
of starting treatment.  With the introduction of host genomic markers into the 
assessment of TFI, infertile women could benefit from a more accurate, yet less 
invasive and timelier diagnosis.
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Introduction
Infertility, the inability to conceive after unprotected intercourse for at least 
one year, poses a great burden on healthcare and society throughout the 
world.  Worldwide, 10-15% of couples trying to conceive suffer from infertility 
[1, 2] and in 11-30% of these couples infertility is related to tubal pathology 
[1].  Persistent Chlamydia trachomatis urogenital infection (here referred as 
Chlamydia infection) is one of the most common causes of damage to the 
fallopian tubes and subsequent tubal factor infertility (TFI). The proportion of 
TFI attributed to Chlamydia trachomatis is estimated to be 45% [3].  This high 
percentage stresses the importance of understanding the basic mechanism 
behind ascending Chlamydia infections and its complications and translating 
this knowledge into practical applications in healthcare.
Two main characteristics of Chlamydia infection make diagnosis, timely treatment 
and prevention of late complications very challenging. First, up to 80 - 90% of 
infections in women and up to 50% in men are asymptomatic [4, 5]. Absence 
of symptoms impedes antibiotic treatment and contributes to the development 
of complications. Second, Chlamydia infection of the lower genital tract can 
have very diverse courses and outcomes.  It is estimated that 45% of women 
clear the infection within the first year without developing any complications 
[6], in others the bacteria causes persistent infections and sequelae, such as 
endometritis, salpingitis, PID (Pelvic Inflammatory Disease), ectopic pregnancy 
and TFI [5, 7, 8].
Twin studies [9] estimated that host genetic factors are responsible for 40% 
of variation in Chlamydia infection characteristics and outcome. This finding 
provided the scientific basis for the immunogenetic approach in the research of 
Chlamydia trachomatis infections.
A previous study reviewing the translational potential of genomic and genetic 
findings related to Chlamydia trachomatis  in healthcare [10] pointed out a 
growing body of research on host immunogenetic factors behind the differences 
in disease outcomes [11–16]. Such immunogenetic factors consist of genetic 
variations, as Single Nucleotide Polymorphisms (SNPs), in genes responsible for, 
amongst others, Pattern Recognition Receptors (PRR) [11]. Toll Like Receptors 
(TLRs) are a family of PRR with the ability to identify pathogens and to initiate 
an innate immune response. TLRs have been recognized as the most important 
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factors in influencing differences in susceptibility to, course and outcome of 
Chlamydia infection [17].  Thus, research on host immunogenetic factors could 
have implications on the future of diagnosing Chlamydia trachomatis -induced 
infertility. 
Chlamydia IgG antibody testing (CAT) in serum is the most commonly used test 
in the screening of TFI. There are a number of studies estimating the accuracy of 
this screening strategy [18–20]. An early meta-analysis on the predictive value 
of CAT [18] found that the sensitivity of evaluating Chlamydia trachomatis titers 
in blood widely ranges from 21-90%, but it has been shown that test accuracy 
depends on the type of the essay used, definition of TFI and on the reference 
test applied for diagnosing tubal pathology [19]. Sensitivity for tubal pathology 
of the most accurate CAT was assessed at approximately 60%, with specificity 
of 85-90% [21].
The most important research priorities related to Chlamydia trachomatis 
are considered to be: correlating host genetics with infection outcomes and 
determining the risk and timing of development of tubal inflammation and 
damage from untreated chlamydial infection, by developing standardized 
algorithms for measuring PID, ectopic pregnancy and TFI on a population level 
[22].
SNPs-based analysis has the potential to improve the accuracy of diagnosing 
TFI and such a non-invasive genomic test is currently under development [14, 
23]. By identifying and combining multiple SNPs in PRR genes and their linked 
pathways, a diagnostic test of high sensitivity, specificity and negative predictive 
value (NPV)  can potentially be developed [23].
The clinical relevance of a screening test based on genomic markers would be 
in adequately assessing the risk of TFI in infertile patients, and postponing or 
completely avoiding the use of expensive and invasive diagnostic procedures in 
patients at low risk of having tubal pathology, and selecting patients at high risk 
in whom laparoscopy is advised.
Today, many gene–disease associations are proven and genetic/genomic testing 
has acquired a role in guiding clinical decision making. However, the translation 
of scientific discoveries into every day clinical practice is still a slow and difficult 
process. It is estimated that only about 5% of discoveries in basic science 
are licensed into healthcare [24], and it may be assumed that translation of 
genomic and genetic findings is even lower. The aim of this study is to facilitate 
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such translation process from bench to bedside by exploring the potential need 
for introducing genomic testing in the routine investigation of TFI by assessing 
health needs of the target population. 
Material and Methods 
 
There is no common understanding of the concept of health needs. They have 
different meaning for different stakeholders among healthcare providers, 
policymakers and patients [25]. In order to explore the possibility of improving 
the diagnostic accuracy of testing for Chlamydia trachomatis -induced infertility 
in women using genomic diagnostics, we designed a framework for assessment 
of health needs based on the National Health Service (NHS) approach [26]. 
The following 3-step analytic framework was developed 
Step 1- Identify services/strategies currently in place in fertility care in the 
Netherlands; 
Step 2- Assess the health needs of infertile women in the Netherlands and/or 
clinicians’ needs  
Step 3- Define the ways in which the use of genomic testing could improve the 
services/strategies currently in place and ameliorate the health outcomes of 
infertile women in the Netherlands. 
 
Data collection
In order to conduct such a study, we combined data collected by literature review 
with data obtained by interviewing gynaecologists, selected for their expertise 
in reproductive medicine in 4 out of 8 academic hospitals in the Netherlands 
(these hospitals will later be referred to by using numbers 1-4).
The literature search focused on identifying the current strategies in the fertility 
work-up, concentrating on tubal infertility, and on defining the population of 
infertile women in the Netherlands. The following databases were searched 
for appropriate references: (PubMed, Cochrane library), Electronic Journals 
collections (Maastricht University EJ collection) and websites (Centraal Bureau 
voor de Statistiek website and Dutch Society for Obstetrics and Gynaecology 
(NVOG) website).
The purpose of the interviews was to explore the topics of fertility investigation 
as well as to corroborate the information gained from the literature search. The 
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interviews took place between February and March 2013. They were semi-
structured interviews, that is, more similar to conversation then to formal 
structured interviews. Before conducting the interviews we created some 
guidelines and decided on the main issues for discussion, but we did not insist 
on always following the same sequence of the questions or the exact formulation 
used in the guidelines. The focus in the interviews was on fertility work-up in 
general, with emphasis on TFI work up, on the type and sequence of diagnostic 
procedures in routine work-up in one’s own clinic and on the main perceived 
problems in everyday practice. Three interviews were conducted face-to-face 
and one via Skype. All the interviews were recorded and later transcribed.
Results
Step 1: Services currently in place
Currently, the investigation and management of infertility in the Netherlands 
is based on the guidelines developed by the working group of the Dutch 
College of General Practitioners (NHG) and the Dutch Society for Obstetrics 
and Gynaecology (NVOG). The guidelines emphasize the importance of shared 
care between gynaecologists and general practitioners (GPs) and the need for 
consensus among professionals in the clinical decision making process. The 
document provides a general outline of the recommended diagnostic procedures, 
GPs and specialists working at the regional level [27]. In the Netherlands, at the 
moment, there is no consensus on the sequence of diagnostic procedures in 
routine fertility work-up, including investigation of tubal pathology as a possible 
considerably. 
In hospital 1 the investigation of tubal function begins with CAT. Whenever CAT 
is negative (CAT-), the patient will undergo Hysterosalpingography (HSG). In 
case of abnormal HSG the patient is referred to laparoscopy. In case that CAT 
is. CAT+ women younger than 39 undergo laparoscopy, whereas women older 
than 39 have no additional testing and are referred for IVF. (Gynaecologist #1, 
13.02. 2013, personal communication).
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In hospital 2 CAT is rarely performed. In most cases HSG is done as the 
primary investigation of tubal patency and laparoscopy is performed only in 
patients with abnormal HSG results (Gynaecologist #2, 12.03.2013, personal 
communication).
patient is assumed to have 50% chance of either tubal blockage or adhesions, 
and laparoscopy is advised. In case of negative CAT, no laparoscopy is performed. 
In this hospital HSG as a screening test is totally abandoned (Gynaecologist#3, 
12.03.2013, personal communication).
In hospital 4 all three screening strategies (CAT, HSG and laparoscopy) are used. 
The screening process starts with CAT. Patients with positive CAT results undergo 
laparoscopy regardless of their age, patients with negative CAT results have 
HSG and, in case of an abnormal HSG they undergo laparoscopy (Gynaecologist 
#4 14.02.2013, personal communication).
Figure1. 
hospitals (HSG- hysterosalpingography; LAP- laparoscopy, CAT-Chlamydia antibody testing; IVF-in 
vitro fertilization;   X- further investigation of tubal factors concluded)
An updated and more comprehensive version of the guidelines for fertility 
work-up in the Netherlands is underway, and it will be based on the guidelines 
on infertility developed in UK by the National Institute for Health and Clinical 
Excellence (NICE) [28]. 
Hospital 1 Hospital 3
LAP IVF
CAT
LAP
CAT
Age ≤ 39 Age >39
(+)
(-)
HSG
LAP
(+)
X
(-) (+)
X
(-)
Hospital 2
LAP
HSG
(+)
X
(-)
Hospital 4
LAP
LAP
CAT
HSG
(+)
(-)
(+)
X
(-)
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The NICE guidelines recommend HSG as the strategy of first choice for the 
screening of tubal pathology in the absence of known comorbidities, such 
as pelvic inflammatory disease (PID), endometriosis or ectopic pregnancy. 
Conversely, women with known comorbidities should undergo laparoscopy, 
which is considered the golden standard for the assessment of tubal function 
[28].
Step 2: Defining the target population and its health needs
Establishing health needs for the introduction of a new diagnostic strategy 
starts with defining the population that will be targeted and may benefit from 
the new intervention.  There are several challenges in defining the population 
of women in the Netherlands who could potentially benefit from introducing 
genetic testing into routine clinical investigation of TFI. The exact incidence and 
prevalence of Chlamydia infection [29] are unknown, and there is uncertainty 
about the proportion of women with Chlamydia infection who will over time 
develop PID and TFI [20].   Therefore, in understanding our target population we 
have to rely on estimates and trends of Chlamydia infection prevalence found in 
the literature. 
In the Netherlands there is no nationwide Chlamydia trachomatis screening, 
nevertheless in the last 10 years several rounds of screening were conducted 
offering an insight into the overall prevalence of Chlamydia infection. In 2003 
a pilot screening project for Chlamydia infection involving 21000 participants 
found a 2% overall prevalence of Chlamydia infection in women and 1,5% in 
men [30]. Following the pilot, a systematic and selective (initiated in three 
regions) Chlamydia screening program, aiming at reducing the prevalence of 
the infection by screen and treat, started in 2008 and lasted till 2011. In the 
first screening round an overall positivity rate of 4.2% was found among 15-29 
years old respondents from Amsterdam, Rotterdam and South Limburg [31]. A 
follow-up study evaluating the effectiveness of three yearly chlamydia screening 
rounds [32] did not find a significant decrease in positivity rates in any region or 
socio-demographic group. 
The surveillance data of the Dutch National Institute for Public Health and 
Environment (RIVM) show that in the period from 2004 till 2012, 10-13% 
of those visiting the Dutch regional STI clinics tested positive for Chlamydia. 
The testing was voluntary, provided free of charge and anonymous, but all the 
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positive cases were reported to the National Centre for Infectious Disease 
Control at the RIVM.  In 2012, with 15.000 diagnoses, Chlamydia became the 
most common bacterial cause of infection in the registries of the Dutch STI 
clinics. Of women who tested positive for Chlamydia 77% were younger than 
25 years. [33]. However, the lack of clear guidelines regarding anatomic sites 
to be tested for Chlamydia (routinely only the urogenital area is tested) may 
underestimate the exact burden of Chlamydia infection [34]. The general trend 
in Europe, based on the data of reported incidence of Chlamydial infections, 
show increasing trends in the last ten years.  This increase in positivity rate is 
partly attributed to the increased testing and partly to the increase in risk taking 
behavior [20].
However, even if exact numbers of prevalence and incidence of the infection 
are known this would not allow to determine the exact number of women with 
Chlamydia induced TFI. It is estimated that almost half of all infected women 
will spontaneously clear the infection [6]. There is a lack of prospective studies 
quantifying the risk of developing TFI over time after an untreated C. trachomatis 
infection [29]. Research offers diversified findings with PID occurring in 2-4.5% 
to 30% in women with a previous untreated Chlamydia infection, and TFI to 
develop 10-20% of them. [29] and from studies using models the estimated 
risk to develop TFI after lower genital tract Chlamydia infections is 0.1-5% [21]. 
Data on the actual prevalence of infertility in the Netherlands are scarce.  In 
a study published in 1995 estimating the prevalence of infertility in South 
Limburg, researchers found that between 14-16.5% of couples visited a 
fertility specialist during their reproductive life [35]. In an international study 
on the prevalence of infertility and the estimate of the demand for fertility 
medical care, Boivin et al. [2] found the prevalence of female infertility in high 
income countries to be ranging from 3.5-16.7% and from 6.9-9% in middle 
income countries. Their analysis of population surveys in 25 countries found an 
overall median prevalence of infertility of 9%, estimating worldwide more than 
72 million women being infertile. In a survey in 1997, Balen et al. reported a 
prevalence of infertility among Dutch couples of 10.7 %, with more than 80% 
of infertile couples seeking medical care [36].
A very important characteristic of the target population is age, as female age 
is the single most important determinant of a couple’s fertility [37]. A study 
conducted in the Netherlands found a strong relation between later conception 
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and the increased demand for fertility care [38].
In the Netherlands, alike other high income countries, there is a trend of 
postponing having children. The mean maternal age at delivery of the first child 
has increased from 25.6 years in 1980 to 29.4 in 2008. [39, 40]. In 2012 
20% of all births were to first time mothers older than 35 [41].  In 2009, 4% 
of children in the Netherlands were born to mothers who were 40 years or older 
[42]. In some fertility clinics in the Netherlands, the proportion of women older 
than 35 years seeking medical care has increased four times in the last 20 
years [38]. 
In summary, Dutch women are postponing having children, consequently the 
population of women undergoing fertility investigation in the Netherlands are 
growing older, increasing their demand for fertility care. Data show a 5-10% 
annual increase in demand for assisted reproduction techniques in many 
developed countries over the last 5 years [43].
Screening and surveillance data on Chlamydia infection show either persistent 
or increasing prevalence rates of the infection among young adults. This might 
have clinical implications 10 to 15 years later when these women decide to 
have children, resulting in increased numbers of women visiting fertility clinics 
and applying for assessing the risk of TFI.
Step 3: Potential of genomic testing in meeting the health needs
Description of the strategy
Our new proposed screening strategy would combine CAT with genomic 
diagnostics early in the fertility work-up by taking blood samples for CAT and 
host genomic biomarkers (SNPs).  Positive CAT is considered a serological proof 
of previous Chlamydia infection but does not inform us about the course of 
infection and probability of tubal pathology [44].  The genome-based companion 
diagnostic, testing for variations in genes encoding for amongst others PRRs 
and inflammatory pathways including tissue scarring, could give us more insight 
in the course of infection. The test, based on combination of SNPs is under 
development and not yet clinically validated, based on the prior research in the 
following text we hypothesize its diagnostic value.  
Since tubal pathology is a multifactorial and polygenic disease, and one single 
SNP usually does not predict a major risk, we are studying combinations of SNPs 
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for the development of tubal pathology following Chlamydia trachomatis 
an accurate assessment of ratio between risk factors and protective traits.
The intended added value of the genome-based companion diagnostic (CAT and 
host genomic markers) would be to improve PPV by decreasing the number of 
false positive CAT results and the number of invasive diagnostic procedures 
performed in CAT+ women without TFI. Improving NPV would reduce the number 
of patients with false negative tests in whom diagnosing TFI would be delayed by 
postponing or omitting laparoscopy. 
Figure 2. Elements of the decision making process based on the implementation of the “CAT 
and genome-based companion diagnostics” in the initial phases of the fertility work-up (HSG- 
hysterosalpingography; LAP- laparoscopy, CAT-Chlamydia antibody testing)
Positive CAT and negative genomic markers for high TFI-risk would indicate 
that, although the patient had a Chlamydia infection in the past, there is a high 
chance of the infection to have been cleared without complications. In this case, 
no laparoscopy would be indicated to exclude tubal pathology. In case both tests 
are negative the risk of TFI is low, and further investigation of tubal function 
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could be omitted. The combination of positive CAT and positive genomic markers 
for high risk would identify women at the highest risk of tubal pathology, and 
laparoscopy would be advised. Lastly, when CAT is negative and the genetic 
test is positive, further investigation of tubal function would be advised based 
on the predictive value of host genetic markers for TFI, as TFI can be caused 
by bacterial STDs other than Chlamydia. (Figure 2). In those cases in which the 
genomic test is  at the same time positive for the SNPs which put the patient 
at high risk of developing TFI, and positive for  the  SNPs recognized for their 
protective role,  the decision making will be more complex and will have to rely 
on additional clinical variables.
CAT and genome-based companion diagnostics are both noninvasive tests for 
which a small quantity of blood is needed, allowing the test to be performed 
in a GP office. In case of a positive test panel result, a GP could refer couples 
who wish to become pregnant to a reproductive specialist regardless of other 
clinical variables.  In case of a negative result timing of referral to a specialist 
could depend on other prognostic factors in the couple. In the fertility clinic, 
combining CAT and genome-based companion diagnostics in the initial phases 
of the infertility investigation would enable to assess the risk of tubal pathology 
at an early stage. This would affect decision making on subsequent investigations 
and treatment (Figure 2). 
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Discussion and conclusion 
Today in many fertility clinics in The Netherlands, in the investigation of TFI, CAT 
and/or HSG are used as the primary tests, and laparoscopy as the reference 
diagnostic. The advantage of CAT is that it is easy to perform, inexpensive, non- 
invasive and not associated with complications. The main disadvantage is the 
relatively low PPV. Research shows that in approximately 40-50% of women 
who are testing positive for CAT, no tubal pathology is found at laparoscopy, 
whereas 10-20%  of women testing CAT negative do have tubal pathology [10, 
17,19].
In the Netherlands, HSG is either performed following CAT or as an independent 
test of tubal patency. HSG’s sensitivity and specificity are estimated at 53% and 
87% respectively (compared to laparoscopy) [45, 46]. The main disadvantage 
of HSG is, apart from its mediocre test characteristics, is that is a painful 
procedure and can be complicated by an ascending infection. 
Laparoscopy is considered the golden standard in the assessment of tubal 
patency, and it also visualizes endometriosis and peritubal adhesions. However, 
it is an invasive procedure associated with discomfort for the patient, has to be 
performed under general anesthesia, and is associated with potential surgical 
complications, a post-surgical recovery period and high costs [47]. 
The ultimate goal is to improve the accuracy of first line testing by correlating 
host genetics with infection outcomes, i.e. by combining serologic and genetic 
testing, to more accurately determine the risk of TFI and to reduce the number 
of misdiagnoses. In defining the target population that could benefit from 
introducing genetic testing into routine fertility work-up, we face several 
challenges. The greatest challenge of them, and the fundamental challenge 
of Chlamydia research, is not knowing the true incidence and prevalence of 
Chlamydia infections and the risk of developing TFI over time after an untreated 
C. trachomatis infection [29]. Additionally, in the Netherlands there are no recent 
data on the prevalence of infertility. A study conducted in 1997 [36] assessed 
that 10.7% of Dutch couples have problems in conceiving, with more than 80% 
of them seeking medical care. More recent data of the prevalence of infertility in 
the Netherlands are needed as since 1997 the mean maternal age at delivery 
of the first child has significantly increased [39], influencing female fertility and 
increasing the demand for fertility care.  Finally, screening and surveillance data 
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from STI clinics in The Netherlands for Chlamydia infection show no decrease 
in prevalence rates of infection among young adults, and therefore it can be 
assumed that Chlamydia trachomatis will continuously play an important role in 
the pathophysiology of TFI. 
Clinical relevance
CAT has been introduced into the fertility work-up as a simple and inexpensive 
screening test for the risk assessment of TFI. The clinical performance of CAT, 
however, has been shown not to be optimal due to the number of false positive 
and false negative test results. [48]. The primary goal of introducing genomic 
tests to CAT as a combined test panel, is to improve test accuracy. This would 
of resources and less expenses for the healthcare system, and minimisation of 
interventions for the patients. 
There are also challenges to be considered when proposing the introduction of 
genomic testing in the routine fertility work-up. One of them is complexity of the 
potential implementation of the new strategy. Some patients may be positive 
for SNPs which increase risk to develop TFI and at the same time be positive 
for SNPs of preventive genetic trait, making clinicians’ decision process more 
complex and calling for precise algorithms to aid decision making. The presence 
of SNPs associated with risk of TFI and SNPs associated with protection against 
TFI could create a grey zone.  This grey area should be as small as possible, but 
it will always exist. 
Healthcare spending in the Netherlands is steadily growing, and in 2012 it 
equaled to 11.9 percent of gross domestic product (GDP), which is higher than 
the average 9.6 percent of OECD countries [42]. Growing costs of healthcare 
proposed diagnostic and treatment strategies. Therefore there is a need for a 
comprehensive analysis comparing costs and outcomes of the course of action 
proposed in our study and the existing combinations of diagnostic strategies 
(CAT, HSG and Laparoscopy) currently performed in the Netherlands. 
Finally, advancements in genomics are driving changes in diagnostic and 
healthcare professionals will be to adjust to the new developments. In the case 
of introduction of genomic testing in routine fertility work-up this could be 
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achieved by setting up continuing medical education courses for reproductive 
specialists in order to increase their familiarity with clinical genetics.  Another 
challenge is creating a test with straightforward results, easy to interpret and 
explain to patients. Such a test could contribute to the acceptance of genomic 
markers in the routine fertility work-up by the medical professionals.
One of the key elements for implementation of genomic applications in clinical 
care is its proof of its applicability and accuracy [49]. Therefore, for successful 
implementation of genome-based companion diagnostics in the investigation of 
TFI, validation of the genomic test is the most important step.  Clinical studies 
need to be performed in order to demonstrate the benefits of the proposed 
strategy and to confirm that the introduction of the host genomic markers as 
an addition to CAT in testing of TFI will result in better patient management and 
improved clinical outcomes.
120
REFERENCES
1. Evers, JL. Female subfertility. Lancet, 2002. 360(9327): p. 151-159.
2. Boivin, J, Bunting, L, Collins, JA, et al. International estimates of 
infertility prevalence and treatment-seeking: potential need and demand 
for infertility medical care. Human reproduction, 2007. 22(6): p. 1506-
1512.
3. Price, MJ, Ades, AE, Welton, NJ, et al. How much tubal factor infertility 
is caused by Chlamydia? Estimates based on serological evidence 
corrected for sensitivity and specificity. Sexually transmitted diseases, 
2012. 39(8): p. 608-613.
4. Lyons, JM, Ouburg, S and Morré, SA. An integrated approach to 
Chlamydia trachomatis infection: the ICTI Consortium, an update. Drugs 
of today, 2009. 45 Suppl B: p. 15-23.
5. Lanjouw, E, Ossewarde, JM, Stary, A, et al. 2010 European guideline 
for the management of Chlamydia trachomatis infections International 
Journal of STD & AIDS, 2010. 21: p. 729-737.
6. Morré, SA, van den Brule, AJ, Rozendaal, L, et al. The natural course 
of asymptomatic Chlamydia trachomatis infections: 45% clearance and 
no development of clinical PID after one-year follow-up. International 
Journal of STD & AIDS, 2002. 13 Suppl 2: p. 12-18.
7. Paavonen, J and Eggert-Kruse, W. Chlamydia trachomatis: impact on 
human reproduction. Human reproduction update, 1999. 5(5): p. 433-
447.
8. WHO. Sexually transmitted infections. 2013; Available from: http://www.
who.int/mediacentre/factsheets/fs110/en/.
9. Bailey, RL, Natividad-Sancho, A, Fowler, A, et al. Host genetic contribution 
to the cellular immune response to Chlamydia trachomatis: Heritability 
estimate from a Gambian twin study. Drugs of today, 2009. 45 Suppl B: 
p. 45-50.
10. Malogajski, J, Brankovic, I, Verweij, SP, et al. Translational potential 
into health care of basic genomic and genetic findings for human 
immunodeficiency virus, Chlamydia trachomatis, and human papilloma 
virus. BioMed research international, 2013. 2013: p. 892106.
11. den Hartog, JE, Ouburg, S, Land, JA, et al. Do host genetic traits in the 
bacterial sensing system play a role in the development of Chlamydia 
trachomatis-associated tubal pathology in subfertile women? BMC 
infectious diseases, 2006. 6: p. 122.
12. Darville, T, O’Neill, JM, Andrews, CW, Jr., et al. Toll-like receptor-2, 
but not Toll-like receptor-4, is essential for development of oviduct 
pathology in chlamydial genital tract infection. Journal of immunology, 
2003. 171(11): p. 6187-6197.
CHAPTER 4
121
13. Morré, SA, Murillo, LS, Bruggeman, CA, et al. The role that the functional 
Asp299Gly polymorphism in the toll-like receptor-4 gene plays in 
susceptibility to Chlamydia trachomatis-associated tubal infertility. The 
Journal of infectious diseases, 2003. 187(2): p. 341-342; author reply 
342-343.
14. Morré, SA, Karimi, O and Ouburg, S. Chlamydia trachomatis: identification 
of susceptibility markers for ocular and sexually transmitted infection 
by immunogenetics. Fems Immunology And Medical Microbiology, 2009. 
55(2): p. 140-153.
15. den Hartog, JE, Lyons, JM, Ouburg, S, et al. TLR4 in Chlamydia 
trachomatis infections: knockout mice, STD patients and women with 
tubal factor subfertility. Drugs of today, 2009. 45 Suppl B: p. 75-82.
16. Laisk, T, Peters, M, Saare, M, et al. Association of CCR5, TLR2, TLR4 
and MBL genetic variations with genital tract infections and tubal factor 
infertility. Journal of reproductive immunology, 2010. 87(1-2): p. 74-
81.
17. den Hartog, JE, Morré, SA and Land, JA. Chlamydia trachomatis-
associated tubal factor subfertility: Immunogenetic aspects and 
serological screening. Human reproduction update, 2006. 12(6): p. 
719-730.
18. Mol, BW, Dijkman, B, Wertheim, P, et al. The accuracy of serum chlamydial 
antibodies in the diagnosis of tubal pathology: a meta-analysis. Fertility 
and sterility, 1997. 67(6): p. 1031-1037.
19. Land, JA, Gijsen, AP, Kessels, AG, et al. Performance of five serological 
chlamydia antibody tests in subfertile women. Human reproduction, 
2003. 18(12): p. 2621-2627.
20. Akande, V, Turner, C, Horner, P, et al. Impact of Chlamydia trachomatis in 
the reproductive setting: British Fertility Society Guidelines for practice. 
Human fertility, 2010. 13(3): p. 115-125.
21. Land, JA, Van Bergen, JE, Morré, SA, et al. Epidemiology of Chlamydia 
trachomatis infection in women and the cost-effectiveness of screening. 
Human reproduction update, 2010. 16(2): p. 189-204.
22. Gottlieb, SL, Martin, DH, Xu, F, et al. Summary: The natural history 
and immunobiology of Chlamydia trachomatis genital infection and 
implications for Chlamydia control. The Journal of infectious diseases, 
2010. 201 Suppl 2: p. S190-204.
23. Lal, JA, Malogajski, J, Verweij, SP, et al. Chlamydia trachomatis infections 
and subfertility: opportunities to translate host pathogen genomic data 
into public health. Public Health Genomics, 2013. 16(1-2): p. 50-61.
24. Khoury, MJ, Gwinn, M, Yoon, PW, et al. The continuum of translation 
research in genomic medicine: how can we accelerate the appropriate 
integration of human genome discoveries into health care and disease 
prevention? Genetics in medicine : official journal of the American College 
of Medical Genetics, 2007. 9(10): p. 665-674.
122
25. Wright, J, Williams, R and Wilkinson, JR. Development and importance of 
health needs assessment. BMJ, 1998. 316(7140): p. 1310-1313.
26. Health Needs Assessment Workshop. in National Health Service2010, 
National Health Service. Available from: http://cehi.org.uk/Health%20
Needs%20Assessment%20Workshop%20Slides%20Dec%202010.
pdf.
27. Subfertiliteit. 1998, Nederlandse Vereniging voor Obstetrie en 
Gynaecologie. Available from: http://www.nvog.nl/.
28. Fertility: assessment and treatment for people with fertility problems 
update. 2013, National Institute for Health and Clinical Excellence 
(NICE). Available from: http://guidance.nice.org.uk/CG156.
29. Haggerty, CL, Gottlieb, SL, Taylor, BD, et al. Risk of sequelae after 
Chlamydia trachomatis genital infection in women. The Journal of 
infectious diseases, 2010. 201 Suppl 2: p. S134-155.
30. van Bergen, J, Gotz, H, Richardus, JH, et al. Prevalence of urogenital 
Chlamydia trachomatis infections in the Netherlands suggests selective 
screening approaches. Results from the PILOT CT Population Study. 
Drugs of today, 2006. 42 Suppl A: p. 25-33.
31. van Bergen, JE, Fennema, JS, van den Broek, IV, et al. Rationale, 
design, and results of the first screening round of a comprehensive, 
register-based, Chlamydia screening implementation programme in the 
Netherlands. BMC infectious diseases, 2010. 10: p. 293.
32. van den Broek, IV, van Bergen, JE, Brouwers, EE, et al. Effectiveness 
of yearly, register based screening for chlamydia in the Netherlands: 
controlled trial with randomised stepped wedge implementation. BMJ, 
2012. 345: p. e4316.
33. RIVM. Chlamydia: Hoe vaak komt het voor en hoeveel mensen sterven eraan? 
2012; Available from: http://www.nationaalkompas.nl/gezondheid 
-en-ziekte/ziekten-en-aandoeningen/infectieziekten-en-parasitaire-
ziekten/soa/chlamydia/omvang/.
34. Koedijk, FD, van Bergen, JE, Dukers-Muijrers, NH, et al. The value 
of testing multiple anatomic sites for gonorrhoea and chlamydia in 
sexually transmitted infection centres in the Netherlands, 2006-2010. 
International Journal of STD & AIDS, 2012. 23(9): p. 626-631.
35. Beurskens, MP, Maas, JW and Evers, JL. [Subfertility in South Limburg: 
calculation of incidence and appeal for specialist care]. Nederlands 
tijdschrift voor geneeskunde, 1995. 139(5): p. 235-238.
36. van Balen, F, Verdurmen, J and Ketting, E. Choices and motivations of 
infertile couples. Patient education and counseling, 1997. 31(1): p. 19-
27.
37. Balen, AH. Infertility in Practice. Fourth edition ed. Reproductive Medicine 
and Assisted Reproductive Techniques Series 2014: CRC Press. 500.
CHAPTER 4
123
38. de Graaff, AA, Land, JA, Kessels, AG, et al. Demographic age shift toward 
later conception results in an increased age in the subfertile population 
and an increased demand for medical care. Fertility and sterility, 2011. 
95(1): p. 61-63.
39. Geboorteregeling 2008. Centraal Bureau voor de Statistiek. Available 
from: www.cbs.nl.
40. Leeftijd moeder bij eerste kind  per gemeente. 2010, Nationale 
Atlas Volksgezondheid Available from: http://www.zorgatlas.nl/
beinvloedende-factoren/demografie/geboorte-en-sterfte/leeftijd-
moeder-bij-geboorte-eerste-kind-per-gemeente/.
41. Geboorte; leeftijd moeder. Centraal Bureau voor de 
Statistiek. Available from: http://statline.cbs.nl/StatWeb/
publication/?VW=T&DM=SLNL&PA=37520&LA=NL.
42. Gezondheid en zorg in cijfers 2012. Centraal Bureau voor de Statistiek. 
Available from: http://www.cbs.nl/NR/rdonlyres/B438B6AC-BAB5-
4F71-A7F3-26EB01FE66EF/0/2012c156puberr.pdf.
43. ART Factsheet. European Society for Human Reproduction and 
Embryology (ESHRE). Available from: http://www.eshre.eu/Guidelines-
and-Legal/ART-fact-sheet.aspx.
44. den Hartog, JE, Lardenoije, CM, Severens, JL, et al. Screening strategies 
for tubal factor subfertility. Human reproduction, 2008. 23(8): p. 1840-
1848.
45. Broeze, KA, Opmeer, BC, Van Geloven, N, et al. Are patient characteristics 
associated with the accuracy of hysterosalpingography in diagnosing 
tubal pathology? An individual patient data meta-analysis. Human 
reproduction update, 2011. 17(3): p. 293-300.
46. Swart, P, Mol, BW, van der Veen, F, et al. The accuracy of 
hysterosalpingography in the diagnosis of tubal pathology: a meta-
analysis. Fertility and sterility, 1995. 64(3): p. 486-491.
47. Bonneau, C, Chanelles, O, Sifer, C, et al. Use of laparoscopy in unexplained 
infertility. European journal of obstetrics, gynecology, and reproductive 
biology, 2012. 163(1): p. 57-61.
48. Land, JA, Evers, JL and Goossens, VJ. How to use Chlamydia antibody 
testing in subfertility patients. Human reproduction, 1998. 13(4): p. 
1094-1098.
49. Manolio, TA, Chisholm, RL, Ozenberger, B, et al. Implementing genomic 
medicine in the clinic: the future is here. Genetics in medicine : official 
journal of the American College of Medical Genetics, 2013. 15(4): p. 
258-267.

125
CHAPTER 5
The attitudes of the Dutch gynaecologists towards the addition of 
genetic testing in the diagnosis of tubal factor infertility (TFI)
J Malogajski, M Jansen, S Ouburg, E Ambrosino, CB Terwee, SA Morré
Publication in preparation
126
Abstract
 
The ability of genomics to have an impact on clinical practice depends, among 
other factors, on clinicians’ knowledge and attitudes regarding genetic tests. 
Research of the host genetic factors influencing the course and outcome of 
Chlamydia trachomatis infections has the potential to improve the accuracy 
of diagnosing tubal factor infertility (TFI) through genetic testing. Genetic 
variations, such as single nucleotide polymorphisms (SNPs) in pathogen 
recognition receptors (PRR) genes are involved in the recognition of Chlamydia 
can influence the course and outcome of the infection. Identifying and combining 
multiple SNPs in PRR genes and their linked pathways, and correlating them 
with infection outcomes offers an opportunity for the development of a new TFI 
screening strategy. In order to explore Dutch gynaecologists’ attitudes towards 
the introduction of genetic testing in the routine screening for TFI we preformed 
research in two phases. In the first phase we performed interviews with 
experienced reproductive specialists working in 4 Dutch Academic Hospitals. 
We used results of these interviews to develop a questionnaire and surveyed 48 
doctors working at Ob/Gyn departments of the Academic hospitals in Groningen, 
Maastricht and Utrecht. Our aim was to understand what respondents perceive 
as barriers and facilitating factors for the use of genetic information for TFI 
screening. Majority of participants agreed that addition of genetic markers to 
the CAT, in screening for tubal pathology could change the sensitivity of testing 
and more than half expressed the opinion that their patients have preferences 
for non-invasive testing.   Results showed that all the respondents, regardless 
of their position at the department or the hospital they work in indicated 
cost-effectiveness as an important factor in gaining their support for the new 
screening strategy. Clinical utility is recognized as the most import indicator of 
the quality of a genetic test. 
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Introduction 
Advances in genomics are contributing to the growing understanding of the 
role genes have as underlying causes in increasing number of diseases. The 
importance of genetic information in appropriate clinical management of 
these diseases is increasing [1, 2].Using genetic information in routine clinical 
practice in order to provide high quality healthcare is one of the major hallmarks 
of modern medicine. 
Advances in genetics have had clinical implications for gynecology practice. 
more than three decades ago with prenatal genetic screening for common birth 
defects during pregnancy [3]. More recently, preimplantation genetic screening 
to improve pregnancy rates in older women undergoing in vitro fertilization 
(IVF) [4]. In the meantime, using genetic testing for assessment of patient’s 
risk for hereditary breast and ovarian cancer became a routine in obstetric and 
gynecologic practice [5]. 
At the same time, there have been new developments in the research of host 
genetic determinants of infectious diseases. Indeed, recent developments in 
immunogenetic research of Chlamydia trachomatis urogenital infections, one 
of the most common causes of damage to the Fallopian tubes and consequent 
of gynecology and infectious diseases and improve the accuracy of diagnosing 
tubal factor infertility (TFI) through genetic testing.
of all cases infertility is attributed to tubal factors [7]. Chlamydia trachomatis 
lower genital infection is an important risk factor for the development of tubal 
pathology and consequent tubal factor infertility (TFI). As much as 45% of tubal 
pathology can be linked to a previous Chlamydia infection [8].  
Despite the fact that chlamydial infections are in most cases asymptomatic 
and therefore not treated with antibiotics, almost half of the women with the 
asymptomatic infection clear it without any within a year [9]. However, other 
women are prone to persistent infections and consequent complications such as 
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of Chlamydia infections among individuals can be attributed to host genetic 
factors [11]. Genetic variations, such as single nucleotide polymorphisms (SNPs) 
in PRR genes involved in the recognition of Chlamydia and in the initiation of an 
adequate immune response can contribute to higher or lower risk of Chlamydia 
induced TFI [12, 13]. Identifying and combining multiple SNPs in PRR genes and 
opportunity for the development of a new TFI screening strategy which would 
be more accurate in identifying patients at low or high risk of having tubal 
pathology.
At the moment, Chlamydia antibody test (CAT) and Hysterosalpingography (HSG) 
are the most commonly used screening tests for TFI in the routine fertility work 
assessed at approximately 60% and 85-90% respectively [14], for HSG these 
numbers are 53% and 87% [15, 16]. This means that some women who test 
negative in these screening tests have tubal pathology, and a number of women 
testing positive do not. Therefore, there is space for increase in accuracy of TFI 
screening. Combining CAT testing with genetic test early in the fertility work up 
could increase the accuracy of screening since CAT and genetic test combined 
would have higher PPV and NPV than any of the existing screening strategies.
Ultimately though, the ability of genomics to have an impact on clinical 
practice depends on clinicians’ knowledge and attitudes regarding genetic 
tests. Clinicians make decisions about ordering genetic tests and they are also 
responsible for interpreting and explaining the results to the patients [17]. 
Measuring their’ experiences and attitudes towards the use of genetic tests 
is increasingly recognized as an important tool for understanding barriers and 
facilitating factors for the use of genetic information in diagnosis and treatment 
of diseases. [18 21]. 
The objective of our study is to explore Dutch gynaecologists’ attitudes towards 
the introduction of genetic testing in the routine screening for TFI and to evaluate 
outcomes of Chlamydia infections.
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Materials and Methods 
In performing our study we used both qualitative and quantitative methods 
(mixed method). We performed our study in two phases, in the first phase we 
performed interviews with experienced reproductive specialists working in 
4 Dutch Academic Hospitals. We used results of these interviews to develop 
a questionnaire for the doctors working at Ob/Gyn departments about their 
attitudes towards the addition of genetic testing in the diagnosis of TFI. In the 
second phase, using the questionnaire, we surveyed 48 doctors working at Ob/
GYN departments and providing fertility care in 3 Dutch Academic hospitals 
in order to investigate what they perceive to be major challenges and major 
facilitating factors in introducing genetic testing in routine fertility work up.
 
Interviews  
Four semi structured interviews with gynaecologists working in Dutch academic 
hospitals, were conducted in February and March of 2013. Before conducting 
them we created some guidelines and decided on the main issues that would be 
discussed, however we did not insist on always following the same sequence of 
the questions or on the exact formulation used in the guidelines. The purpose of 
these interviews was to explore the topic of infertility in general, to get information 
and an inner perspective on current guidelines and practices in the screening 
for TFI. The interviews also provided information on potential facilitators and 
barriers for broad implementation of genetic testing in the diagnosis of TFI. The 
interviews served as a foundation for building questionnaires. Three interviews 
were conducted face-to-face and one via Skype. All the interviews were recorded 
and later transcribed. The transcripts of interviews were later analyzed. 
Development of the questionnaires Based on the analysis of interviews 
we made a theoretical framework in order to group and give an overview of 
the factors which emerged as important in influencing the attitudes towards 
introduction of genetic testing in TFI investigation.
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Table 1
into diagnosis of TFI
Five factors were most frequently mentioned in the interviews and were 
that genetic testing would bring to the routine fertility work-up, the cost of the 
genetic testing and additional costs that would mean for the healthcare system, 
patient’s preferences for non-invasive testing and their fear of complications 
associated with certain diagnostic procedures and the issue of gynecologist’s 
roles and competences related to the introduction of genetic testing in routine 
fertility work up were used as the foundation for the questionnaire statements. 
the questionnaire to an expert panel consisted of a gynecologist with more than 
30 years of experience in fertility care and an epidemiologist with background 
expertise in the development and evaluation of outcome measures. Based on 
their feedback we made changes in the questionnaire. 
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FACTOR ELEMENTS ASPECTS
Added value for 
clinical investigation
Increasing  diagnostic 
accuracy
Lower number of 
misdiagnosis
Quality of the test Costs
Clinical validity Identifying patient’s clinical status correctly
Clinical utility
Patient preferences Invasiveness Fear from a procedure
Complications related to a 
diagnostic procedure
Fear from complications
Roles/competences Collaborating with clinical 
geneticists 
Time Saving  time Optimizing timing 
in the  diagnostic 
investigation
Optimizing timing of 
beginning a treatment
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their demographics and the level of experience in gynecology. In the second 
section participants were asked to answer question related to immunogenetic 
research of Chlamydia trachomatis and its possible implications for the clinical 
practice. Finally, in the third section we asked the respondents to express their 
attitudes towards introduction of genetic testing in screening for Chlamydia 
induced TFI. They expressed their attitudes, ranging from very negative to very 
positive, by showing how strongly they agreed or disagreed with our composed 
agree, neutral, partly disagree, disagree, and no opinion.
 
Conducting the survey  
In the period from May to July 2014 we visited Academic hospitals in Maastricht, 
Groningen and Utrecht. These visits were organized in advance with the chiefs of 
the Gynecology departments of the hospitals. The participation in the survey was 
voluntary. The questionnaires were distributed to the gynaecologists attending 
Statistical analysis  
displayed separately. First the demographics are described, followed by the 
answers to the questions on the second part of the questionnaire. Each question 
and corresponding answers are shown in a bar diagram, comparing the relative 
outcomes of the responses. Lastly, the scores on the statements in part three 
of the questionnaire are provided, also in bar diagrams with the relative scores.
Results 
 
Participants of the survey were 48 physicians working at the OB/GYN 
departments of the 3 Dutch Academic Hospitals, 19 at the Maastricht University 
Hospital (MUMC), 17 at the University Medical Center of Groningen (UMCG) and 
12 at the University Medical Center Utrecht (UMCU). Main characteristics of 
the participants are summarized in Table 2,3. Most of the respondents, 
29.2%, were resident physicians at Gynecology departments followed by 25% 
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of respondents who checked the box “Other” and mostly worked as IVF and 
fertility specialists at Gynecology departments. According to the age groups, 
most of the participants, 27 of them were between 25 and 35 years of age. 
Table 2. Demographic characteristics of the participants 
In the questionnaire we asked respondents about the opinions regarding 
possible implications of Chlamydia trachomatis immunogenetic research for 
their clinical practice. Answering the question whether genetic information 
could be used in the screening of Chlamydia induced subfertility more than 60% 
of participants gave positive answers (Figure 1). Giving their opinion about the 
ability of the combination of tests (CAT& host genetic markers) to change the 
sensitivity of tubal factor subfertility diagnosis, 77 % of the respondents believe 
that a combination of CAT and genetic markers will increase the sensitivity of 
subfertility diagnosis (Figure 2). 53 % of respondents would be willing to support 
introduction of genetic test in the screening for tubal factor infertility (Figure 3). 
Regarding the location where the combination of tests CAT and genetic markers 
should be performed, 83% of respondents agreed that the testing should be 
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Sex   N %
 Male  7 14.6
 Female  41 85.4
Position Resident Physician  14 29.2
  Physician  6 12.5
 Gynaecologist  9 18.8
  Intern  7 14.6
 Other  12 25.0
Position Female % Male %
Gynaecologist 6 66.7 3 33.3
Intern 6 85.7 1 14.3
Other 11 91.7 1 8.3
Physician 5 83.3 1 16.7
Resident physician 13 92.9 1 7.1
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In the questionnaire we also asked the participants to express their attitudes 
towards the introduction of genetic testing in screening for Chlamydia induced 
TFI. Each statement came with 6 response alternatives: agree, partly agree, 
respondents at least partially agrees that the adding genetic tests to CAT will 
increase the diagnostic accuracy (Figure 5). Expressing their attitudes about 
the ability of genetic testing to reduce the number of false positive and false 
negative results, 45% of the respondents at least partially agreed that the 
introduction of genetic tests in the diagnosis of subfertility will reduce their 
number (Figure 6). 31% of participants disagreed with the statement that the 
combination of genetic test and CAT would, in fact, prolong the time needed to 
arrive at the diagnosis, compared to 10% who expressed the attitude that the 
combination of tests will increase the time to diagnosis (Figure 7). Asked about 
the costs of genetic testing, 60% respondents agreed and partially agreed that 
genetic tests are too expensive (Figure 8).
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their support for the introduction genetic markers the most, respondents 
100% of respondent found it important (Figure 9.), as were clinical validity and 
utility, by around half of respondents (Figures 9, 10, 11, 12).
Expressing the attitudes about their patients’ preferences when it comes to 
fertility investigation, 55% of respondents stated that their patients prefer 
non-invasive testing (Figure 13.), more than half also agreed that their patients 
would prefer genetic testing over HSG and laparoscopy (Figures 14 and 15). 
Most respondents stated that they would consider their patients’ preferences 
for the testing of tubal pathology (Figure16.)
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Responding to the statement about to the possible change that introduction 
of genetic test would bring to the role of gynaecologists in the diagnosis of 
tubal pathology, most of respondents did not feel that such a development 
would reduce their role in the diagnosis (Figure 17). However, majority did state 
that they would require additional training if a genetic test was added to the 
diagnosis of subfertility (Figure 18.)
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Discussion and Conclusion
 
The present study was designed to investigate the Dutch gynaecologists’ 
attitudes towards the introduction of genetic testing in the routine screening 
for TFI, and to identify factors they perceive as barriers and facilitators for the 
introduction of genetic testing in the current Dutch fertility care.         
by 100% of participants as an important factor in gaining their support for the 
new screening strategy regardless of their position at the department or the 
hospital they work in. Clinical utility is recognized as the most import indicator 
of the quality of a genetic test with 56% of the respondents fully agreeing 
that clinical utility is the most important indicator. Clinical utility is considered 
somewhat more important than clinical validity. These results are in concordance 
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Several questions/statements have been identiﬁed as the major uniﬁers of participants’
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testing which found cost effectiveness and clinical utility to major concerns 
expressed. [22]. 
Another example of a uniting position among participants is their attitude about 
the expenses associated with genetic testing. Genetic tests are considered too 
expensive by the majority of the participants. We found no difference in opinions 
between participants in different academic hospitals. However, physicians were 
mostly neutral, 50%. 
When it comes to the potential of Chlamydial host genetic factors to improve the 
accuracy of the tubal pathology prediction and the support for the introduction of 
genetic tests in subfertility diagnosis gynecologist seem to be more “optimistic” 
than the other participants.
Asked if the addition of genetic markers to the CAT, in screening for tubal 
pathology can change the sensitivity of the diagnosis 77% of the respondents 
gave a positive answer, all the participating gynaecologists believed so. Also 
gynaecologists are the most positive about their support for the introduction 
of genetic tests in subfertility investigation. Out of 58% of respondents who 
supported the introduction of the test 89% were gynaecologists. 
Interestingly enough, when asked if, in general, host genetic factors could be 
used in diagnosis of Chlamydia trachomatis induced subfertility, only 67% of 
gynaecologists expressed positive opinion. The highest support came from the 
interns (86%) followed by the physicians (83%). Younger respondents seem 
more likely to support the use of host genetic factors.
We also got some contradicting results related to the many respondents (more 
than 60%) believes that the diagnostic accuracy increases with genetic testing, 
but only 45 % accepts that the number of false positive/negative results will be 
reduced by the genetic testing.
As the most polarizing questions we identified the question about the effect 
genetic test would have on the time needed for diagnosis. Around one third of the 
respondents agreed that combined test would increase time to diagnosis at the 
same time 31% disagreed with this notion. Most gynaecologists (56%) believed 
that the time to diagnosis will be reduced, while 57% of the resident physicians 
and 42% of the ‘others’ (partially) agree that time to diagnosis will increase.
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Responding to the statement about the need for additional training if a genetic 
test was added to subfertility diagnostic procedures. Most respondents agreed 
they would need additional training. Gynaecologists and resident physicians felt 
the most that they would require additional training. Also, older respondents 
were more likely to reply that they would require additional training.
When it comes to the participants’ attitudes toward their patients’ preferences 
tubal pathology investigation, 55% of them replied that their patient’s prefer 
noninvasive testing. Only 6% of participants agreed to honor their patients’ 
preferences. Most respondents (around 50%) would, however, consider the 
preferences of their patients.
In conclusion, in spite of the high percentage of respondents who believe  that 
addition of genetic markers to CAT, in routine screening for TFI can change 
the sensitivity of the diagnosis, respondent perceive some barriers for the 
implantation of such a test. All the respondents, regardless of their position at 
the department or the hospital they work in agreed that cost-effectiveness is an 
important factor in gaining their support for the new screening strategy. Clinical 
utility is recognized as the most import indicator of the quality of a genetic test. 
In addition to the justified expectations of the proven cost-effectiveness and 
clinical utility of the new screening strategy, perceived high costs associated 
with genetic testing pose the biggest barrier in acceptance of genetic testing in 
diagnosis of TFI. 
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GENERAL DISCUSSION
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The topic of this thesis is the translation of genomic information into clinical 
practice for infectious diseases, and specifically the potential of host genomic 
determinants to improve the tubal factor infertility (TFI) work up in the 
Netherlands. The first part of the thesis focuses on the translation of genomic 
information and on the development of genomic applications for everyday clinical 
practice of sexually transmitted infectious of high public health relevance. In the 
first part of the thesis we also explore the role of biobanks as an important 
element of research infrastructure in the process of integration of genome-
based knowledge in clinical practice of infectious diseases. The second part of 
the thesis focuses on the potential of Chlamydia trachomatis host immunogenetic 
research to improve accuracy of TFI screening through introduction of genetic 
biomarkers into routine fertility work up. The current chapter will discuss the 
findings presented in this thesis and the implications of these findings for future 
research.
Public Health Genomics of Infectious diseases 
One of the aims of Public Health Genomics is to identify opportunities for 
genomics to improve health and to demonstrate how genomic information has 
potential to transform healthcare from promise to reality [1]. In the first part of 
the thesis we focused on exploring that potential in the field of three infectious 
diseases of high public health relevance. 
As described in Chapter 1, in our review of the translational potential of 
basic genomic and genetic findings for Human Immunodeficiency Virus (HIV), 
Chlamydia trachomatis (CT), and Human papillomavirus (HPV), we looked for 
promising examples of translation of basic scientific discovery into a clinical 
application. In concordance with a prevailing sense of lack of integration of 
the new technologies into clinical practice [2], in the review we found scarce 
examples of the current application of genomic/genetic information in the 
aforementioned field of infection diseases. 
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HIV  
HIV remains one of the biggest public health challenges. The incidence of 
HIV is decreasing, but due to anti-retroviral therapy (ART), the prevalence con-
tinues to increase and 35 million people were living with the infection at the end 
of 2013 [3]. Host genetic variation related with HIV/AIDS has been a topic of 
interest for researchers last 30 years [4].
Host genetic studies aim to increase understanding of inter-individual differences 
in, susceptibility to and outcome of infectious diseases. In the field of HIV 
research, high numbers of host genomic determinants were found to influence 
HIV infection, progression and outcome. However, few of these associations 
were positively confirmed. Chemokine receptor and chemokine ligand genes 
as well as HLA class I and related genes are identified as the most influential 
in modulating the susceptibility and outcome of HIV infection [5–10]. In the 
case of HIV infection, the research of host genetic determinants has had so far 
predominantly pharmacogenomics applications.
Absence or reduction of the number of CCR5 co-receptors on the CD4+ cell 
surface has been identified as HIV resistance factor and served as a foundation 
for the development of a family of drugs known as entry inhibitors. At the time 
of this study, only two entry inhibitors were approved for the treatment of HIV-
infected patients. Maraviroc is a CCR5 antagonist and Enfuvirtide, is a fusion 
inhibitor, it disables conformational changes in gp41 that drive membrane 
fusion [11,12]. The number of approved entry inhibitors has not changed since. 
The development of Vicriviroc, also a CCR5 co-receptor antagonist designed to 
block the virus from penetrating the cells, which was considered promising at 
the time of the study has since been cancelled at the end of 2010. The research 
on other promising molecules continues [13]. 
Research on HLA class I genes lead to important pharmacogenomics application. 
Patients expressing B*5701 allele are hypersensitive to an antiretroviral drug 
called Abacavir prescribed to patients with HIV. By routinely testing every 
potential drug recipient and identifying patients with the mentioned allele, very 
serious, and possibly life threatening drug reactions are avoided [14].
The focus of more recent research in HIV host genomics is on the analysis of 
killer cell immunoglobulin-like receptor (KIR) genes and HLA class II alleles 
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[15]  has been established recently that HIV + individuals expressing the HLA 
class II allele DR B1*1303 show significantly lower viral loads. The protective 
effect of this allele is found to be independent of sex, ethnical background or 
HIV virus subtypes [16]. Additionally, Alter et al. suggested that NK cells have 
an important role in the control of HIV infection. They demonstrated that KIR 
positive NK cells can put immunological pressure on HIV-1. In order to evade 
the immune response, the virus is evolving through so called escape mutations, 
therefore NK cells might have a very important role in contributing to viral 
evolution [17]. The evolution of HIV at the population level is driven by these 
alternative escape mechanisms and understanding all the factors behind them 
is of highest importance for designing successful HIV vaccines. [18]. The review 
of the recent HIV research demonstrates renewed efforts for the HIV vaccine 
development [19].
Recent insights into HIV host genomic research indicate change in research 
approaches in the near future. HIV host genetic research is moving away 
from candidate gene studies and genome wide association studies (GWAS), 
responsible for so far identified host genetic factors, towards investigating 
small-scale changes such as single-nucleotide variants through comprehensive 
sequencing [20].
HPV   
For the development of cervical cancer, infection with an oncogenic type of 
human papillomavirus (HPV) is crucial but not sufficient. Variability of factors 
that control the immune response to infection has a great impact on the outcome 
of the infection [21].
Review of the host genetic variants influencing HPV infection identified several 
alleles associated with higher risk of persistent HPV infection and development 
of cervical cancer. There were also polymorphisms identified to have a 
protective role, making an individual less susceptible to cervical cancer [22, 
23]. So far these findings have not been used in the prevention or treatment of 
HPV infection. Indeed, we found (Chapter 1) that when it comes to using genetic 
information in prevention of cervical cancer, methylation based triage of high-
risk human papilloma virus (hrHPV) offered the most promising possibilities. 
A number of tumor suppressor genes were found to have methylated gene 
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promoters in cervical cancer tissue. Methylation of the promoters CCNA1 and 
C13ORF18 in cervical scrapings was found to be strongly associated with CIN2 
(moderate cervical intraepithelial dysplasia) and higher grade stages of cervical 
dysplasia [24] making them ideal for triage of patients positive for hrHPV. This 
combination of tests was considered a solution for a more effective stratification 
in the group of hrHPV positive women, by identifying those at high risk for 
cervical cancer and, at the same time, reducing the number of unnecessary 
referrals to colposcopy in those with negative methylation test.  
Ongoing research on this topic confirms the importance of DNA methylation 
analysis of promoter regions of tumor suppressor genes as an objective 
triage tool for hrHPV positive women [25]. Recent research also suggest 
HPV multiplex ligation-dependent probe amplification assay   (HPV MLPA) as 
a recommended triage method following hrHPV. The added value of recently 
developed HPV MLPA assay is in classifying samples as high risk based on the 
detection of a high viral load and/or viral integration in cytological samples. 
hrHPV screening has a high negative predictive value ( NPV ) of 97%, but 
it’s positive predictive value (PPV) is evaluated at 50%, Combining hrHPV 
screening with HPV MLPA test and assessing additional risk factors such as 
viral load and the viral integration, has the potential of increasing the PPV 
of screening and reducing the number of unnecessary colonoscopies [26]. 
 
Chlamydia trachomatis   
Chlamydia trachomatis is the cause of the most common sexually transmitted 
infection worldwide and it has a persisting high incidence of 90-100 million 
cases per year. Host genetic twin studies of Chlamydia have established that 40 
% of the course and the outcome of the infection can be explained by host genetic 
factors [27]. The ultimate question is which factors are the most predictive, area 
of research which got much attention in the last 5 years. Chlamydia infection can 
be symptomatic or asymptomatic, the latter is more common, therefore most 
of the time this infection is not treated by antibiotics. Both symptomatic and 
asymptomatic infections can either spontaneously clear or ascend to the upper 
genital tract causing complications, such as salpingitis, pelvic inflammatory 
disease (PID), ectopic pregnancies and tubal factor infertility (TIF). The innate 
immune response relies on the proper recognition of bacterial peptidoglycan 
by Pathogen Recognition Receptors (PRRs) [28]. It has been established that 
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these differences in the course and outcome of the infection are often determined 
by genetic variations, such as single nucleotide polymorphisms (SNPs), in genes 
encoding for Pathogen Recognition Receptors (PRRs) located on macrophages, 
vaginal and tubal epithelial cells or intracellularly. Carrying polymorphism in genes 
encoding PRRs, such as Toll Like Receptors (TLRs) or he Nucleotide-binding 
Oligomerization Domain Receptors (NODs), can put an individual at high risk 
for development of tubal pathology, or act in the protective way, protecting an 
individual from persistent Chlamydia infection and consequent complications. 
In Chapters 1 and 3 we provided an overview of host genetic factors related to 
Chlamydia infection. TLRs 2, 4 and 9 are well-researched TLR family members. 
Several studies observed that carrying SNPs in TLR4 has a role in making women 
more prone to infertility as a late complication of Chlamydia infection. Nevertheless, 
the exact role of TLR 4 in infertility has not been yet been fully understood [29, 
30]. The likelihood of carrying TLR4 +896 A allele was found to be 2x higher in 
women positive for Chlamydia trachomatis IgG antibodies ( CAT +) then in women 
without tubal pathology [30]. In a study aiming at understanding the role of two 
TLR2 SNPs in the susceptibility to infection and contribution to the development 
of tubal pathology, a statistically significant association between certain TLR2 
haplotypes and the protection from tubal pathology [31]. Carrying two or more 
SNPs in TLR9, TLR4, CD14, and CARD15/NOD2 increased the risk of developing 
tubal pathology following Chlamydia infection [32]. Recent research confirmed the 
role of NOD1 polymorphisms in the development of tubal pathology. Chlamydia 
IgG CAT (+) women with TFI were significantly more frequent carriers of a certain 
insertion polymorphism in the NOD1 gene compared to CAT (-) women [33]. 
Immunogenetic research demonstrates that genetic and genomic markers 
influencing the course and outcome of Chlamydia infection could have successful 
application in the prediction of risk of Chlamydia trachomatis infection and of its 
late complications. Identifying genomic markers responsible for the course and 
outcome of Chlamydia infection and developing a screening test based on them 
would allow the discrimination between infertile women with high risk of tubal 
pathology versus infertile women with low risk of tubal pathology. 
Recently, in a key study in the field of Chlamydia immunogenetic research, GWAS 
was used for the first time to scan for pathway-wide genomic differences between 
cases of scarring trachoma and controls [34, 35] 
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Relevance of biobanks 
As described in Chapter 2, biobanks have an increasing role in the field of 
genetic susceptibilities of infectious diseases. Large scale genome-wide 
association studies and candidate gene studies, performed on samples stored 
in biobanks are becoming essential for confirming new gene-infectious disease 
associations. Examining various networks and biobanks that specialize in 
infectious diseases we noticed a trend of increasing number of studies deriving 
from them. Our search confirmed another noticeable trend in infectious disease 
genomics, the development of nation-wide or transnational collections and 
building large consortia and biobanks networks [36]. A good example of this 
is the EpiGenChlamydia Consortium, European funded transnational research 
network which has been establishing biobanks and data warehouses aiming to 
perform comparative genomic and genetic epidemiology studies. The goal is to 
understand inter-patient differences in the course and outcome of Chlamydia 
infection and ultimately develop an accurate diagnostic tool for predicting the 
risk of tubal pathology [37]. 
For biobanks to realize their full potential in supporting the research on genetic 
susceptibilities of infectious diseases (and other fields of research), researchers 
should be able to freely access a number of them worldwide. Legal and ethical 
issues surrounding the establishment of global biobanking networks, which have 
been hindering this process for years, ought to be resolved for the benefit of 
population health.
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Chlamydia induced infertility- genomic testing in the routine  
investigation of TFI
Estimating the risk of tubal pathology following the infection is one of the biggest 
challenges of Chlamydia research [38] Almost half of all asymptomatic infected 
women will spontaneously clear the infection in one year [39]. The reported risk 
of infertility following Chlamydia infection shows great variation, from 2-4.5% 
to 30% women with a previous untreated Chlamydia infection are developing 
PID and 10-20% of them are developing TFI [38, 40].
As we described in Chapter 4, detecting C. trachomatis IgG antibodies is the 
most commonly used screening test for TFI in the Netherlands. In the group 
of subfertile women with TFI the incidence of CAT positivity is much higher 
compared to women without TFI. There are a number of studies reporting on the 
accuracy of CAT. Overall the sensitivity for tubal pathology of the most accurate 
CATs is assessed at approximately 60%, with a specificity of 85-90 % [41]. As 
we found out investigating strategies currently in place, in fertility care in the 
Netherlands there is no consensus on the sequence of diagnostic procedures 
in routine fertility work-up. CAT is performed alone or in combination with HSG, 
laparoscopy is used as a reference diagnostic standard (Chapter 4). 
The main problem with TFI screening based on CAT, is the high numbers of 
false positive cases, in other words, high number of women with positive IgG 
Chalmydia trachomatis antibodies without tubal pathology are undergoing 
unneeded laparoscopies.  
We proposed a screening strategy that would introduce SNPs-based analysis 
into routine TFI screening by combining CAT with genomic diagnostics early in 
the fertility work-up.
This combination of tests (CAT and genomic markers) would potentially have 
higher (PPV) and (NPV). Meaning that the number of women with positive CAT, 
who are at the moment considered at risk of tubal pathology would not undergo 
invasive diagnostic procedures if their genetic markers would not attribute 
them with the high risk of TFI (Figure1). Further, despite being CAT negative 
and not considered at risk of TFI, a certain number of women, in fact, have tubal 
pathology. In their case, testing positive for high risk of TFI would speed up 
further investigations. Therefore, the overall outcome would be fewer women 
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undergoing not needed diagnostic procedures and more women getting the 
intervention they need. 
Figure1. Elements of the decision making process based on the implementation of the “CAT + 
genome-based companion diagnostic” in the initial phases of the infertility screening strategy
For improving the prediction of risk for TFI, further immunogenetic studies need 
to focus on identifying and precisely combining SNPs into genetic traits. SNPs 
in a way to provide an accurate assessment of ratio between risk factors and 
protective traits.
In addition to better predict tubal pathology, genetic markers could also improve 
the timing of infertility investigation. The timing of infertility investigation and 
treatment are crucial factors for avoiding both over and under treatment and 
providing an optimal management of infertility [42]. One of the advantages 
of the genome-based companion diagnostic is non-invasiveness which 
could justify earlier investigation of tubal pathology. The potential of genetic 
markers to improve the timing of infertility investigation, as well as timing of 
starting an adequate treatment should be explored. Women undergoing fertility 
investigation in the Netherlands are growing older (Chapter 4) making the timing 
of the fertility work up even more of an issue. 
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Further, European surveillance and screening data on Chlamydia infection among 
young adults are showing a trend of persisting or increasing prevalence. At the 
same time, the trend of postponing the first pregnancy to the late 30s has been 
noticed, leaving a long period of time for Chlamydia induced tubal pathology to 
be developed and not diagnosed. The future of TFI screening should preferably 
be studied considering the influence of these trends on the future demand for 
fertility care.  
Then, the resources consumed by the new diagnostic strategy need to be weighed 
against the benefits of performing the test and the effects of redirecting these 
resources away from existing strategies. Genetic testing may undeservedly be 
labeled as high-priced. Recent study reviewing the entire spectrum of economic 
evaluations associated with genetic testing used for guidance treatments 
and interventions, found no evidence that genetic testing is either inferior or 
superior in terms of cost-effectiveness to other medical interventions. They 
found that how the genetic test is used, rather than whether it was used, had 
the economic significance [43]. Further research about economic implications 
of the introduction of genomic markers in the routine fertility work up is needed.
As discussed earlier, advances in the research of Chlamydia trachomatis host 
genetic factors could have significant implications for gynecology practice. 
In Chapter 5 we explored the potential barriers and facilitating factors for 
the introduction of genetic testing in screening for Chlamydia induced TFI, 
perceived by the Dutch gynaecologists. Clinicians’ knowledge and attitudes 
regarding genetic tests influences the ability of genomics to have an impact on 
clinical practice. 77% of participants gave a positive response answering the 
question about the potential of genetic markers to increase the sensitivity of 
the diagnosis of tubal pathology. Cost-effectiveness was indicated by 100% of 
participants as an important factor in gaining their support for the new screening 
strategy regardless of their position at the department or the hospital they work 
in. Clinical utility is recognized as the most import indicator of the quality of a 
genetic test, with 56% of the respondents fully agreeing on it. Clinical utility is 
also considered somewhat more important than clinical validity. Earlier research 
regarding physician attitudes toward genetic testing for cancer susceptibility also 
identified cost-effectiveness and uncertainty about the accuracy, interpretation, 
and clinical utility of genetic tests for cancer as the main concern [44].  Results 
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study also demonstrated the awareness of respondents of the fact that 
genomic advances are changing clinical management of diseases and the role 
of physicians in it.  The majority of respondents expressed preferences for an 
additional training in clinical genetics prior to the introduction of the test. Earlier 
study on the promise of genomic research identified education and training for 
health-care professionals, designed to enable them to interpret more complex 
genomic data,  as very important facilitating factors in translation of innovative 
genomic tests into clinical practice [45].
Evaluation of the potential of TFI screening based on host genetic determinants 
to meet the need of women undergoing fertility work up for a simple, accurate 
and noninvasive screening tool and exploration of the attitudes of fertility 
care doctors towards the use of genetic testing in the routine fertility work up, 
established a first step into a pre-implementation research. Preferably it should 
be followed by comprehensive cost-effectiveness evaluations of existing and 
proposed TFI screening strategies and by studies confirming improved health 
outcomes associated with the introduction of genetic testing into fertility work 
up.
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Valorisation  
 
At the core of the valorisation process is the notion of translation of knowledge 
into products and services. The topic of our research was the translation of 
genomic information in the diagnosis and treatment of infectious diseases and, 
in particular, the facilitation of this translation in the diagnosis of Chlamydia 
trachomatis induced tubal factor infertility (TFI). Therefore, parts of our research 
were specifically addressing the concept of valorisation. We proposed a way of 
translating the knowledge generated through host immunogenetic research of 
Chlamydia trachomatis infection into routine fertility care and explored potential 
facilitators and barriers to the process of creating a healthcare service from 
such knowledge.
Advances in genomics reshaped our understanding of pathogenesis of infectious 
diseases, highlighted the role of host genetic determinants in modulating 
immune response and showed us that the differences in clinical course and 
outcome of infection between individuals can be attributed to their genetic 
differences, among other factors. 
In the case of the intracellular bacteria Chlamydia trachomatis, host genetic 
research showed that the differences in the course and outcome of the infection 
can be explained by a patient’s genetic makeup. Persistent and ascending 
Chlamydia trachomatis urogenital infection is one of the most common causes 
of damage to the fallopian tubes and consequent tubal factor infertility (TFI). 
Almost half of the cases of TFI can be attributed to a previous Chlamydial 
infection. 
In the Netherlands, Chlamydia IgG antibody test (CAT) and Hysterosalpingography 
(HSG) are the two most commonly used tests for the primary investigation of TFI, 
they are usually followed by laparoscopy as the reference diagnostic. A positive 
CAT result means that a woman had an infection at some point in the past, but 
the test is often positive in the absence of tubal pathology. Almost half of women 
will clear the infection without any consequences within 12 months. Thus, the 
main disadvantage of CAT is a relatively high number of false positive results 
for identifying women with TFI. In 40- 50% of women who are testing positive 
for CAT no tubal pathology is found by laparoscopy. HSG is either performed 
following CAT or as an independent test of tubal patency. Its main disadvantage 
is that it is a painful procedure and can be complicated by an ascending infection.
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As a part of valorisation process we explored the health needs of women 
undergoing fertility investigation as well as the needs of clinicians for an 
accurate screening tool. Through our research we recognized the potential of 
host genetic findings to improve the investigation of Chlamydia induced TFI. We 
proposed combining genomic markers and CAT in the routine fertility work up 
with the aim of improving the accuracy of TFI investigation by correlating host 
genetics with infection outcomes, therefore more accurately determining the 
risk of TFI and reducing the number of misdiagnosis. The clinical relevance of 
such a change would be an improved clinical decision making for gynaecologists, 
a more efficient use of resources, thus less expenses for the healthcare system, 
and reduced interventions for the patient.
The social relevance of our topic and our findings stems from the high public 
health relevance of the Chlamydia trachomatis urogenital infection, shown by 
high prevalence of the infection and the serious complications associated with 
it. Costs associated with diagnosis and treatment of the associated infertility 
(including costs caused by complications of unnecessary laparoscopy and HSG) 
poses a significant economic burden for healthcare systems and individuals. In 
fact, it has been established that infertility is an area where healthcare costs, in 
many countries, are born more often by individual, creating significant economic 
disparities and having a wide societal impact. Furthermore, infertility has a 
strong impact on the quality of life of the affected couples thus having a wide 
societal impact as well. 
Data on the prevalence of Chlamydia trachomatis urogenital infection prevalence 
obtained through the Dutch National Institute for Public Health and Environment 
surveillance efforts showed that in the period from 2010-2012 10-13% of 
people visiting the Dutch regional Sexually Transmitted Infection (STI) clinics 
tested positive for Chlamydia. A pilot nationwide screening project for Chlamydia 
infection, conducted in 2003 in the Netherlands, found a 2% overall prevalence 
of Chlamydia infection in women. Later follow up screening projects found no 
indication of the decrease of these positivity rates. Additionally, European 
surveillance data demonstrate that Chlamydia trachomatis is at the moment 
the most commonly diagnosed bacterial STI and still no decline in prevalence is 
found overall. Therefore we can assume that Chlamydia will continue to play an 
important role in the pathophysiology of TFI. 
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Additionally, a strong relation has been established between women’s age and 
the demand for fertility care. The demand for fertility care is increasing with 
women’s age. Recently in the Netherlands, similarly to in other high income 
countries, there is a trend of postponing the first pregnancy. In 2012, 20% 
of all births were to first time mothers older than 35. We can assume that this 
trend will persist.  At the same time Chlamydia infection show trend of either 
persistent or increasing prevalence rates of the infection among young adults. 
These trends might have full impact on demand for fertility care in 10-15 years 
when now young adults become women in their late 30s deciding to become 
mothers. 
Genetic testing already has an important diagnostic/screening role in in the field 
of gynaecology. Prenatal genetic screening, essential part of new born screening, 
was in fact the first established program of population-wide genetic testing, and 
it has been a great public health success. Testing of chromosomal abnormalities 
and single gene disorders, such as such as cystic fibrosis and sickle cell anaemia 
traditionally done by invasive techniques, such as amniocentesis and chorionic 
villi sampling, was recently replaced by non-invasive genetic testing of free 
foetal DNA and free foetal cells in the mother’s blood.    
Additionally, genetic testing for cancer susceptibility to breast and ovarian 
cancer is often first discussed in the gynaecologist’s office. Gynaecologists are 
advising patients of the possibility and necessity of that the appropriate cancer 
risk assessment and they are responsible for providing appropriate information 
about the test and consequent treatment options. However, genetic information 
has not been used so far in fertility investigation. Using patient’s genomic 
information in routine fertility work up represents a novel approach in fertility 
care.
The primary audience for our research are clinicians. Advancements in genomics 
are driving change in diagnostic and treatment strategies, therefore clinicians 
need to repeatedly adjust to these changes. They are always in need of a good 
screening test, accurate in assessing the risk of TFI in patients and at the same 
time simple and inexpensive. Combining CAT testing and genetic test would affect 
the clinicians’ decision making on subsequent investigations and consequent 
treatment. We believe, it could help avoiding unnecessary laparoscopies, 
expediting further investigation and use of Assisted Reproductive Technology 
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(ART) when needed. Additionally, we think that patients’ organization and health 
policy makers, scanning the horizon for more accurate and less invasive TFI 
screening strategies with the potential to improve fertility care, might be our 
audience too. Finally, our target group are also other researchers, especially 
those with in-depth knowledge about economic evaluations, who would build on 
our research by determining the efficiency of a new proposed TFI investigation 
strategy compared to the existing ones.
We also presented the results of our survey-based research about the attitudes 
of Dutch gynaecologists towards the addition of genetic biomarkers in the 
investigation of Chlamydia induced infertility. The results of this research provide 
a good foundation for the planning of further steps in the implementation of 
genetic testing into routine fertility work up. The first step in the further process 
of valorisation would be developing a high quality genetic test by combining 
different genetic marker traits in a way that provides an accurate assessment 
of risk factors and protective traits. Some patients may be positive for SNPs 
which increase the risk to develop TFI and at the same time be positive for SNPs 
of preventive genetic trait, making clinicians’ decision process more complex 
and calling for precise algorithms to aid decision making. The combined genetic 
and CAT test will need to be optimized in a way which makes the grey zone of 
decision making as small as possible. Additionally, it is important that test has 
straightforward results, easy to interpret and explain to patients. 
Finally, crucial steps in the implementation process would be establishing cost-
effectiveness and clinical utility of the test. Insufficient evidence on benefits and 
harms of genomic tests in clinical setting has been identified as a translational 
barrier. Clinicians involved in our survey put the emphasis on the importance of 
clinical utility. Proven clinical utility of the test means the ability of the test to lead 
to improved health outcomes. In the case when test is used for disease screening 
and/or risk assessment, clinical utility is defined as improved health outcomes 
based on provision of information useful for personal or clinical decision making 
and better patient management and/or improved health outcomes based on 
prevention or early detection strategies.
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Furthermore, in our survey about the clinicians’ attitudes towards the 
introduction of genetic testing in the routine screening for TFI cost-effectiveness 
was indicated by all of the participants, regardless of their position at the 
department or the hospital they work, as an important factor in gaining their 
support. Cost-effectiveness analysis is the most commonly used form of full 
economic evaluation, in this analysis costs and consequences of two or more 
alternatives are being compared. Cost-effectiveness analysis can be performed 
from different perspectives. The most appropriate in this case would be to 
perform the analysis from the societal perspective, thus taking into consideration 
all the relevant costs.
In summary, the research in my thesis has shown great potential for valorisation 
since increase in accuracy of TFI screening could significantly improve the quality 
of fertility care.
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Advances in genomics created high expectations regarding the impact that those 
discoveries would have on healthcare. This process of responsible, effective and 
timely translation of genome-based information and technologies into health 
policies and practice for the benefit of population health is the core task of the 
field of Public Health Genomics. The focus of this thesis is the effective and timely 
translation of genome-based information in the field of infectious diseases. 
General Introduction provides an introduction of the topic and the outline 
of the thesis. The aim of this thesis was to explore the translation of genomic 
information in the diagnosis and treatment of infectious diseases in general and 
to improve and facilitate this translation in the diagnosis of Chlamydia induced 
tubal factor infertility (TFI) in particular. The objective of the Part I (Chapters 
1and 2) of the thesis was to provide an overview of the basic genomic and genetic 
findings with translational potential for application in diagnosis and treatment of 
Sexually Transmitted infections (STIs) of a high public health relevance and to 
explore the role of biobanks in research of infectious disease host genomics. 
The objective of the Part II (Chapters 3-5) of the thesis was to assess health 
needs of the Dutch women seeking fertility care, to explore strategies for the 
introduction of genomic biomarkers into the diagnosis of tubal infertility and to 
evaluate the attitudes of the Dutch gynecologist toward the implementation of 
the genomic biomarkers into routine infertility diagnosis.
Part I
The Human Genome Project opened the door for the translation of genome-based 
knowledge into every day clinical care. In Chapter 1 the translational potential 
of basic genomic and genetic findings for HIV, CT, and HPV for application in 
public health and in diagnostics, treatment, and prevention of late complications 
of these infectious diseases was reviewed. We found many host genetic variants 
having a role in modulating the immune response to HIV, HPV and Chlamydia 
infections in the literature. Nevertheless, we also noticed an imbalance between 
the number of confirmed gene-disease associations and the number of practical 
applications of that knowledge. 
In Chapter 2 we examined the role of biobanks in basic research of infectious 
disease genomics, as well as their relevance in the translation of impending 
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knowledge and in the clinical uptake of genome-based knowledge in infectious 
diseases. We described the trend of growing numbers of biobanks which are 
founded and governed by hospitals and academic institutions and support the 
research in infectious disease genomics. We explored successful examples 
of research deriving from these biobanks. We also noticed that the trend of 
development of nation-wide or transnational collections of human and microbial 
samples and building large consortia and networks is ever increasing.
Part II
In Chapter 3 an overview of the current state of the art of host genetic markers 
related to Chlamydia trachomatis infection is provided. By combining multiple 
SNPs in the Pathogen Recognizing Receptor (PRR) genes and genes in linked 
pathways, and combining them as susceptibility markers, a highly predictive 
test for tubal pathology-based subfertility can potentially be developed. 
We investigated the potential translational and clinical value of adding these 
diagnostic host genetic marker profiles to the current clinical management 
of infertility. A public health genomic (PHG) model as a possible facilitator in 
the process of implementing host genetic markers into clinical applications is 
considered.
In order to facilitate the translation process of Chlamydia trachomatis related 
host genomic markers influencing the course and outcome infection, in Chapter 
4 we explored the potential need for introducing genomic testing in the routine 
investigation of tubal factor infertility (TFI) by assessing health needs of the 
target population. We designed a 3-step framework for the assessment of 
fertility care-related health needs. In step 1, we identified services/strategies 
currently in place in fertility care in the Netherlands and found no consensus 
on the sequence of diagnostic procedures in routine fertility work-up, including 
investigation of tubal pathology as a possible cause. In step 2, we defined the 
characteristics of the target population for fertility care in the Netherlands 
and assessed their health needs. The population of women undergoing fertility 
investigation in the Netherlands is growing older and their demand for fertility 
care greater. Overall, the data show 5-10% annual increase in demand for 
medical assisted reproduction in many developed countries over the last 5 years. 
Screening and surveillance data on Chlamydia infection show either persistent 
or increasing prevalence rates of the infection among young adults. This might 
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have clinical implications in 10 to 15 years, resulting in increased number 
of women being assessed for the risk of TFI. Finally, in step 3 we proposed a 
strategy for improving the accuracy of the first line testing by correlating host 
genetics with infection outcomes. Our new proposed screening strategy would 
aim to more accurately determine the risk of TFI and to reduce the number of 
misdiagnosis through synergistic action of serology and genetic testing, by 
taking blood samples for testing Chlamydia serology (CAT) and host genomic 
biomarkers (SNPs) early in fertility work-up. 
In Chapter 5 we assessed Dutch gynaecologists’ attitudes towards the 
introduction of genetic testing in the routine screening for TFI and evaluated their 
knowledge about the genetic background behind different courses and outcomes 
of Chlamydia infection. We developed a questionnaire for the doctors working at 
the OB/GYN departments about their attitudes towards the addition of genetic 
testing in the diagnosis of TFI. Using the questionnaire, we surveyed 48 doctors 
providing fertility care in Academic hospitals in Maastricht, Groningen and 
Utrecht, in order to investigate what they perceive to be major challenges and 
major facilitating factors in introducing genetic testing in routine fertility work 
up. Cost-effectiveness was indicated by 100% of participants as an important 
factor in gaining their support for the introduction of the new screening strategy 
regardless of their position ate the department or the hospital they work in. 
Clinical utility is recognized as the most import indicator of the quality of a 
genetic test with 56% of the respondents fully agreeing that clinical utility is 
the most important indicator.
In Chapter 6 we discussed the findings described in this thesis and offered 
some recommendations for future studies. 
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De vooruitgang geboekt in genomics heeft hoge verwachtingen geschept wat 
betreft de invloed die deze ontwikkelingen hebben op de gezondheidszorg. 
Het proces van verantwoorde, effectieve en tijdige translatie van informatie 
en technologieën gebaseerd op het genoom naar beleid en beoefening in de 
gezondheidszorg ter bevordering van de volksgezondheid is de kerntaak van 
het veld Public Health Genomics. Dit proefschrift focust op de effectieve translatie 
van genoomgebaseerde informatie in relatie tot infectieziekten.
De General Introduction geeft een algemeen overzicht en beschrijft de 
achtergrond van translatie van genoom-gebaseerde informatie gerelateerd aan 
infectieziekten, daarna volgt in dit eerste hoofdstuk een uiteenzetting van de 
onderwerpen in dit proefschrift. Het doel van dit proefschrift was het exploreren 
van de translatie van genoominformatie naar de diagnose en behandeling 
van infectieziekten in het algemeen en in het bijzonder om deze translatie te 
faciliteren en te verbeteren binnen de diagnose van Chlamydia-geïnduceerde 
tubal factor infertiliteit (TFI). Het doel van Part I (hoofdstukken 1 en 2) van dit 
proefschrift is om een overzicht te geven van bevindingen binnen het veld van 
de genetica met translationele potentie voor de toepassing in de diagnose en 
behandeling van seksueel overdraagbare aandoeningen (SOAs) met een hoge 
relevantie voor de volksgezondheid en om de rol te exploreren van biobanken 
in het onderzoek naar de host genomics bij infectieziekten. Het doel van Part II 
(hoofdstuk 3-5) van het proefschrift is om de gezondheidszorgbehoeften in te 
schatten van Nederlandse vrouwen die fertiliteitszorg zoeken, om strategieën 
te bepalen voor de introductie van genetische biomarkers in de diagnose van 
TFI en om de mening van Nederlandse gynaecologen is ten opzichte van de 
toepassing van genetische biomarkers in hun klinische routine te inventariseren.
Part I  
Het Human Genome Project verschafte toegang tot de translatie van genoom-
gebaseerde kennis in de dagelijkse klinische zorg. Chapter I geeft een overzicht 
van de translationele mogelijkheden van genetische bevindingen voor HIV, 
CT, en HPV in volksgezondheid, diagnose, behandeling en preventie van late 
complicaties van deze infectieziekten. Wetenschappelijke literatuur beschrijft 
vele genetische varianten van de gastheer die een rol spelen in het modelleren 
van de immuunreactie tegen HIV, HPV en CT infecties. Desalniettemin blijkt er 
een disbalans te zijn tussen het aantal gene-disease associations en het aantal 
klinische toepassingen gerelateerd aan deze associaties.
SUMMARY
167
SAMENVATTING

169
In Chapter 2 hebben we de rol van biobanken onderzocht aangaande het 
onderzoek naar genomics binnen infectieziekten, alsmede hun rol in de translatie 
van kennis en het toepassen van infectious disease genomics in de klinische 
praktijk. In dit hoofstuk wordt de trend beschreven van een groeiend aantal 
biobanken die opgericht en bestuurd worden door ziekenhuizen en academische 
instituten en die het onderzoek naar genomics in infectieziekten ondersteunen. 
We hebben succesvolle voorbeelden van onderzoek voortkomend uit informatie 
van deze biobanken, beschreven en daarnaast tevens een trend opgemerkt in de 
toenemende ontwikkeling van nationale of transnationale databases van humane 
en micro-organische samples en de opzet van grote consortia en netwerken.
Part II  
Chapter 3 biedt een overzicht van de huidige stand van zaken met betrekking 
tot host genetic markers gerelateerd aan Chlamydia trachomatis infectie. Door het 
combineren van meerdere single nucleotide polymorfisms (SNPs) in de  pathogen 
recognition receptor (PRR) genen en van genen in gerelateerde pathways, welke 
vervolgens als vatbaarheidsmarkers gecombineerd kunnen worden, kan mogelijk 
een hoog-voorspellende test voor TFI-geïnduceerde subfertiliteit ontwikkeld 
worden. We hebben onderzocht wat de potentiële translationele en klinische 
waarde van het toevoegen van deze diagnostische genetische markers uit het 
gastheerprofiel zou kunnen zijn voor het huidige klinische management van 
infertiliteit. Als een mogelijke faciliterende factor in het implementatieproces 
van host genetic markers in klinische toepassingen wordt een public health 
genomic (PHG) model beschreven.
Om de translatie van Chlamydia trachomatis gerelateerd aan host genetic markers 
te faciliteren, hebben we in Chapter 4 de mogelijke behoefte om genoomtesten 
in de triage van TFI te introduceren verkend door de gezondheidszorgbehoeften 
in de doelpopulatie te bestuderen. We hebben een 3-staps kader ontworpen 
om deze inschatting te kunnen maken. In de eerste stap hebben we services/
strategieën geïdentificeerd die momenteel in de fertiliteitszorg in Nederland 
gebruikt worden. Daarbij hebben we geen consensus gevonden over de volgorde 
van diagnostische handelingen in de klinische routine ook niet aangaande 
onderzoek naar ovariumpathologie als mogelijke oorzaak. In stap 2 hebben 
we de karakteristieken gedefinieerd van de doelpopulatie voor fertilteitszorg in 
Nederland en is de gezondheidszorgbehoeften van deze populatie bestudeerd. 
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De gemiddelde leeftijd van de populatie vrouwen die fertiliteitsonderzoek 
ondergaat neemt toe evenals de vraag vanuit deze populatie naar fertiliteitszorg. 
Gedurende de afgelopen 5 jaar is in een groot aantal Westerse landen een jaarlijkse 
toename gevonden van 5-10% in de vraag naar medische interventie bij de 
reproductie. Screening en surveillance data van Chlamydia-infecties beschrijven 
persistente of toenemende prevalentie aantallen aangaande de infecties onder 
jongvolwassenen. Dit heeft mogelijk klinische implicaties over 10 tot 15 jaar, 
resulterend in een toenemend aantal vrouwen die onderzocht zullen worden op 
mogelijke TFI. Ten slotte, in stap 3 hebben we een strategie voorgesteld om de 
nauwkeurigheid van de eerstelijnstest te verbeteren door host genetic markers te 
combineren met de huidige anamnese. Onze voorgestelde screeningsmethode 
richt zich op een meer nauwkeurig geïnventariseerd risico op TFI en om het 
aantal misdiagnoses te verkleinen door synergistische aanpak van serologie en 
genetisch testen door middel van het nemen van bloedmonsters vroeg in het 
onderzoek naar fertiliteit en te testen op Chlamydia serologie (CAT) en host 
genetic markers (SNPs).
In Chapter 5 hebben we de houding van Nederlandse gynaecologen onderzocht 
met betrekking tot het introduceren van genetisch testen in de routine screening 
voor TFI en we hebben hun kennis geëvalueerd aangaande de genetische 
achtergrond van verschillend verloop en uitkomsten van Chlamydia infecties. 
We hebben een vragenlijst ontwikkeld voor artsen die bij OB/GYN-afdelingen 
werkzaam zijn betreffende hun attitude jegens het toevoegen van genetisch 
testen in de diagnose van TFI. Gebruik makend van deze vragenlijst hebben we 
48 artsen bevraagd die fertiliteitszorg voorzien in academische ziekenhuizen 
in Maastricht, Groningen en Utrecht, met als doel om te onderzoeken wat zij 
als belangrijke uitdagingen en faciliterende factoren zien in het introduceren 
van genetisch testen in de routinezorg voor fertiliteit. Kost-effectiviteit werd 
door 100% van de deelnemers als een belangrijke factor aangegeven voor hun 
steun voor de introductie van de nieuwe strategie, onafhankelijk van hun positie 
binnen de afdeling of het ziekenhuis waar zijn werkzaam zijn. Klinische utiliteit 
werd door 56% van de respondenten aangegeven als de meest belangrijke 
indicator van de kwaliteit van een genetische test.
In Chapter 6 worden de bevindingen die in deze thesis zijn beschreven nogmaals 
uiteengezet en worden een aantal aanbevelingen gedaan voor toekomstig 
onderzoek.
SAMENVATTING
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Attitude ten opzichte van de toevoeging de diagnose van subfertiliteit 
ten gevolge van een Chlamydia trachomatis infectie
Deel I: Algemene gegevens 
In deze vragenlijst staat de diagnosemethode van subfertiliteit als gevolg van een 
infectie met Chlamydia trachomatis centraal. Binnen de context van deze infectie, 
proberen wij te achterhalen of het volgens artsen en specialisten waardevol zou 
zijn om een genetische test toe te voegen. Over de genetische test volgt later 
meer informatie, we beginnen deze vragenlijst namelijk met een aantal algemene 
gegevens en een inventarisatie van de huidige stand van zaken, vanuit uw oogpunt.
Wat is uw huidige positie?
□	 Co-assistent
□	 AIOS
□	 ANIOS
□	 Gynaecoloog
□	 Anders n.l., ……………………………………………………………………………………
1. Kunt u hieronder aangeven binnen welke leeftijdsgroep u valt?
□	 < 25 jaar
□	 25 – 30 jaar
□	 30 – 35 jaar
□	 35 – 40 jaar
□	 40 – 45 jaar 
□	 45 – 50 jaar
□	 50 – 55 jaar
□	 55 – 60 jaar
□	 ≥ 60 jaar
2. Wat is uw geslacht?
□	 Man
□	 Vrouw
3. Wat is de naam van het ziekenhuis waar u werkzaam bent?
……………………………………………………………………………………………………………
4. Wat is de naam van de afdeling? 
……………………………………………………………………………………………………………
5. Hoeveel jaar ervaring heeft u binnen uw huidige positie?
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□	 0 – 5 jaar
□	 5 – 10 jaar
□	 10 – 20 jaar
□	 ≥ 20 jaar
Deel II: Genetica
Chlamydia trachomatis kan als gevolg van de lichamelijke immuunrespons 
complicaties in de lagere delen van de tractus genitalis veroorzaken. Als de 
immuunrespons verstoord is, kan dit risico toenemen. Variaties in de immuunrespons 
zijn deels te verklaren door variaties in het genetisch profiel van een persoon. 
Genen die hierbij gerelateerd worden aan Chlamydia trachomatis complicaties 
zijn bijvoorbeeld genen die coderen voor receptoren voor pathogeen herkenning 
op immuuncellen. In kaart brengen van deze variaties zou gecombineerd met de 
Chlamydia Antilichaam Test (CAT) tijdens de diagnose van subfertiliteit mogelijk 
meer informatie kunnen bieden. Tijdens deze test worden de relevante variaties 
gefilterd tijdens de analyse en alleen die variaties bekeken die van belang zijn voor 
de diagnose.
1. Uit onderzoek is gebleken dat 40% van het verschil in het klinisch verloop 
van Chlamydia trachomatis tussen personen toegerekend kan worden aan 
genetische factoren van de patiënt.
Vindt u deze informatie bruikbaar voor diagnostiek van subfertiliteit die door 
Chlamydia trachomatis geïnduceerd is?
□ Ja      
□ Nee   
□ Geen mening
2. Denkt u dat het samenvoegen van genetische markers met een CAT de 
sensitiviteit van het diagnoseproces voor subfertiliteit zal veranderen?
□ Ja, verlagen
□ Ja, verhogen
□ Nee
□ Geen mening
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3. Zou u het introduceren van genetische testen in het onderzoek naar 
subfertiliteit steunen?
□ Ja
□ Nee
□ Geen mening 
4. Als deze test ingevoerd zou worden, waar vindt u dat de voorgestelde 
combinatie van de twee testen plaats zou moeten vinden?
□ Bij de huisarts
□ Door de gynaecoloog in het ziekenhuis
□ Door de klinisch geneticus in het ziekenhuis
□ Anders, namelijk ……………………………………………………………
Deel III: CAT en genetische test in het diagnoseproces
Geef alstublieft aan in hoeverre u het eens bent met de volgende stellingen.
1. Het introduceren van genetische testen in het diagnoseproces van subfertiliteit 
zal de accuraatheid van de diagnose vergroten.
Mee eens Deels mee eens Neutraal Deels mee oneens Mee oneens Geen mening 
2. Het introduceren van genetische testen in het diagnoseproces van subfertiliteit 
zal het aantal fout positieve of negatieve diagnoses verkleinen.
Mee eens Deels mee eens Neutraal Deels mee oneens Mee oneens Geen mening 
3. De gecombineerde test zal de tijd tot de diagnose van tubapathologie 
verlengen.
Mee eens Deels mee eens Neutraal Deels mee oneens Mee oneens Geen mening 
4. Genetische testen zijn te duur.
Mee eens Deels mee eens Neutraal Deels mee oneens Mee oneens Geen mening 
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5. Ik zou de introductie van combinatie van serologie en genetische test in de 
dagelijkse praktijk steunen als de test kosteneffectief is. 
Mee eens Deels mee eens Neutraal Deels mee oneens Mee oneens Geen mening 
6. De belangrijkste indicatie van de kwaliteit van een g enetische test, is de 
mogelijkheid van de test om accuraat en betrouwbaar de relevante aandoening 
vast te stellen of te voorspellen (klinische validiteit)
Mee eens Deels mee eens Neutraal Deels mee oneens Mee oneens Geen mening 
7. De belangrijkste indicatie van de kwaliteit van een genetische test, is een 
verbeterde gezondheidsuitkomst door de diagnose en daarop afgestemde 
behandeling (klinische utiliteit) 
Mee eens Deels mee eens Neutraal Deels mee oneens Mee oneens Geen mening 
8. Ik zou de introductie van deze genetische test in de dagelijkse praktijk steunen 
mits de klinische validiteit en utiliteit aangetoond zijn.
Mee eens Deels mee eens Neutraal Deels mee oneens Mee oneens Geen mening 
9. Mijn patiënten zouden de voorkeur geven aan niet-invasieve tests.
Mee eens Deels mee eens Neutraal Deels mee oneens Mee oneens Geen mening 
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10. Mijn patiënten zouden de voorkeur geven aan een genetische test in plaats 
van een HSG. 
Mee eens Deels mee eens Neutraal Deels mee oneens Mee oneens Geen mening 
11. Mijn patiënten zouden de voorkeur geven aan een laparoscopie in plaats van 
een genetische test.
Mee eens Deels mee eens Neutraal Deels mee oneens Mee oneens Geen mening 
12. Ik zou de voorkeur van mijn patiënten wat betreft testen voor tubapathologie 
honoreren.
Mee eens Deels mee eens Neutraal Deels mee oneens Mee oneens Geen mening 
13. Als er een klinisch geneticus bij het diagnoseproces betrokken zou worden, zou 
ik het gevoel hebben dat de rol van de gynaecoloog binnen het diagnoseproces 
verkleind wordt. 
Mee eens Deels mee eens Neutraal Deels mee oneens Mee oneens Geen mening 
14. Ik zou een training nodig hebben als een genetische test aan het diagnoseproces 
van subfertiliteit zou worden toegevoegd.
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Heeft u nog overige opmerkingen of aanvullingen?
…………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………
Hartelijk dank voor het invullen van deze vragenlijst.
Hartelijk dank voor uw deelname aan dit onderzoek. Als u graag meer 
informatie ontvangt over het onderzoek of nog vragen heeft over bijvoorbeeld 
deze vragenlijst, kunt u contact met ons opnemen.

